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ABSTRACT

REGULATION OF EGF RECEPTOR DYNAMICS BY
PROTEIN TYROSINE PHOSPHATASES

Calixte Stillman Monast
Matthew J. Lazzara

The phosphorylated epidermal growth factor receptor (EGFR) initiates
intracellular signaling processes that regulate cell growth, survival, and migration, and
disregulated EGFR-mediated signaling occurs in many cancers. While the processes that
lead to EGFR activation and phosphorylation have been studied in detail, quantitative
aspects of the spatiotemporal regulation of EGFR by protein tyrosines phosphatases
(PTPs) are not well understood.

To begin to address this, we developed a new

compartmentalized mechanistic model of EGFR phosphorylation dynamics and used it to
interpret quantitative biochemical measurements to show that EGFR is dephosphorylated
at the plasma membrane and in the cell interior with a time scale that is small compared
to the time scales for EGFR internalization. By expanding our computational model and
experimental data set, we went on to demonstrate that EGFR dephosphorylation at the
plasma membrane surprisingly does not affect phosphorylation-dependent EGFR
internalization because a separation of phospho-dependent time scales enables EGFR to
enter clathrin-coated pits prior to being acted upon by PTPs. This same separation of
iv

time scales does, however, allow PTPs to control EGFR association with adapter proteins
that regulate downstream signaling.

Thus, our model provides new quantitative

understanding of how EGFR participates in a number of simultaneous processes that
compete for EGFR C-terminal phosphotyrosines.

We went on to apply this new

quantitative understanding of EGFR regulation by PTPs by developing predictive models
to understand how such regulation might differentially impact the efficacy of antibodies
and kinase inhibitors targeting EGFR. We also developed new computational models to
quantitatively predict how receptor dephosphorylation kinetics as rapid as we found for
EGFR might differentially control signaling initiated by receptor tyrosine kinases that
dimerize in structurally distinct ways observed naturally among the family of receptor
tyrosine kinases (RTKs).

Ultimately, the new quantitative understanding of EGFR

regulation by PTPs developed in this thesis significantly refines our understanding of the
dynamics of EGFR-mediated signaling, provides a number of additional testable
predictions related to fundamental aspects of EGFR signaling complex nucleation and
efficacy of EGFR-targeted therapeutics, and offers a basic quantitative framework for
exploring the regulation of other receptor tyrosine kinases by PTPs.
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Chapter 1 : Introduction

1-1 CELL SIGNALING AND PROTEIN PHOSPHORYLATION
Cell signaling is a biological process in which information is transferred to cells
via sequential protein-protein interactions and protein modifications (1-3). Of the
numerous protein modification processes that occur within cells, the most well-studied is
the process of phosphorylation, during which a protein kinase covalently attaches a
phosphate group to a tyrosine, serine or threonine on a substrate protein (4).
Phosphorylation serves multiple purposes. For example, a phosphorylated residue on one
protein may serve as a docking site for other proteins via interaction with specific protein
domains such as the phosphotyrosine binding (PTB) or Src-homology 2 (SH2) domains,
in the case of tyrosine phosphorylation (5). Phosphorylation can also positively or
negatively regulate a protein’s ability to mediate protein modifications. For example, the
kinase activity of the protein tyrosine kinase Src is negatively or positively modulated by
phosphorylation of distinct Src tyrosines (6). These interactions and modifications
facilitate the sequential transfer of information from one protein to the next and represent
a fundamental aspect of signaling networks, which are responsible for translating various
cues into cellular outcomes such as survival, growth, motility, or differentiation (1).
Cell signaling initiated by extracellular cues commonly involves receptors, which
are proteins that span the plasma membrane and translate extracellular events into
intracellular responses (3). Often, cues take the form of receptor-binding ligands, which
1

bind to the extracellular domains of receptors and promote receptor alterations that link
the receptor to downstream cellular processes. For the receptors on which this thesis
focuses, ligand-receptor binding promotes receptor oligomerization and activation of a
cytoplasmic receptor kinase domain that mediates receptor phosphorylation, which links
the receptor to various adapter proteins involved in initiating signaling processes and
influencing cellular outcomes (1, 3).
Considering the receptor phosphorylation requirement for receptor-mediated
signaling by some receptors, it is not surprising that disregulated growth factor receptor
phosphorylation is a key alteration in cancer (3), which is characterized by uncontrolled
cell growth and invasion of surrounding tissue. For example, specific point mutations in
the epidermal growth factor receptor (EGFR) that promote receptor phosphorylation in
the absence of EGFR ligands are associated with non-small cell lung carcinoma
(NSCLC) (7). Similarly, activated fibroblast growth factor receptor mutants, formed
through chromosomal translocations, have been identified in multiple cancers, including
lymphomas and chronic myelogenous leukemia (8). Also, activating mutations in the
receptors KIT and platelet-derived growth factor receptor have been identified in
gastrointestinal stromal tumors (9). Wild-type receptors can also mediate disregulated
signaling via receptor overexpression. For example, overexpression of HER2 is
associated with poor prognosis in breast cancer patients (10), while overexpression of
wild-type EGFR is associated with some NSCLC patients (11). To interrupt aberrant
signaling, receptor-targeted therapeutics (e.g., the EGFR kinase inhibitor gefitinib (12))
have been developed. These therapeutics generally function by impairing processes
2

required for receptor phosphorylation, leading to reduced receptor phosphorylation and
downstream signaling. The relatively limited, yet promising, clinical success of some
receptor-targeted cancer therapies (e.g., gefitinib in some NSCLC patients (13)) has
inspired rigorous development of therapeutics designed interrupt processes required for
receptor phosphorylation.
The processes leading to receptor phosphorylation account for only some of the
processes that influence receptor phosphorylation. Receptor phosphorylation, and indeed
protein phosphorylation in general, is negatively regulated by proteins phosphatases,
which mediate the removal of a phosphate group from a phosphorylated residue in the
process of dephosphorylation (14). Given that the balance between phosphorylation and
dephosphorylation dictates net levels of phosphorylated protein, it follows that
phosphatases may be important regulators of receptor-mediated signaling in the context
of receptors for which phosphorylation provides linkage to downstream signaling
processes. Consistent with this, phosphatases have been shown to be altered in the
context of multiple human cancers (15). Unfortunately, our quantitative understanding of
the kinetics of dephosphorylation has lagged significantly behind our understanding of
kinases and phosphorylation. Thus, it is unclear to what extent phosphatases control the
many processes involved receptor-mediated signaling and to what extent phosphatase
disregulation might contribute to disregulated receptor-mediated signaling.

3

1-2 EPIDERMAL GROWTH FACTOR RECEPTOR
The receptor tyrosine kinases (RTKs) are a particularly important receptor superfamily due to their roles in human physiology and disease (3). Signaling mediated by
these proteins influences a diverse set of cellular outcomes including cell growth,
survival, motility, and differentiation via activation of many intracellular signaling
pathways (1). In general, RTK-mediated signaling is initiated through the binding of
extracellular ligands to the RTK extracellular domain, which promotes receptor
oligomerization. RTK oligomerization activates the receptor kinase by relieving autoinhibition of the cytoplasmic kinase domain, which is a shared feature among all RTKs.
Once the kinase is activated, it mediates trans-auto-phosphorylation of C-terminal
receptor tyrosine residues (3, 16). RTK phosphotyrosines generated by this process serve
as binding sites for SH2 and PTB domain-containing cytoplasmic adapter proteins, which
link the receptor to a diverse set of downstream processes, including receptor-mediated
signaling and internalization (3, 17, 18).
The ErbB family of RTKs is composed of ErbB1 (EGFR), ErbB2 (HER2), ErbB3,
and ErbB4 (19). The ErbB receptors have been particularly well-studied due to their roles
in multiple areas of human health, including multiple human cancers (20) and cardiac
health (21). Of the ErbBs, EGFR has been the focus of particularly intense study due to
its role in human health and disease. EGFR functions through the binding of any of a
family of ligands, including epidermal growth factor (EGF) and amphiregulin (AR),
triggering EGFR-mediated signaling and internalization processes by promoting EGFR
dimerization and phosphorylation (Figure 1-1) (22, 23). Given the central role of
4

phosphorylation in initiating multiple receptor-mediated processes, mechanistic studies of
EGFR have generally focused on the ways in which EGFR becomes phosphorylated,
including in-depth investigation of ligand-EGFR binding, EGFR dimerization, and
regulation of EGFR kinase activity (e.g., (24-26)). However, EGFR phosphorylation
levels are also controlled by protein tyrosine phosphatases (PTPs), which act in
opposition to the EGFR kinase by dephosphorylating EGFR phosphotyrosines (27).
Despite a potentially important role in controlling EGFR phosphorylation, and by
extension EGFR-mediated cellular processes, the kinetics of EGFR dephosphorylation
and how these kinetics might influence EGFR-mediated process have not been wellstudied.

Figure 1-1: EGFR phosphorylation and EGFR-mediated signaling.
Ligand binding to EGFR promotes EGFR dimerization, which activates the EGFR kinase
(K)

permitting

trans-auto-phosphorylation

of

C-terminal

tyrosines

(Y).

Once

phosphorylated, tyrosines may bind adapter proteins involved in initiating downstream
signaling cascades, which ultimately influence cellular outcomes by regulating
transcription.

5

1-3 EGFR INTERNALIZATION
In addition to downstream cell signaling, EGFR phosphorylation initiates at least
one EGFR internalization mechanism through the binding of GRB2 (Figure 1-2), an SH2
domain-containing adapter protein that binds phosphorylated EGFR (28). GRB2 mediates
EGFR association with the E3 ubiquitin ligase CBL through its SH3 domains (29, 30).
CBL may also associate with EGFR directly, however GRB2-mediated EGFR-CBL
association was found to be more important for EGFR internalization (31). As an E3
ubiquitin ligase, CBL mediates EGFR ubiquitination (32), during which the protein
ubiquitin is covalently attached to EGFR lysines. Recent studies suggest that EGFR
ubiquitination is required for EGFR internalization (33-35), however this requirement has
been debated (36, 37). Presently, it is thought that EGFR ubiquitination promotes EGFR
association with proteins, such as Epsin1 (33), in a process that is required for efficient
translocation of EGFR to membrane structures called clathrin-coated pits (CCPs) (18,
36). Once enough cargo (e.g., receptors) is bound to a particular CCP, the CCP forms a
vesicles called an endosome, which is actively transported to the cell interior (38). While
this mechanism is thought to represent the principle internalization mechanism in the
presence of physiological ligand concentrations (39), other EGFR internalization
mechanisms exist. For example, the protein MIG6 mediates internalization of EGFR by
linking the receptor to AP-2 and intersectins (40, 41). EGFR can also internalize via a
mechanism dependent upon EGFR ubiquitination and lipid rafts or through basal
turnover of the plasma membrane (18, 42). Experiments demonstrate that internalization
of EGFR in absence of ligand is unaltered by deletion of the EGFR cytoplasmic domain
6

and that internalization rates of EGFR lacking the cytoplasmic domain are unaltered by
EGF addition suggest that basal EGFR turnover does not require receptor
phosphorylation or even specific intracellular interactions (43).
During internalization the endosomal lumen becomes acidified, which promotes
dissociation of ligand from endosome-associated receptors (44, 45). Ultimately, the
internalization process results in lysosome-mediated degradation or recycling to the cell
surface of endosome-localized receptors (18). Due to the endosome acidification and
receptor degradation components, the internalization process has traditionally been
considered a negative regulator of receptor-mediated signaling. However, multiple
studies have demonstrated that EGFR internalization can positively regulate EGFRmediated signaling (18) through the MAP kinase pathway (46) or AKT pathway (34, 47).
Furthermore, impaired EGFR internalization may promote cellular sensitivity to EGFR
kinase inhibitors via sequestration of intracellular EGFR-binding proteins, which impairs
EGFR-mediated activation of the ERK signaling pathway (48-50).

Thus, EGFR

internalization, as EGFR-mediated signaling, is an important EGFR phosphorylationdependent regulatory process that influences multiple downstream signaling processes
and cellular phenotypes (18).
Given the EGFR phosphorylation requirement for its internalization, it is feasible
that PTPs could regulate EGFR internalization (Figure 1-2). Indeed, one previous study
suggests that the receptor-like PTP DEP1 may control EGFR internalization rates by
dephosphorylating EGFR prior to internalization (51). The general notion that PTPs
could potentially regulate EGFR internalization is supported by numerous mechanistic
7

studies, which almost universally support a role for EGFR phosphorylation in
internalization (18, 36). For example, deletion of the cytoplasmic domain removed the
ability of exogenous ligand to induce EGFR internalization (43). Also, mutation of EGFR
tyrosines that are targets for EGFR autophosphorylation reduced ligand-mediated EGFR
internalization rates in porcine aortic endothelial (PAE) (28). Finally, pretreatment of
PAE cells with EGFR kinase inhibitors significantly slowed EGFR internalization (52).
In the same study, cells treated with EGF at 4°C, which promotes recruitment of EGFR to
CCPs but very little EGFR internalization, and then treated with EGFR kinase inhibitors
were characterized by normal EGFR internalization rates upon warming cells to 37°C,
despite a significant reduction in EGFR phosphorylation following inhibitor treatment
(52). Thus, EGFR phosphorylation appears to be required for initiation of EGFR
internalization, but may become dispensable once EGFR is localized to CCPs. Given the
finding that EGFR ubiquitination is important for EGFR association with coated pits
(36), one hypothesis is that EGFR ubiquitination replaces EGFR phosphorylation as the
internalization driving force at some point during the internalization process. If this were
true, EGFR

PTPs

could

regulate EGFR

internalization provided that they

dephosphorylate EGFR prior to EGFR ubiquitination (Figure 1-2). While the study by
Tarcic and coworkers (51) suggests that PTPs are capable of regulating EGFR
internalization, they based their conclusion on a flow cytometry-based measurement of
the effect of DEP1 knockdown and expression on EGFR surface localization for a single
time point after EGF stimulation (51). More extensive study is required not only to

8

understand the role of DEP1 in regulating EGFR internalization, but also to understand
the general role of EGFR dephosphorylation in regulating EGFR internalization.

Figure 1-2: EGFR dephosphorylation and EGFR-mediated internalization and
signaling.
Ligand-initiated EGFR tyrosine (Y) phosphorylation by the EGFR kinase (K) promotes
EGFR-mediated signaling and internalization. EGFR internalization is initiated by
EGFR-GRB2 binding, which mediates EGFR association with CBL. CBL mediates
EGFR ubiqutination which promotes EGFR interaction with clathrin-coated pit (CCP)
proteins, which is required for recruitment of EGFR to CCPs. Once enough cargo
(EGFR) is bound, CCPs form endosomes which are transported to the cell interior in a
process that influences EGFR-mediated signaling. Ultimately, EGFR localized to
endosomes is either recycled back to the cell surface or degraded.
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1-4 EGFR DEPHOSPHORYLATION
While the kinetics of EGFR dephosphorylation are not well-understood, much is
known about specific phosphatases that can regulate EGFR (14, 53). The first PTP to be
purified and characterized was PTP1B in 1988 (54, 55). Since then, over 100 PTPs have
been identified and classified into four families: Class I Cys-based PTPs, Class II Cysbased PTPs, Class III Cys-based PTPs, and Asp-based PTPs (53). Many of the specific
PTPs described here are Class I Cys-based PTPs, which represent the largest PTP family
with 38 so called “classical” PTPs and 61 “dual-specificity” phosphatases (53). Classical
PTPs are further subcategorized into transmembrane receptor-like PTPs and nontransmembrane PTPs (14).
Several years after its identification, PTP1B was shown to localize to the
endoplasmic reticulum (ER) (56) and dephosphorylate several RTKs, including EGFR, in
cells (57), suggesting the hypothesis that EGFR was only regulated by PTPs after
internalization. This hypothesis gained traction because typical ligand-mediated EGFR
phosphorylation dynamics (e.g., (58)) involve a decay in EGFR phosphorylation with a
timescale similar to the time scale measured for EGFR internalization (int ~ 10 min,
(59)). A more recent study demonstrated that EGFR could only interact with PTP1B after
EGFR endocytosis (60). Together, these studies and observations have contributed to the
wide-spread assumption that EGFR dephosphorylation occurs only in the cell interior,
after EGFR internalization (e.g. (61)).
In addition to PTP1B, multiple PTPs, with wide-ranging subcellular localizations,
have been shown to regulate EGFR phosphorylation, including PTPRS (62), PTPRK (51,
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63), LAR (64, 65), SHP1 (66, 67), TCPTP (68, 69), CDC25A (70), DEP1 (51, 71), LRP
(64), and PTP-PEST (72). PTPRS, PTPRK, LAR, DEP1, and LRP have extracellular
domains and transmembrane regions anchoring them to the cell surface (73). SHP1 (74)
and PTP-PEST (75) are present in the cytoplasm. PTP1B is localized to the ER (56), but
this localization may not limit the ability of PTP1B to interact with proteins localized to
the cell surface (76). TCPTP is localized to the nucleus (77), ER (77) and cytoplasm (78).
And, lastly, CDC25A is present in both the nucleus and the cytoplasm (79). The notion
that EGFR regulation by PTPs may not be restricted to the cell interior is suggested by
the identification of multiple cell surface-localized PTPs that are capable of
dephosphorylating EGFR but is also supported by other studies. Offterdinger and
coworkers used a FRET construct to visualize EGFR phosphorylation dynamics in living
MCF7 and COS7 cells and noted that EGFR phosphorylation was reduced to basal levels
after roughly 2 min of treatment with an EGFR tyrosine kinase inhibitor (TKI) regardless
of EGFR cellular localization (80). The same study demonstrated that EGFR could
become phosphorylated at the cell surface in the absence of stimulatory ligand if cells
were treated with pervanadate (80), a potent and irreversible inhibitor of PTPs (81).
These data led the authors to hypothesize that EGFR phosphotyrosines are under control
by PTPs regardless of EGFR cellular localization. In aggregate, these studies support the
hypothesis that EGFR phosphorylation levels are in fact controlled by PTPs at the cell
surface, contrary to the classic view of EGFR dephosphorylation. These data also support
the possibility that PTPs are important controllers of EGFR-mediated signaling and
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internalization, but only if EGFR dephosphorylation occurs fast enough to disrupt these
processes.
In addition to their potential roles as regulators of EGFR-mediated signaling and
trafficking, PTPs are also integral to the efficacy of EGFR-targeted therapeutics. Some
EGFR-targeted therapeutics mediate reductions in phosphorylated EGFR levels by
disrupting at least one process required for EGFR phosphorylation. For example, binding
of the EGFR-targeted TKI gefitinib to the EGFR kinase domain prevents ATP binding,
which is required for receptor phosphorylation (12). Gefitinib can also mediate a
reduction in existing receptor phosphorylation by displacing ATP from EGFR which
impairs the EGFR phosphorylation process and allows PTPs to reduce existing EGFR
phosphorylation. The involvement of PTPs in EGFR-targeted therapeutic efficacy is
supported by a recent study of the receptor-like phosphatase PTPRS in head and neck
squamous cell carcinoma (HNSCC) (82). This study found that HNSCC tumors with
PTPRS deletion and endogenous levels of WT EGFR exhibited increased EGFR and
AKT phosphorylation compared to control. Furthermore, artificially reducing PTPRS
expression promoted ligand-independent EGFR phosphorylation in HNSCC cells and
increased resistance of HNSCC and NSCLC cells to treatment with the EGFR TKI
erlotinib. Finally, reduced PTPRS expression predicted cellular resistance to treatment
with the EGFR-targeted inhibitory antibody cetuximab in HSNCC cells and poor
prognosis in lung adenocarcinoma patients with tumors characterized by EGFRactivating mutations.
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In aggregate, careful consideration of previous studies supports the hypothesis
that, contrary to the classical view of regulation of receptor phosphorylation by
phosphatases, PTPs control EGFR phosphorylation at the cell surface via receptor
dephosphorylation. What remains unclear is how rapidly this regulation occurs, how it
extends to downstream receptor-mediated, phosphorylation-dependent processes, and
how it may impact the cellular response to drugs.

1-5 EGFR COMPUTATIONAL MODELING
Quantifying the regulation of phosphorylated EGFR and EGFR phosphorylationinitiated processes by PTPs would require simultaneous consideration of multiple EGFRlevel

processes,

including

EGFR

phosphorylation,

dephosphorylation,

and

internalization. Due to the complexity of these processes, mechanistic computational
models are appropriate tools for a study of this nature. Mechanistic models of EGFRmediated processes have, in fact, been used extensively to interpret complex
experimental data (83). For example, Starbuck and Lauffenburger used a mechanistic
model to quantify the various processes involved in EGFR trafficking (84). Kholodenko
and coworkers used a mechanistic model of EGFR phosphorylation and adapter protein
binding trained on experimental data to study the EGFR-level processes that occur tens of
seconds after stimulation of cells with ligand (85). More complex models have been used
to quantify the role of ErbB receptors in promoting signaling through various
downstream pathways (e.g., (86)). Another study used a mechanistic model to quantify
the effect of HER2 expression on EGFR internalization and sorting (87). Thus,
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mechanistic models, especially when paired with experimental data, are proven tools for
quantification and interpretation of receptor-mediated processes.
Despite an important role for receptor phosphorylation in the processes considered
in each of the mentioned computational studies, receptor dephosphorylation and
internalization were treated very differently in each. Schoeberl and coworkers assumed
EGFR dephosphorylation occurred at the same rate regardless of EGFR localization (86),
while Kholodenko and coworkers considered dephosphorylation without considering
EGFR internalization (85). Hendriks and coworkers considered receptor internalization
but did not explicitly account for receptor phosphorylation and therefore did not include a
dephosphorylation

process

(87).

Also,

in

general,

the

magnitudes

of

the

dephosphorylation rate constants used in these models were not determined using data
that fully reveals the rate at which EGFR is dephosphorylated. One computational study
directly assessed the compartmentalization of ErbB dephosphorylation following
stimulation with ErbB ligands (88). This study concluded that ErbB phosphorylation
dynamics are consistent with dephosphorylation only occurring in the cell interior but did
so without explicitly including a phosphorylated receptor species in their model and only
visually compared model results to experimental data (88). Thus, computational studies
have generally reflected, rather than remedied, the absence of a consensus regarding
where in the cell EGFR undergoes dephosphorylation and how rapid EGFR
dephosphorylation occurs.
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1-6 PROBLEM SUMMARY
Phosphorylation of EGFR initiates multiple cellular processes, including EGFRmediated internalization and signaling, that influence cell growth and survival and the
cellular response to EGFR-targeted therapeutics. This important role for EGFR
phosphorylation has prompted significant study of the processes required for EGFR
phosphorylation.

However,

a

quantitative

understanding

of

how

EGFR

dephosphorylation influences EGFR phosphorylation and EGFR-mediated processes has
not been undertaken. Thus, there is no clear consensus on: 1. where in the cell EGFR is
dephosphorylated, 2. how rapidly EGFR dephosphorylation occurs at different subcellular locations, 3. how EGFR dephosphorylation influences downstream EGFRmediated and phospho-dependent processes, and 4. how EGFR dephosphorylation plays a
role in determining EGFR-target therapeutic efficacy. Thus, there are important
fundamental and quantitative questions that must be addressed in order to more
completely understand the mechanisms by which EGFR mediates cellular processes and
improve the design of EGFR-targeted therapeutics.

1-7 THESIS SUMMARY
In this thesis, we explore the regulation of EGFR by PTPs using quantitative
biological measurements paired with mechanistic models that include EGFR
phosphorylation and dephosphorylation. In Chapter 2, we quantify the rates of EGFR
dephosphorylation at the plasma membrane and in the cell interior by training a
mechanistic model on quantitative measurements of the EGFR phosphorylation response
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to exogenous ligand, PTP inhibition, and EGFR inhibitors (89). We find that EGFR is
dephosphorylated at the plasma membrane multiple times after the addition of
stimulatory ligand prior to internalization, contrary to the classical view of receptor
regulation by PTPs, and with a similar rate in the cell interior. Our analysis suggests that
instead of becoming statically phosphorylated, EGFR cycles between phosphorylated and
unphosphorylated states more than once each minute in a process that is predicted to
influence the efficacy of EGFR-target therapeutics.
In Chapter 3, we explore the implications of relatively rapid EGFR
dephosphorylation by investigating how a single EGFR phosphotyrosine is able to initiate
receptor-mediated signaling, initiate receptor internalization and undergo relatively rapid
dephosphorylation all in the first few minutes after the addition of exogenous ligand to
cells. We find that differences among the time scales with which each of these processes
allows them to effectively occur independently. We conclude that PTPs are able to
control EGFR phosphorylation without slowing EGFR internalization or significantly
impairing the ability of EGFR to engage multiple adapter proteins.
In Chapter 4, we explore the receptor-level processes responsible for determining
EGFR-targeted therapeutic efficacy in the context of two kinetically distinct EGFR
ligands. We found that receptor dephosphorylation is an important determinant of the
efficacy of gefitinib, a small-molecule, and cetuximab, an inhibitory antibody. We also
identified EGFR internalization and sorting processes as important determinants of
cetuximab efficacy. Overall, our results suggest that multiple receptor-level processes
contribute to the efficacy of a particular EGFR-targeted therapeutic beyond processes that
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influence EGFR-therapeutic competitive binding and that EGFR dephosphorylation is
indeed important in the context of EGFR-targeted therapeutics.
In Chapter 5, we investigate how receptor dephosphorylation might differentially
affect receptor phosphorylation generated by receptor dimerization through direct
receptor-receptor contacts (receptor-mediated dimerization, RMD) or indirect contacts
via an interposed bivalent ligand (ligand-mediated dimerization, LMD). Our analysis
revealed significant differences between LMD and RMD. For example, LMD versus
RMD was characterized by an increased number of phosphorylated receptors per
receptor-bound ligand due to the ability of LMD to facilitate a single receptor dimerizing
with and phosphorylating multiple other receptors. Interestingly, this process was tightly
controlled by receptor dephosphorylation. We conclude that different receptor
dimerization

mechanisms

could

significantly

affect

ligand-initiated

receptor

phosphorylation in cells, which may contribute to the diversity in signaling dynamics
downstream of different RTKs.
Lastly, in Chapter 6 we discuss the implications of our findings, which support an
emerging paradigm involving protein phosphorylation and protein-protein interactions
persisting with a far smaller time scale than previously assumed. This paradigm has
significant implications for the mechanisms by which receptors such as EGFR mediate
cell signaling and initiate cellular process, which suggests multiple avenues for future
investigation.
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Chapter 2 : Computational Analysis of the Regulation of
EGFR by Protein Tyrosine Phosphatases

2-1 ABSTRACT
The tyrosine phosphorylated epidermal growth factor receptor (EGFR) initiates
numerous cell signaling pathways.

Although EGFR phosphorylation levels are

ultimately determined by the balance of receptor kinase and protein tyrosine phosphatase
(PTP) activities, the kinetics of EGFR dephosphorylation are not well understood.
Previous models of EGFR signaling have generally neglected PTP activity or computed
PTP activity by considering data which do not fully reveal the kinetics and
compartmentalization of EGFR

dephosphorylation.

We developed a

compartmentalized,

model

the

mechanistic

to

elucidate

kinetics

of

novel
EGFR

dephosphorylation and the coupling of this process to phosphorylation-dependent EGFR
endocytosis. Model regression against data from HeLa cells for EGFR phosphorylation
response to EGFR activation, PTP inhibition, and EGFR kinase inhibition led to the
conclusion that EGFR dephosphorylation occurs at the plasma membrane and in the cell
interior with a timescale which is smaller than that for ligand-mediated EGFR
endocytosis. The model further predicted that sufficiently rapid dephosphorylation of
EGFR at the plasma membrane could potentially impede EGFR endocytosis, consistent
with recent experimental findings.

Overall, our results suggest that PTPs regulate

multiple receptor-level phenomena via their action at the plasma membrane and cell
18

interior and point to new possibilities for targeting PTPs for modulation of EGFR
dynamics.
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2-2 INTRODUCTION
The binding of SH2- and PTB-domain-containing proteins to phosphorylated Cterminal tyrosines of the epidermal growth factor receptor (EGFR) links the receptor to
cell signaling pathways and to receptor trafficking mechanisms (18).

Whereas the

processes leading to EGFR tyrosine phosphorylation have been studied in detail,
relatively little is known about quantitative aspects of receptor dephosphorylation by
protein tyrosine phosphatases (PTP) (27, 90). Estimates of the rates of EGFR tyrosine
dephosphorylation are limited (85, 86, 88), and the extent to which individual PTPs
contribute to the net dephosphorylation kinetics of specific EGFR phosphotyrosines is
unknown. The relative rates of EGFR tyrosine dephosphorylation at different cellular
locations also remain poorly understood.
Beyond this fundamental knowledge gap, there are additional reasons why a
quantitative understanding of EGFR tyrosine dephosphorylation is important. Indeed,
dephosphorylation rates may influence receptor inhibition by targeted therapeutics (90),
receptor trafficking (51), and downstream signaling (91). Tyrosine cycling between
phosphorylated and unphosphorylated forms may also influence receptor sensitivity to
noise (92), system responses to changes in ligand concentration (93), and sensitivity to
changes in PTP and receptor concentrations (94). Of course, phosphatases play important
roles in regulating signaling downstream of the receptor as well. In linear signaling
cascades such as those associated with MAP kinases, phosphatases have a role in
regulating signal induction, duration, amplification, and dampening (95).
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A number of PTPs which regulate EGFR have been identified, including RPTPσ,
RPTPκ, LAR, SHP-1, PTP1B, TCPTP, CDC25A, DEP-1, and LRP, with some
information available on PTP localization. RPTPσ, RPTPκ, LAR, DEP-1, and LRP are
anchored to the plasma membrane (73), while SHP-1 is present throughout the cytoplasm
(74). PTP1B is tethered to the cytoplasmic side of the endoplasmic reticulum (56) and
may be released into the cytoplasm (77), while TCPTP (77) and CDC25A (79) are
shuttled between the nucleus and cytoplasm. Such spatial organization leads to important
consequences for the dynamics of EGFR phosphotyrosine regulation by specific PTPs.
For example, PTP1B dephosphorylates EGFR mainly after receptor endocytosis (96). In
contrast, DEP-1’s localization to the plasma membrane allows it to dephosphorylate
EGFR prior to endocytosis in a process which may affect EGFR internalization (51).
The incomplete understanding of EGFR tyrosine dephosphorylation is reflected
by the different ways this process has been incorporated in computational models of
EGFR dynamics. One recent model simply assumed identical EGFR dephosphorylation
rate constants for the plasma membrane and cell interior (86), while another included
PTP effects without incorporating receptor trafficking (85). In previous models assuming
that EGFR internalization is driven by ligand occupancy, neither phosphorylated species
nor receptor dephosphorylation were explicitly included (87, 97). In previous models of
EGFR-mediated signaling focused on effects of receptor internalization on downstream
signaling (98) and network branching (99), dephosphorylation was omitted, presumably
due to a focus on downstream dynamics. Another recent computational study concluded
that ErbB receptors are mainly dephosphorylated in the cell interior (88). However, that
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model did not include explicit phosphorylation or dephosphorylation reactions, equated
dimers with phosphorylated receptors, and assumed that dephosphorylation was
equivalent to dimer uncoupling.
Here, we develop a novel mechanistic model to gain quantitative insight into the
process of EGFR tyrosine dephosphorylation and its impact on other EGFR rate
processes. The model consists of a set of coupled ordinary differential equations which
describe the kinetics of EGFR phosphorylation, dephosphorylation, and trafficking. The
model considers the dynamics of a single representative cytoplasmic EGFR tyrosine and
accounts for the well-established coupling between receptor phosphorylation and
endocytosis by requiring that receptors be phosphorylated in order for endocytosis to
occur. Most parameters were taken from the literature or estimated using established
methods.

A novel aspect of our approach is fitting the four unknown parameters

(including rate constants for EGFR tyrosine dephosphorylation at the plasma membrane
and in the cell interior) to data gathered in HeLa cells for EGFR Y1068 phosphorylation
response to EGFR activation by EGF, EGFR kinase inhibition, and PTP inhibition.
These dynamic responses were quantified as percentages of phosphorylated EGFR using
an immunoprecipitation based method. Overall, our model results suggest that EGFR
dephosphorylation occurs rapidly at the plasma membrane and in the cell interior in HeLa
cells with a timescale which is smaller than that for EGF-mediated EGFR endocytosis.
These dephosphorylation kinetics are predicted to exert control over EGFR endocytosis,
EGFR inhibition, and phosphorylation sensitivity to changes in EGFR expression levels.
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Figure 2-1: Model topology.
(A) Reversible binding processes include EGFR interactions with itself, EGF, ATP, and
an EGFR kinase inhibitor (INH). (B) Irreversible processes include phosphorylation,
dephosphorylation, and receptor trafficking.
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Table 2-1: Model parameters.
parameter

description

-1

-1

kE,fs (μM ·min )
kE,rs (min )
kE,fi (endosome∙min )
-1

kE,ri (min )
kA,f (μM ·min )
kA,r (min )
ki,f (μM ·min )
ki,r (min )
kd,fs (cell·min )
kd,fi (endosome·min )
-1

kd,r (min )

(100)

1.0 × 10

5

see text

1.1 × 10

7

see text

1.0 × 10

5

see text

2.1 × 10

2

see text

6.7 × 10

-4

see text

1.1 × 10

-2

see text

1.2 × 10

4

fit

1.0 × 10

-10

fit

2.7 × 10

0

(101)

1.3 × 10

1

(101)

1.7 × 10

0

fit

dephosphorylation, interior

1.5 × 10

0

fit

EGFR synthesis

varies

phosphorylated EGFR internalization

varies

EGFR dimerization, forward, interior
EGFR dimerization, reverse, unoccupied

-1

kdE,r (min )

EGFR dimerization, reverse, EGF-occupied

-1

kcat (min )

phosphorylation, unoccupied dimer

-1

kcatE (min )

phosphorylation, EGF-occupied dimer

-1

kdp,s (min )

dephosphorylation, surface

-1

kdp,i (min )
-1

SE (cell ·min )

-1

6.6 × 10

EGFR dimerization, forward, surface
-1

kexE (min )

(100)

-1

inhibitor binding to EGFR, reverse
-1

-1

3.9 × 10

EGF binding to EGFR, forward, interior

inhibitor binding to EGFR, forward

-1

ke,m (min )

(100)

-4

ATP binding to EGFR, reverse
-1

-1

1.6 × 10

ATP binding to EGFR, forward

-1

-1

(100)

-1

EGF binding to EGF, reverse, interior
-1

-1

6.3 × 10

EGF binding to EGFR, reverse, surface
-1

source
1

EGF binding to EGFR, forward, surface

-1

-1

value

endosomal exit, EGF-occupied

see text
see text

4.0 × 10

-2

(97)

-2

(97)

kex (min )

endosomal exit, unoccupied

4.0 × 10

frE

recycle fraction, EGF-occupied

0.5

fr

recycle fraction, unoccupied

0.8

(97)
(97)
3

ATP (μM)

cellular ATP concentration

1.0 × 10

EGF (μM)

extracellular EGF concentration

varies

see text

INH (μM)

inhibitor concentration

varies

see text
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(102)

2-3 MATERIALS AND METHODS
General model considerations and topology. The model consists of a set of
coupled ordinary differential equations which describe interactions of EGFR with itself
(dimerization and phosphorylation), PTPs, EGF, ATP, and the EGFR kinase inhibitor
gefitinib (Figure 2-1A). As these processes occur, EGFR is routed from the plasma
membrane to an endosomal compartment where it is sorted for recycling or degradation
(Figure 2-1B). Essential processes and model parameters are summarized in Figure 2-1
and Table 2-1, respectively. The model includes 169 reactions, 52 species, and 25
parameters.
EGF binding, trafficking, and concentration. EGF binding at the plasma
membrane and in the endosome was modeled as a reversible process characterized by
rate constants for binding at pHs characteristic of these locations (100).

EGF

concentration was assumed to be constant in the extracellular space and time-dependent
in the endosomal compartment.
ATP and inhibitor binding. Rate constants for ATP and gefitinib association
with EGFR were estimated assuming diffusional limitations. Gefitinib was assumed to
have a diffusivity of 2.5 × 10-6 cm2·s-1, equal to that of ATP (103), and an interaction
radius of 1 nm with EGFR (104). The rate constant for gefitinib dissociation was
computed using its affinity for the EGFR kinase (12).

The rate constant for ATP

dissociation was estimated using an equilibrium binding model and assuming that, for an
ATP concentration of 1 mM (102), half of EGFR is inhibitor-bound at 21 nM gefitinib,
consistent with experimental measurements (105).
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EGFR dimerization. Rate constants for receptor dimerization were estimated
assuming diffusional limitations (104), as in previous models (85, 87). The diffusivity of
EGFR was set to 1 × 10-10 cm2·s-1 (85), and the interaction radius was set to 1 nm (104).
Cells and endosomes were approximated as spheres of radii 10 m and 350 nm (106),
respectively. Dimerization constant estimates were sensitive to changes in area but not to
changes in EGFR levels. Thus, distinct dimerization rate constants were computed for
the plasma membrane and endosome assuming 5 × 104 EGFR per compartment. Because
EGF binding to EGFR promotes dimer formation (107), we defined dimer uncoupling
rate constants for ligand-bound (kdE,r) and ligand-free (kd,r) EGFR, as in previous models
(87, 99). These constants were included in the parameter fit.
EGFR phosphorylation. EGFR phosphorylation was modeled as a process
occurring within ATP-bound EGFR dimers during which both receptors are
phosphorylated at a representative tyrosine. These reactions were characterized by rate
constants for EGFR catalytic activity in the presence or absence of EGF (101). This
structure allows for a small amount of EGFR phosphorylation in the absence of ligand,
which has been observed even in the presence of a ligand-blocking antibody (108). The
simplification of modeling EGFR phosphorylation at a single tyrosine residue has been
used in previous EGFR models [e.g. (85, 98)]. Provided that the tyrosine considered
plays a critical role in receptor endocytosis, this simplification should be acceptable for
our purposes.

Since the dynamics with which different EGFR tyrosines become

phosphorylated (109) and dephosphorylated (105) appear to be roughly equivalent, the
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kinetics of tyrosine phosphorylation suggested by our model are likely representative of
most EGFR tyrosines.
PTP activity. EGFR dephosphorylation was modeled as zeroth order with respect
to PTPs, which obviates the need to specify PTP concentrations. To accommodate the
possibility of different dephosphorylation rates at the plasma membrane and in the cell
interior, we defined distinct parameters for these locations (kdp,s and kdp,i, respectively),
which were included in the parameter fit.
EGFR endocytosis and synthesis. Movement of phosphorylated EGFR from the
plasma membrane to the cell interior (endocytosis) was modeled as a first-order process
with a rate constant ke,m. The specific endocytosis rate constant ke,e has been measured
using 125I-EGF, with ke,e computed as the slope of internalized 125I-EGF counts versus the
integral of surface-bound

125

I-EGF counts from t = 0 to the time of the measurement, for

a series of times (59). A ke,e computed in this way is not generally interchangeable with
the ke,m used in model rate equations describing endocytosis of phosphorylated species,
even though the constants have similar units. This inconsistency arises because PTP
activity at the plasma membrane results in at least some of the ligand-bound, membranelocalized receptors being unphosphorylated. In the limit of vanishing PTP activity at the
membrane and rapid dimerization and phosphorylation, ke,m → ke,e. To ensure that our
results accurately reflected experimentally determined ke,e values, ke,m was iteratively
determined for each simulation to achieve agreement between predicted internal and
plasma membrane EGF dynamics and a ke,e = 0.13 min-1 (48).

27

For our best-fit parameters, ke,m was ~1.6-fold larger than ke,e. Based on the
discussion above, it is not surprising that the difference depends upon kdp,s (Figure 2-2A),
with larger kdp,s values increasing the discrepancy between ke,e and ke,m. The difference
also depends upon EGFR expression since increased expression promotes dimerization
and phosphorylation (Figure 2-2B). In Figure 2-2A and 2B, ke,e plateaus for arbitrarily
large ke,m values as other processes become rate-limiting.

Figure 2-2: Relationship between model (ke,m) and experimental (ke,e) rate constants
for EGFR endocytosis.
The relationship between ke,m and ke,e was determined for 10 ng/mL EGF and (A) kdp,s =
1.7, 17 and 170 min-1 and (B) EGFR expression of 5 × 103, 5 × 104 or 5 × 105 cell-1. For
a given ke,m, SE was computed and ke,e was calculated.

Because our model accounts for a small rate of EGFR degradation even in the
absence of EGF, we incorporated an EGFR synthesis rate SE to allow for steady initial
EGFR levels. SE and ke,m values were determined iteratively prior to model calculations.
Endosomal exit and sorting. Receptor exit from the endosome was modeled
using previously published parameters (97).
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The sorting of exiting species for

degradation and recycling was modeled by assuming that constant fractions were routed
to these pathways (97).

EGFR sorting fractions were taken from measurements in

mammary epithelial cells (97).
Parameter fitting. To determine the four unknown parameters, we first fit the
model to data gathered from parental HeLa cells, including the phosphorylation response
of EGFR Y1068 to 1 and 10 ng/mL EGF, 100 μM pervanadate, and EGF-gefitinib pulsechase (Figure S2-7). To refine our fits, we also included pulse-chase data from HeLa
cells with conditional expression of dominant negative dynamin (HeLa.DynK44A), which
inhibits EGFR endocytosis (Figure S2-7).

Measurements in cells with conditional

expression of wild-type dynamin (HeLa.DynWT) matched data from parental HeLa cells
and were not included to avoid biasing the regression. Time-courses were restricted to t
≤ 20 min to minimize potential effects of transcriptional regulation.

Because our

preliminary analysis revealed that data for the fraction of receptor phosphorylated would
constrain parameter estimates more than data for relative changes in phosphorylation
alone, we converted our immunoblot data to estimates of the percentage of EGFR
phosphorylated at Y1068 (%pEGFR) using immunoprecipitation-based measurements
(Figure S2-8).
Parameter fitting was accomplished using simulated annealing to minimize the
total error between model predictions and experimental data. For most data points, errors
were computed as the square of the difference between model prediction and the
experimental value divided by the magnitude of the experimental value. For pulse-chase
data points, a similar form was used, except that experimental and model values were
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normalized to their values at 8 min post EGF. This emphasized the fold-changes in
pEGFR signals observed in the pulse-chase experiments. The error associated with each
treatment (e.g., 1 ng/mL EGF) was computed as the sum of individual data point errors
divided by the number of points for that condition, and the total error was computed as
the sum of these treatment condition errors. The best-fit results are included in Table 2-1.
Sensitivity analysis. Model sensitivity to changes in parameters was computed by
increasing and decreasing the values in Table 2-1 by factors of 2, 10, and 100. To
compute raw measures of sensitivity, we summed the integrated differences between the
base model and the two perturbed outputs over time. To compare different perturbation
magnitudes, raw sensitivities for a given perturbation were reported as percentages of the
maximum.
Model scope. To aid computational efficiency, our model topology assumed all
dimer species to be symmetric (e.g., EGF binds both or neither EGFR monomers in a
dimer). To test if this simplification significantly affected our conclusions, we expanded
the model to allow for asymmetric ligand binding. This increased the number of species
from 52 to 119 and the number of reactions from 169 to 499, without changing the
number of parameters. We refit the unknown parameters and found that kdp,s and kdp,i
were nearly identical to the values found in the first fit (Table S2-2), although the dimer
uncoupling constants changed to accommodate the increased number of species. All
remaining calculations were based on the more compact model.
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Representative HeLa cell. Unless otherwise noted, calculations reflect 5 × 104
EGFR/cell (110) and ke,e = 0.13 min-1 (48). For HeLa.DynK44A cells, calculations reflect
ke,e = 0.01 min-1 (48).
Model implementation. Codes were generated and compiled using the Systems
Biology Toolbox 2 (SBT2) package for MATLAB (111). The simulannealbnd function
in the Global Optimization Toolbox was used to fit the model to experimental data.
Cell culture. HeLa cells were obtained from the American Type Culture
Collection and cultured in DMEM supplemented with 10% fetal bovine serum (FBS),
100 units/mL penicillin, 100 μg/mL streptomycin, and 1 mM L-glutamine. HeLa cells
conditionally expressing wild-type or dominant negative dynamin (HeLa.Dyn WT and
HeLa.DynK44A, respectively; Dr. Sandra Schmid, Scripps Research Institute, La Jolla,
CA) were cultured as described previously (48). Prior to lysis, cells were serum starved
in media containing 0.1% FBS for 15-20 hrs. All media components were purchased
from Invitrogen (Carlsbad, California, USA).
Western blotting. Cells in aspirated wells were washed with ice-cold PBS prior
to addition of a standard lysis buffer. The lysis buffer base (Invitrogen) contained 10 mM
Tris (pH 7.4), 100 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 20 mM sodium
pyrophosphate, 2 mM sodium orthovanadate, 1% Triton X-100, 10% glycerol, 0.1%
SDS, and 0.5% deoxycholate. This base was supplemented with 1 mM PMSF, additional
protease inhibitors (Sigma, St. Louis, MO, USA), and phosphatase inhibitors (Sigma).
Lysates were clarified by centrifugation at 13,200 rpm for 10 min at 4°C and assayed for
total protein concentration using the micro bicinchoninic acid assay (Thermo Scientific,
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Waltham, MA, USA).

Proteins were resolved by SDS-PAGE and transferred to

nitrocellulose membranes, which were blocked in Odyssey Blocking Buffer (LI-COR
Biosciences, Lincoln, NE, USA) for 1 hr before incubation with primary antibodies at
4°C overnight. Membranes were stripped with 0.2 M NaOH as needed. Blots were
imaged and analyzed using a LI-COR Odyssey Infrared Imaging System (LI-COR
Biosciences).
Immunoprecipitation. For immunoprecipitations (IPs), the lysis buffer base
(Cell Signaling Technology, Danvers, MA, USA) contained 20 mM Tris hydrochloride
(pH 7.5), 150 mM NaCl, 1 mM disodium ethylenediaminetetraacetate, 1 mM EGTA, 1%
Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 mM sodium
orthovanadate, and 1 μg/mL leupeptin. This base was supplemented with 1 mM PMSF,
other protease inhibitors (Sigma), and phosphatase inhibitors (Sigma). Lysates were
clarified and total protein concentrations determined as previously described. For each
sample, 200-400 μg of total protein was incubated with 20 μL of resuspended protein A
agarose beads conjugated to a pEGFR Y1068 antibody at 4°C overnight. Beads were resuspended in LDS sample buffer (Invitrogen, Carlsbad, CA, USA) and boiled for 10 min
prior to immunoblotting.
Calculation of percent phosphorylated EGFR. The percentage of total EGFR
phosphorylated at Y1068 (%pEGFR) was determined using two different methods. For 1
ng/mL EGF or pervanadate treatments, the amount of EGFR in a whole cell lysate was
compared to the amount of EGFR in a pEGFR Y1068 IP by immunoblotting. To
compare EGFR signals on an equal basis, IP signal intensities were corrected for capture
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efficiency (determined by comparison of the pEGFR Y1068 signal in the whole cell
lysate to the same signal in the capture). Serial dilutions of whole cell lysate were used to
establish linearity for the EGFR signal with protein amount and to correct the EGFR
signal intensity for a non-zero y-intercept (Figure S2-8). Linearity of the pEGFR Y1068
signal with protein amount over a range of signal intensities inclusive of those observed
was independently confirmed for the antibody dilution used to probe all western blots.
For experiments with 10 ng/mL EGF, immunoprecipitated pEGFR was not
efficiently recognized by the EGFR antibody we used throughout our studies (or by
several other EGFR antibodies we tried). This effect, which was very small for samples
treated with 1 ng/mL EGF or 100 μM pervanadate, probably resulted from EGFR
ubiquitination altering the ability of total EGFR antibodies to bind to cognate epitopes, an
effect for which corrective measures have been previously implemented (37).
Accordingly, we chose to instead measure the percentage of unphosphorylated EGFR for
samples treated with 10 ng/mL EGF. True total EGFR levels in whole cell lysates were
determined by chasing 10 ng/mL EGF with 4 M gefitinib for 45 min (Figure S2-8B, L1L3), which was shown in a separate experiment to allow the EGFR signal to reach a
higher steady value (data not shown) and which is consistent with previous studies where
inhibition

of

the

EGFR

kinase

resulted

in

EGFR

deubiquitination

(112).

Unphosphorylated EGFR was measured by first clearing pEGFR using a pEGFR Y1068
IP from whole cell lysates collected from cells treated with 10 ng/mL EGF for 4 min and
quantifying the remaining EGFR levels in the supernatant by western blot (Figure S2-8).
This approach worked well because the affinity of the EGFR antibody appeared to be
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unchanged for unphosphorylated EGFR. The ratio of the unphosphorylated EGFR signal
in the supernatant to the total EGFR signal in whole cell lysate from cells treated with 4
M gefitinib for 45 min allowed for estimation of the fraction of unphosphorylated
EGFR. Serial dilutions of the whole cell lysate from a single replicate were used to
establish linearity of EGFR and extracellular regulated kinase 1/2 (ERK) signals with
protein amount and to correct the appropriate signal intensities for non-zero y-intercepts.
ERK was used as the loading control for these blots, instead of actin, due to better
linearity of this signal at the higher total protein amounts needed for this method.
pEGFR timecourse data for EGF-treated samples. EGF timecourse data were
corrected for the disruption of EGFR antibody binding by determining pEGFR and EGFR
dynamics separately. To determine pEGFR dynamics, cells were treated with EGF, and
lysates were analyzed by immunoblotting (Figure S2-7). pEGFR levels were normalized
to actin and converted to a fold change with respect to a reference time point (4 min for
10 ng/mL and 20 min for 1 ng/mL). Corrected EGFR levels were determined via
immunoblot by treating parallel samples of cells with EGF for the same times and
chasing EGF at each time point with 4 M gefitinib for 45 min (Figure S2-7). These
samples were also analyzed by immunoblotting, and EGFR levels were normalized to
actin and converted to a fold change with respect to the same reference time point. Final
fold changes in pEGFR/EGFR were estimated by dividing the actin-normalized pEGFR
signal by the corrected, actin-normalized EGFR signal at each time point.
To correct EGF-gefitinib pulse-chase data, 8-min treatments of 1 or 10 ng/mL
EGF with or without a 45 min chase of 4 M gefitinib were performed (Figure S2-7).
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The ratio of EGFR/actin for the unchased and gefitinib-chased conditions was used to
correct the EGFR levels for t ≥ 8 min in the pulse-chase data.
We independently verified that the background intensities for both the EGFR and
actin signals were negligible compared to the average sample intensities, enabling the
non-background-corrected calculations as described.

For the higher protein

concentrations used in IPs, data were corrected using calibration curves, as described.
Reagents. Antibodies for EGFR (NeoMarkers, #MS-400-P0, Fremont, CA,
USA), pEGFR Y1068 (Epitomics, #1138 (IP) and #1727 (WB), Burlingame, CA, USA),
ERK (Cell Signaling Technologies, #4695, Beverly, MA, USA) and actin (Millipore,
#MAB1501, Billerica, MA, USA) were titrated to ensure linearity of signals with protein
amount on immunoblots. Infrared dye-conjugated secondary antibodies were purchased
from Rockland Immunochemicals (Gilbertsville, PA, USA). Pervanadate was prepared
by combining equimolar solutions of hydrogen peroxide and sodium orthovanadate at
room temperature for 15 min and used immediately after preparation. Gefitinib was
purchased from LC Laboratories (Woburn, MA, USA), and recombinant human EGF was
purchased from Peprotech (Rocky Hill, NJ, USA).
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2-4 RESULTS
EGFR phosphorylation dynamics in HeLa cells. Experimental measurements
of %pEGFR for 20 min treatment with 1 ng/mL EGF, 4 min treatment with 10 ng/mL
EGF, and 20 min treatment with 100 μM pervanadate were 11.6 ± 0.7%, 35.7 ± 6.8%,
and 13.1 ± 2.7%, respectively. These measurements were used to convert immunoblot
data to estimates of %pEGFR for all time points (Figure 2-3).

Figure 2-3: Model recapitulation of experimental EGFR phosphorylation
measurements.
The percentage of EGFR phosphorylated at Y1068 (%pEGFR) was measured for several
experimental conditions. Data are represented as averages ± s.e.m. and were fit to
determine four parameters, as described in Materials and Methods. Measurements and
model calculations were made for: (A) 1 or 10 ng/mL EGF treatment of parental HeLa
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cells; (B) 100 μM pervanadate (PV) treatment of parental HeLa cells (simulated by
setting kdp,s = kdp,i = 0 min-1); (C) 8 min treatment with 1 or 10 ng/mL EGF followed by 4
μM gefitinib (pulse-chase) of parental HeLa cells; and, (D) pulse-chase conditions as in
panel C in HeLa.DynK44A cells [ke,e = 0.01 min-1 (48)]. Note that in panels C and D t = 0
min corresponds to the time when the gefitinib chase was added to cells. Model results
indicated by dashed lines were generated using parameters from a fit to parental HeLa
data only (A-C), while results indicated by solid lines were generated using parameters
from a fit to all data (A-D). Model and experimental results corresponding to 1 ng/mL
EGF, 10 ng/mL EGF and PV are indicated by grey lines/open circles, black lines/filled
circles and black lines/open diamonds, respectively.

Treatment of parental HeLa cells with EGF or pervanadate resulted in timedependent induction of EGFR Y1068 phosphorylation (Figs. 3A,B and S1), with
estimated %pEGFR values as high as ~45% for a 20 min treatment with 10 ng/mL EGF.
In response to pervanadate, %pEGFR levels rose as high as ~15%, an effect which is
qualitatively consistent with previous results [e.g., (80)]. When parental cells were
treated for 8 min with 1 or 10 ng/mL EGF and then treated with 4 M gefitinib, pEGFR
levels returned to baseline levels within ~1 min after gefitinib addition (Figs. 3C and S1).
Similar trends in EGFR phosphorylation dynamics for such pulse-chase experiments have
been previously reported [e.g., (80)]. To directly probe EGFR dephosphorylation at the
plasma membrane, pulse-chase experiments were also performed in HeLa.DynK44A cells.
Even with impaired EGFR endocytosis, EGFR was dephosphorylated within ~1 min after
gefitinib addition (Figs. 3D and S1).
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Model fitting to experimental data. Parameter fitting revealed that data from
parental HeLa cells only were best recapitulated when kdp,i and kdp,s were of similar
magnitudes, with kdp,i > kdp,s (Table S2-3, entry for K44A PC removed). Even though
kdp,i was larger than kdp,s, the magnitude of kdp,s suggests significant regulation of EGFR
by PTPs at the plasma membrane. The fit results also suggest a difference in kdE,r and kd,r
which is larger than previously reported (87, 99), which is a consequence of topological
differences between our model and previous models. Using these fitted parameters, the
model recapitulated the EGFR phosphorylation data in parental cells reasonably well
(Figure 2-3A-C, dashed lines). Response to pervanadate was well captured by the model,
and, with the exception of the response to 10 ng/mL EGF at 4 min, recapitulation of data
for 10 ng/mL EGF (ligand-only and pulse-chase) was also generally good. The largest
discrepancies between model and experiment were observed for ligand-only and pulsechase kinetics for 1 ng/mL EGF, with the model underestimating the former and
overestimating the latter. Thus, the model could not completely reconcile the best-fit
PTP kinetics with the modest induction of EGFR phosphorylation for 1 ng/mL EGF.
Using parameters from fitting parental data only, the model predicted that EGFR
dephosphorylation would occur within ~2 min in pulse-chase experiments in
HeLa.DynK44A cells, which is slower than the rate observed experimentally (Figure 23D). To refine our parameters, we refit the model to data including the HeLa.DynK44A
pulse-chase data. Doing this, kdp,s increased to a value slightly larger than kdp,i (Table 21) and model agreement with HeLa.DynK44A pulse-chase data improved (Figure 2-3D,
solid black line) without altering recapitulation of data from parental HeLas (Figure 238

3A-C, solid lines). All remaining calculations use the refined model parameters (Table 21).
Variations in the fit results among replicate fits led to negligible variation in
model output. Thus, we reported parameters for the lowest error among fits for given
conditions.
Contributions of specific data and topological features to fitting results. We
further explored the fit results by examining variation in the total model error and errors
for individual experimental conditions for variations in kdp,s and kdp,i. The other two fitted
parameters were left as listed in Table 2-1 since the model was relatively insensitive to
changes in these (Figure S2-9).
As expected, added consideration of the HeLa.DynK44A pulse-chase data tightened
the domain in kdp,s/kdp,i parameter space in which the total error was minimized (Figure 24A,B). Agreement with data for response to EGFR alone was best for a kdp,i which was
lower than that found by regression against the complete data set (Figure 2-4C), while
agreement with pulse-chase data was best for a kdp,i which was larger than that found by
regression against all data (Figure 2-4D). Not surprisingly, optimal model agreement
with HeLa.DynK44A cell pulse-chase data alone required a kdp,s larger than that found for
regression against all data (Figure 2-4E). Interestingly, the HeLa.DynK44A cell pulsechase data also constrained kdp,i tightly, since this data includes an initial 8 min response
to EGF alone. Optimal model agreement with data from pervanadate (Figure 2-4F) was
achieved for kdp,s ~100 min-1 and higher, resulting from a need to explain increased
receptor phosphorylation when receptors were mainly at the cell surface. Interestingly,
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all data considered tended to push kdp,s to non-negligible values. It may seem somewhat
surprising, for example, that consideration of the EGF data alone should require a
substantial kdp,s. Because our model framework considers phosphorylation in the absence
of EGF, however, even explanation of data for response to EGF alone requires PTP
activity at the plasma membrane.

Figure 2-4: Effect of variation in surface (kdp,s) and interior (kdp,i) dephosphorylation
rate constants on model agreement with EGFR phosphorylation measurements.
Model error was calculated for ranges of kdp,s and kdp,i considering: (A) all data from
parental HeLa cells, (B) all data from parental and HeLa.DynK44A cells, (C) EGF
treatment in parental HeLa cells only, (D) EGF-gefitinib pulse-chase experiments in
parental HeLa cells only, (E) EGF-gefitinib pulse-chase experiments in HeLa.DynK44A
cells only, and (F) pervanadate treatment in parental HeLa cells only.
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For these

calculations, kdp,s and kdp,i were set prior to computing ke,e and SE. Red circles correspond
to error minima. To compare different plots on an equal basis, the scale was defined as
the log of the error divided by the log of the global error minimum.

The impact of different data used for regression was also assessed by refitting
parameters excluding various data (Table S2-3) or considering the various data
individually (Table S2-4). Excluding each type of data (e.g., EGF treatments only)
individually revealed that no single treatment condition was required for the conclusion
that dephosphorylation is rapid at the cell surface because each fit resulted in a kdp,s of
~100 min-1 (Table S2-3). Fitting to data for each treatment condition individually also
resulted in kdp,s values of at least ~100 min-1 for all cases (Table S2-4). kdp,i varied
significantly among these fits, indicating that consideration of multiple types of data are
required to tightly constrain this parameter.
To probe the impact of the phosphorylation-dependent endocytosis model, we
substituted the more common modeling assumption that ligand-occupancy governs
endocytosis. These fits also resulted in a substantial value of kdp,s, which was greater than
kdp,i in some cases (Table S2-5). Only when we eliminated receptor phosphorylation in
the absence of ligand and fit the model to data for response to ligand alone was kdp,i
significantly larger than kdp,s (Table S2-6).

To confirm that the ligand-independent

phosphorylation topology was not the only factor resulting in a kdp,s ≥ kdp,i, we refit the
parameters with added consideration of pulse-chase data, which resulted in a fitted kdp,s >
kdp,i. (Table S2-6).
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Sensitivity analysis. To identify parameters which exert control over key model
behaviors, we performed a sensitivity analysis for the simulation of a pulse-chase
experiment and the calculation of ke,e for 10 ng/mL EGF (Figure S2-9). Both analyses
identified parameters for EGF binding (kE,fs and kE,rs), EGFR dimerization at the cell
surface (kd,fs), phosphorylation in EGF-bound dimers (kcatE), and kdp,s as important model
parameters, consistent with the key roles played by EGFR phosphorylation (which is
promoted by ligand binding and dimerization) and dephosphorylation at the membrane.
Interestingly, the sensitivity of computing ke,e to changes in kdp,s (Figure S2-9A) is
consistent with the recently reported role of the receptor-like PTP DEP-1 in EGFR
internalization and degradation in HeLa cells (51). Pulse-chase dynamics were also
moderately sensitive to kdp,i (Figure S2-9B). Sensitivity to kdp,s and kdp,i suggests that
substantial dephosphorylation occurs before and after endocytosis for these conditions.
Predicted effects of PTP activity on ligand-mediated EGFR endocytosis. A
key model assumption is that only phosphorylated receptor species are endocytosed.
Since the fit suggested significant EGFR dephosphorylation at the membrane, and since
ke,e is somewhat sensitive to changes in kdp,s (Figure S2-9A), we used the model to predict
the effect of PTP activity on the rate of EGFR endocytosis. For a range of base kdp,s
values, SE and ke,m were first computed. The values of kdp,s and kdp,i were then set to 0
min-1, and ke,e was calculated as previously described (59). For all nominal kdp,s values,
ke,e increased when PTP activity was eliminated (Figure 2-5A, fold change in ke,e). The
predicted effect on ke,e increased as the base value of kdp,s increased because larger ke,m
values are required to maintain a constant base value of ke,e as the nominal kdp,s increases
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(Figure 2-5A, ke,m). For the parameters in Table 2-1, the model predicted a modest
increase in ke,e from the base value of 0.13 to 0.15 min-1 when PTP activity was
eliminated.

Figure 2-5: Predicted effect of dephosphorylation kinetics on EGF-mediated EGFR
endocytosis and EGFR phosphorylation inhibition.
(A) The predicted effect of eliminating all PTP activity on ke,e for 10 ng/mL EGF was
calculated as a function of kdp,s. Data are presented as a fold-change relative to the value
of ke,e prior to elimination of PTP activity (black line). Corresponding ke,m values are also
shown (grey line). (B) The effect of 5 min pretreatment with 10-3-102 μM gefitinib on
EGFR phosphorylation response to a 20 min treatment with 10 ng/mL EGF was
calculated. For each curve, model output was normalized to the pEGFR value predicted
without inhibitor. Predictions were made for the base model (no change to PTP activity)
and for elimination of PTP activity (at t = 0) at the plasma membrane, in the cell interior,
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and in both compartments. For each curve, ke,m was chosen to be consistent with a ke,e =
0.13 min-1.

Effects of PTP activity on EGFR inhibition. We also used the model to predict
the effect of eliminating PTP activity on the inhibition of EGFR phosphorylation by
gefitinib. For each scenario, ke,m was consistent with a ke,e = 0.13 min-1, and the effects of
10-3-102 μM gefitinib on EGFR phosphorylation response to 10 ng/mL EGF were
predicted (Figure 2-5B). The inhibition curves predicted for elimination of internal or
surface PTP activity were similar, with IC50 shifts from ~0.1 μM for the base case to ~0.3
μM for PTP elimination. The effect was slightly larger for surface-compartmentalized
PTPs at higher gefitinib concentrations because EGFR internalization is impeded by
gefitinib, resulting in surface-compartmentalized PTPs exerting greater influence.
Elimination of all PTP activity had a much larger predicted effect (IC50 shift from ~0.1 to
~2 M) due to a coupling of kinetic phenomena beyond the scope of this discussion.
Overall, these results suggest that EGFR inhibitor efficacy depends heavily upon the
magnitude and localization of PTP activity.
EGFR phosphate cycling.

Our results suggest that EGFR tyrosines cycle

between phosphorylated and unphosphorylated states more rapidly than is generally
appreciated. This is analogous to the well-known example of phosphofructokinase and
fructose-1,6-bisphosphatase and the so-called futile cycling process they mediate between
fructose-6-phosphate and fructose-1,6-bisphosphate (113). The term futile cycling refers
to a switching between states on a timescale smaller than other important process
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timescales.

Although this cycling is more rapid than necessary for signal output

magnitudes achievable with slower cycling, rapid cycling may result in key system
robustness qualities (92-95).

For EGFR, this cycling may also regulate receptor

endocytosis and pharmacological inhibition, as will be discussed.
Using the relevant phosphorylation and dephosphorylation rate constants, rates of
EGFR phosphate cycling were estimated for ligand-bound and -free EGFR at the
membrane and in the cell interior (Figure 2-6A). The estimated rate was highest (~1.5
cycles/min) for ligand-bound receptors at the cell surface because the kinetics of
phosphorylation and dephosphorylation are most rapid for that scenario.

We also

estimated dynamic rates of ATP consumption by EGFR for four EGF concentrations
(Figure 2-6B) and compared these to an estimate of ATP consumption for cultured cells
of 4 × 108 ATP·min-1·cell-1 (114). We thus estimated that EGFR phosphate cycling for a
single tyrosine represents ≤ 0.008% of cellular ATP consumption in a cell with 5 × 104
EGFR.
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Figure 2-6: Analysis of EGFR tyrosine phosphate cycling.
(A) Estimates of tyrosine phosphate cycling rates were made for EGF-occupied and unoccupied EGFR at the cell surface (S+E and S−E, respectively) and for EGF-occupied
and -unoccupied EGFR in the cell interior (I+E and I−E, respectively). (B) EGFR
phosphate flux was calculated by computing the total phosphorylation rate as a function
of time for treatment with 0 to 100 ng/mL EGF. (C and D) Steady-state phosphorylated
(% max pEGFR, solid lines) and unphosphorylated (% max upEGFR, dashed lines)
EGFR levels, reported as percentages of the maximum steady value for each curve, were
calculated for ke,m = 0 min-1, a range of EGFR levels, 1 ng/mL EGF, and (C) kdp,s = 10-4,
10-2, or 100 min-1 and (D) kd,fs = 10-5, 10-4, or 10-3 min-1.

We also explored analogies of our results with those of the well-known study of
phosphate cycling by Goldbeter and Koshland (94), who demonstrated that sensitivity to
changes in reaction velocities depends upon Michaelis-Menten-like constants for
phosphorylation and dephosphorylation.

While Goldbeter and Koshland analyzed a
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model where the enzyme and substrate were distinct species, EGFR is both an enzyme
and a substrate, which introduces an important topological difference. In addition, PTP
concentration is not specified in our model, since dephosphorylation is treated as a zeroth
order process. To explore model similarities, we varied the analog of their velocity V1 in
our model by changing EGFR expression and the analog of their dephosphorylation rate
constant k2 by changing our kdp,s and computed the EGFR phosphorylation response to 1
ng/mL EGF as a percent of the maximum phosphorylated EGFR level achieved for a
given parameter set (Figure 2-6C-D). Consistent with the general behavior described by
Goldbeter and Koshland, lowering kdp,s increased the sensitivity of steady EGFR
phosphorylation levels to changes in EGFR level (Figure 2-6C). Lowering the rate
constant for EGFR dimerization, an analog for lowering the a1 parameter of Goldbeter
and Koshland (94), decreased the sensitivity of steady EGFR phosphorylation levels to
changes in EGFR levels (Figure 2-6D). EGFR phosphorylation was not sensitive to
changes in the EGFR phosphorylation rate constant because the phosphorylation step is
not rate-limiting for the model as described by the parameters in Table 2-1 (Figure S210).
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2-5 DISCUSSION
Our results suggest that the EGFR phosphorylation dynamics we observed
experimentally are consistent with timescales for EGFR dephosphorylation at the plasma
membrane and in the cell interior which are smaller than the timescale for EGF-mediated
EGFR endocytosis. This result stands in stark contrast to the classical view of EGFR
phosphorylation dynamics wherein receptor phosphorylation occurs at the plasma
membrane and dephosphorylation occurs after endocytosis. Of course, the classical view
is generally consistent with the apparent timescale for receptor dephosphorylation
suggested by EGFR phosphorylation in response to EGFR ligands alone. Given that
most studies of EGFR phosphorylation dynamics probe response to ligands alone, it is
perhaps not surprising that this classical view of receptor phosphorylation is so pervasive.
While certain experiments in our study plainly revealed the importance of EGFR
dephosphorylation at the plasma membrane (e.g., experiments with HeLa.Dyn K44A cells),
the incorporation of certain novel model topological features revealed the same thing
when considering other data where the need for PTP activity was less obvious. For
example, substantial PTP activity in the membrane compartment is required to maintain
low basal levels of EGFR phosphorylation in a model which allows receptor
phosphorylation in the absence of ligand to proceed as rapidly as we observed with
pervanadate treatment.
The possibility that EGFR dephosphorylation may occur at different rates at the
plasma membrane and in the cell interior was explored in a previous computational study
(88), but the authors of that study concluded that ErbB receptor dephosphorylation
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occurred primarily in the cell interior for two different ErbB ligands. That study sought
to qualitatively reconcile model predictions with receptor phosphorylation response to
ligands only. There are also a number of topological differences between that model and
ours, among them that the previous model did not consider receptor phosphorylation in
the absence of ligand. All of these differences together likely explain the very different
conclusion reached in that study versus the conclusions of our study.
Our implementation of a phosphorylation-dependent internalization model (which
has been used in at least one previous study (98)), instead of a ligand occupancy model as
in other studies (87, 88, 97), is well supported by experimental data, as reviewed by
Sorkin and Goh (18). For example, mutation of key EGFR tyrosines reduced EGFmediated EGFR internalization rates in mouse fibroblasts, suggesting that tyrosine
phosphorylation is indeed required for efficient ligand-mediated EGFR endocytosis (18).
It should also be emphasized, however, that our particular implementation of
phosphorylation dependent receptor internalization is novel. Specifically, our iterative
calculation of ke,m values which lead to optimum model matching of experimentally
reported ke,e values is an important and unique way in which our model recapitulates
experimental data.
Since our studies concluded that substantial EGFR dephosphorylation occurs at
the plasma membrane, and since we have implemented a phosphorylation dependent
model for EGFR endocytosis, it was not surprising that the model predicted that PTP
activity at the plasma membrane may impede EGFR endocytosis (Figure 2-5A).
Interestingly, this model-predicted increase in ke,e is qualitatively consistent with the
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apparent effect of knockdown of the receptor-like PTP DEP-1 on EGFR internalization
observed recently in HeLa cells (51). We applied our model to estimate that Tarcic and
coworkers (51) observed a decrease in surface-localized EGFR in response to EGF
consistent with ke,e = 0.2 min-1 in their flow cytometry data for control cells and a threefold increase in ke,e with DEP-1 knockdown. Assuming DEP-1 accounts for all PTP
activity at the plasma membrane, our model predicts a three-fold increase in ke,e with a
kdp,s ~3 × 101 min-1 (Figure 2-5A), which is significantly larger than the best fit kdp,s
(Table 2-1). Of course, our model results represent the predicted effect of instantaneous
inhibition of PTP activity. It is possible that knockdown of DEP-1 resulted in an adaptive
response which amplified the effect of DEP-1 knockdown in the experiments of Tarcic et
al. (51). In addition, it is possible that the tendency of at least some EGFR antibodies to
not efficiently recognize pEGFR (noted in Materials and Methods) resulted in an effect
on EGFR levels which was more apparent than real in the data of Tarcic et al. (51).
Our model results regarding PTP activity at the plasma membrane were directly
tested through comparison of model predictions with pulse-chase experiments in
HeLa.DynK44A cells. While the model parameters fitted through consideration of parental
HeLa cell data only did a reasonable job of predicting the rate at which plasmamembrane-sequestered

receptors

were

dephosphorylated,

consideration

of

the

HeLa.DynK44A cell data in a refitting of the model aided in refining our parameter
estimates. In the future, it will be interesting and important to also directly test other
model predictions (e.g., the effects of PTP inhibition on EGFR pharmacological
inhibition) and to use such results to refine the model in a similar way.
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Another

particularly important aspect of the biochemistry we investigated which would be
important to understand more deeply is the extent to which PTP activity with respect to
EGFR is time-dependent for the various cell treatment conditions utilized in our study.
Surprisingly, very little has been reported on this subject. As far as we are aware, only
changes in the activity of the cytosolic PTP SHP2 in response to ligands including EGF
have been studied in any detail (115).
While our study focuses on receptor-level regulation, phosphatases have been
considered in some models of signaling processes distal to receptors. For example, the
models developed by Rapoport and coworkers (95) for generalized linear signaling
cascades demonstrated the role of phosphatases in setting the amplitude, duration, and
amplification of signaling responses to upstream changes in receptor activation. Our
model similarly points to a key role for PTPs in determining EGFR phosphorylation
amplitude and duration. Importantly, this regulation is revealed by our model to occur on
a timescale which is smaller than that for other important process timescales, including
the typical timescale for complete activation of MAP kinase cascades and receptor
trafficking. Incorporation of these new receptor-level considerations revealed by our
study in models including downstream cascades may help to more fully recapitulate
dynamic signaling data which spans the space from the receptor to key downstream
signaling intermediates.
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2-7 SUPPLEMENTAL MATERIAL
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Figure S2-7: Immunoblot results
Relative

levels

of

the

indicated

proteins

from

parental

HeLa

and

HeLa.DynWT/HeLa.DynK44A cell lysates were analyzed by immunoblotting following
treatment for the indicated times with (A) 1 or 10 ng/mL EGF, (B, F, G) 1 or 10 ng/mL
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EGF followed by 4 M gefitinib (INH), or (C) 100 μM pervanadate (PV). (D) To correct
for the disruption of EGFR antibody binding to pEGFR during immunoblotting, cells
were treated as in (A), but EGF was also chased with 4 M gefitinib for 45 min. (E, H, I)
To correct EGF-gefitinib pulse-chase data for the same disruption of EGFR antibody
binding, parallel samples of cells were treated for 8 min with the indicated concentrations
of EGF, and EGF was chased for the indicated times with 4 M gefitinib. Results for
biological triplicates are shown in panels E, H, and I, while all other panels show singlet
data representative of n = 3.
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Figure S2-8: Generating immunoprecipitation-based estimates of EGFR
phosphorylation percentages.
The percent of total EGFR phosphorylated at Y1068 was estimated for parental HeLa
cells treated with (A) 1 ng/mL EGF for 20 min, (B) 10 ng/mL EGF for 4 min, and (C) 100
μM pervanadate (PV) for 20 min. Lanes for triplicate samples contained whole cell
lysates (L1-L3), IP supernatants (S1-S3), or IP captures (C1-C3). Where provided, ratios
indicate dilution factors for lysates used to establish linearity of signal with protein
56

amount. In panel B, IP supernatants (S) and whole cell lysates (L) for a particular
replicate were not generated from the same whole cell lysate, as IP captures (C) and
whole cell lysates (L) were in panels A and C. In panel B, whole cell lysates (L) were
from cells treated with 4 M gefitinib for 45 min to accurately assess total EGFR levels,
while IP supernatants (S) were generated with whole cell lysates from cells that were not
treated with gefitinib in order to preserve pEGFR levels and allow for removal of pEGFR
by IP.
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Figure S2-9: Parameter sensitivity analysis.
The sensitivity of model predictions for (A) a ke,e value for 10 ng/mL EGF and (B) EGFinhibitor pulse-chase dynamics (8 min pulse with 10 ng/mL EGF with 2 min chase of 4
μM gefitinib) to changes in 23 model parameters were computed as described in
Materials and Methods.
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Figure 2-10: Effect of variation in kcatE on the sensitivity of steady EGFR
phosphorylation levels to changes in EGFR expression.
Steady-state phosphorylated (% max pEGFR) and unphosphorylated (% max upEGFR)
EGFR levels, reported as percentages of the maximum steady value for each curve, were
calculated for ke,m = 0 min-1, a range of EGFR levels, 1 ng/mL EGF, and a range of values
of the phosphorylation rate constant in the presence of EGF (kcatE). Solid and dashed
lines indicate % max pEGFR and % max upEGFR, respectively.

Table S2-2: Expanded model fit results.
parameter

value

kdp,s (min-1)

2.2 × 100

kdp,i (min-1)

3.5 × 100

kd,r (min-1)

1.4 × 104

kdE,r (min-1)

5.5 × 10-4
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Table S2-3: Parameter fit results generated for exclusion of different types of data
from the data set used for fitting.
parameter

EGF
removed

pervanadate
removed

pulse-chase
removed

K44A pulse-chase
removed

kdp,s (min-1)

1.5 × 100

1.6 × 100

2.0 × 100

1.0 × 100

kdp,i (min-1)

1.8 × 101

1.5 × 100

1.3 × 10-1

4.5 × 100

kd,r (min-1)

1.4 × 104

9.5 × 103

1.6 × 104

1.4 × 104

kdE,r (min-1)

1.0 × 10-10

1.0 × 10-10

1.0 × 10-10

1.0 × 10-10

Table S2-4: Parameter fit results generated by considering different types of data
exclusively.
parameter

EGF only

pervanadate
only

pulse-chase
only

K44A pulse-chase
only

kdp,s (min-1)

1.0 × 100

1.4 × 100

1.1 × 100

5.7 × 102

kdp,i (min-1)

1.0 × 10-1

1.1 × 103

8.3 × 100

8.5 × 10-1

kd,r (min-1)

1.0 × 104

1.5 × 104

1.0 × 104

5.1 × 103

kdE,r (min-1)

2.9 × 10-10

2.7 × 10-3

4.1 × 10-1

3.4 × 10-1

Table S2-5: Parameter fit results for a model of receptor internalization based upon
ligand occupancy.
parameter

all data

1 and 10 ng/mL
EGF only

1 ng/mL EGF
only

10 ng/mL EGF
only

kdp,s (min-1)

1.6 × 100

5.0 × 10-1

3.9 × 10-1

6.1 × 10-1

kdp,i (min-1)

1.8 × 100

1.0 × 10-5

1.0 × 10-5

1.2 × 100

kd,r (min-1)

1.4 × 104

9.9 × 103

1.0 × 104

1.0 × 104

kdE,r (min-1)

1.0 × 10-10

1.4 × 10-6

8.9 × 10-8

3.7 × 10-9
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Table S2-6: Parameter fit results for altered internalization topology.
10 ng/mL
EGF only

10 ng/mL
EGF only

10 ng/mL EGF
and pulse-chase

kdp,s (min-1)

occupancy-based
internalization
2.3 × 10-1

phosphorylation-based
internalization
6.5 × 10-2

phosphorylation-based
internalization
5.8 × 100

kdp,i (min-1)

3.5 × 100

3.7 × 100

9.4 × 10-1

kd,r (min-1)

9.8 × 103

1.0 × 104

1.0 × 104

kdE,r (min-1)

1.9 × 10-5

8.1 × 10-7

1.0 × 10-10

parameter

Fit results were generated with removal of model topological features allowing for
receptor phosphorylation in the absence of ligand. With that topological change made,
fits were generated for different assumptions regarding receptor endocytosis and for
consideration of different types of data.
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Chapter 3 : A Separation of Time Scales Enables EGFR
Multitasking

3-1 ABSTRACT
In the first few minutes following ligand binding, kinase activation, and initial
phosphorylation of cytoplasmic tyrosines, receptor tyrosine kinases initiate downstream
signaling, recruit endocytosis machinery, and are acted upon by protein tyrosine
phosphatases (PTPs).

How receptor phosphotyrosines participate in all of these

potentially competitive processes is not fully understood. Here, through development of
a novel mechanistic model trained against quantitative experimental measurements, we
show that for the epidermal growth factor receptor (EGFR) in HeLa cells this
multitasking is achieved in part through a separation of time scales for phosphotyrosinedependent processes. For example, despite the fact that EGFR is acted upon by PTPs at
the plasma membrane, PTP activity surprisingly does not regulate phosphorylationdependent EGFR endocytosis.

This apparent paradox was reconciled by the model

through the conclusion that recruitment of phosphorylated EGFR into clathrin-coated pits
occurs faster than EGFR regulation by PTPs, a result we validated experimentally.
Interestingly, another separation of time scales enables PTPs to regulate the association
of EGFR with the intracellular adapter GRB2, but in a way which again does not affect
ligand-mediated EGFR endocytosis but should regulate downstream signaling.

Our

model provides a new quantitative framework for understanding how differences in such
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time scales enable EGFR, and perhaps other receptors, to participate in a number of
competing phosphorylation-dependent processes, and provides predictive capability for
understanding how the balance of these time scales may be tipped in a cell-type specific
manner to alter receptor-mediated processes.
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3-2 INTRODUCTION
Intracellular adapter protein binding to C-terminal phosphotyrosines on receptor
tyrosine kinases (RTKs) links receptors to downstream signaling pathways and receptor
endocytic trafficking processes. In many cases, RTKs initiate signaling and trafficking
over the same general time scale in response to ligand binding. For example, in HeLa
cells, epidermal growth factor receptor (EGFR) promotes substantial phosphorylation of
SHC and PI3K over the same 5-10 min time scale with which it internalizes in response
to EGF (46). Similarly, vascular endothelial growth factor (VEGF) and hepatocyte
growth factor each drive substantial ERK phosphorylation over the same time scales with
which these ligands drive VEGF receptor and c-Met internalization, respectively (116,
117). Recent evidence also suggests that phosphotyrosines on RTKs such as EGFR may
be dephosphorylated multiple times over the same general time scale with which
downstream signaling and trafficking are initiated (89). How receptors can multitask in
this way is not understood.
One possible explanation for receptor multitasking ability is that phosphotyrosinedependent processes occur sequentially. For example, receptor phosphotyrosines might
first initiate signaling from the plasma membrane, then drive endocytic trafficking, and
finally be dephosphorylated in the cell interior. Substantial evidence argues against this
model, including the finding that receptors such as EGFR are readily dephosphorylated at
the plasma membrane (80, 89). Alternatively, a division of labor might exist among
receptor tyrosines such that each regulates a distinct phosphorylation-dependent process.
However, internalization (28, 118) and downstream signaling (119, 120) can be regulated
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by the same EGFR and c-MET tyrosines. These tyrosines are also regulated by protein
tyrosine phosphatases (PTPs), with EGFR dephosphorylation occurring with a time scale
that is small compared to that for receptor endocytosis (89, 121). Steric limitations may
also preclude multiple adapters from binding to an individual receptor cytoplasmic tail at
once (122). While a quantitative picture of how receptor phosphorylation-dependent
multitasking has yet to be presented, an understanding of how these processes occur
simultaneously in normal cells may provide important clues as to how they are perturbed
in disease.
A clue as to how multitasking might be achieved for receptors such as EGFR is
offered by growing appreciation that EGFR phosphorylation and phospho-dependent
processes are more transient than is generally appreciated. For example, rate constants
for GRB2-EGFR binding, which links EGFR to pathways such as ERK (119), have been
measured by analyzing time-lapse fluorescence microscopy (123) and are consistent with
GRB2-EGFR association occurring less than one second after EGFR phosphorylation
(for 100 nM GRB2 (85)).

Rate constants suggesting similarly rapid binding and

unbinding have also been quantified for p85 SH2 domain binding to IRS-1
phosphopeptides using Biacore (124) and estimated computationally from data gathered
from A431 cells for EGFR binding to SHC, PLCγ1, STAT5 and GRB2 (122). Thus,
even with receptor regulation by PTPs prior to endocytosis (89), the speeds of various
binding and unbinding processes, and relative differences among those speeds, may be
key to the ability of RTKs to multitask.
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Here, we explore the quantitative basis for receptor multitasking using EGFR as a
model system. We developed a novel mechanistic model of EGFR phosphorylation,
dephosphorylation, adapter association, recruitment to endocytic pits, and internalization,
based on the topology shown in Figure 3-1. We used this model to interpret and predict
quantitative measurements of EGFR endocytosis, EGFR binding to adapter proteins, and
EGFR phosphorylation, with or without perturbation of PTP activity. We found that a
separation of time scales for phospho-dependent processes explains EGFR’s ability to
participate in several competitive processes in the first few minutes after addition of
exogenous EGF to HeLa cells. For example, while EGFR is acted upon by PTPs at the
plasma membrane, PTPs do not regulate phosphorylation-dependent EGFR endocytosis.
The model reconciled these observations by finding that receptor recruitment into
clathrin-coated pits occurs faster than PTP regulation of EGFR, a result we validated
experimentally. At the same time, GRB2 binding to EGFR is highly influenced by PTP
regulation of EGFR, but in a way which does not impact EGFR endocytosis. Our study
also finds that EGFR endocytosis regulation is resilient to changes of several-fold in the
expression of PTPs and SH2 domain-containing proteins which can compete for EGFR
phosphotyrosines that regulate receptor trafficking.
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Figure 3-1: Model topology.
The model topology includes three compartments: 1. cell surface, 2. endocytic pit, and 3.
endosome. All receptor processes considered are shown except for degradation and
recycling.

Within receptor dimers, the EGFR kinase domain (K) mediates

phosphorylation (P) of a representative tyrosine (Y).

In each compartment, EGFR

interacts with ligand (EGF), ATP (A), kinase inhibitor (I), protein tyrosine phosphatases
(PTP), and GRB2. A complete list of model parameters is given in Table 3-1.
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Table 3-1: Model parameters.
parameter

description

-1

-1

kE,fs (μM ·min )

EGF-EGFR association, surface

-1

kE,rs (min )

EGF-EGFR dissociation, surface
-1

kE,fi (endosome∙min )
-1

kE,ri (min )
-1

kA,f (μM ·min )

ATP-EGFR association

-1

kA,r (min )

ATP-EGFR dissociation
-1

ki,f (μM ·min )

inhibitor-EGFR association

-1

ki,r (min )

inhibitor-EGFR dissociation
-1

kG,f (cell·min )

GRB2-EGFR association

-1

kG,r (min )

GRB2-EGFR dissociation
-1

kd,fs (cell·min )

EGFR-EGFR association, surface
-1

kd,fi (endosome·min )
-1

kd,r (min )
-1

kdE,r (min )
-1

kcat (min )
-1

kcatE (min )
-1

kdp,s (min )
-1

kdp,i (min )
-1

kpit (min )
-1

ke,m (min )
-1

kex (min )
frE
fr

EGF-EGFR association, interior
EGF-EGFR dissociation, interior

-1

-1

value

EGFR-EGFR association, interior
EGFR-EGFR dissociation, unoccupied
EGFR-EGFR dissociation, EGF-occupied
phosphorylation, unoccupied dimer
phosphorylation, EGF-occupied dimer
dephosphorylation, surface
dephosphorylation, interior
pit recruitment
internalization
endosomal exit
recycle fraction, EGF-occupied
recycle fraction, unoccupied
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source

3.1×10

2

(125)

8.0×10

-1

KD (100)

3.1×10

-4

(100)

6.6×10

-1

(100)

1.0×10

5

(89)

1.1×10

7

(89)

1.0×10

5

(89)

2.1×10

2

(89)

3.3×10

-3

(123)

4.5×10

2

(123)

6.7×10

-4

calculated (89)

2.7×10

-3

calculated (89)

1.0×10

4

KD (126)

1.0×10

-1

(87)

2.7×10

0

(101)

1.3×10

1

(101)

4.9×10

0

fit

2.2×10

0

fit

4.4×10

1

fit

1.7×10

-1

calculated (89)

4.0×10

-2

(97)

5.0×10

-1

(97)

8.0×10

-1

(97)

RESULTS
Effects of PTP inhibition or knockdown on EGF-mediated EGFR
phosphorylation and endocytosis. We previously demonstrated in HeLa cells that
EGFR Y1068 is dephosphorylated at the plasma membrane with a time scale that is small
compared to that for EGF-mediated EGFR endocytosis (89).

Since EGFR

phosphorylation at Y1068 is required for EGFR endocytosis (52), we asked if EGFR
dephosphorylation might influence EGF-mediated EGFR endocytosis. HeLa cells were
treated for ≤ 5 min with EGF, with or without the PTP inhibitor pervanadate. As
expected, pervanadate significantly augmented EGFR phosphorylation (Figure 3-2A).
siRNA-mediated knockdown of the receptor-like PTP DEP1 also promoted EGFmediated EGFR phosphorylation (Figure 3-2B), consistent with a previous study (51).
Despite their effects on EGF-mediated EGFR phosphorylation, neither pervanadate nor
DEP1 knockdown altered the rate constant for EGF-mediated EGFR endocytosis (ke)
measured using 10 ng/mL 125I-EGF (Figure 3-2C). To verify the sensitivity of our assay,
we demonstrated that ke was reduced by lowering temperature or by hydrogen peroxide,
each of which is known to inhibit EGFR endocytosis (127, 128). Note that, in addition to
inhibiting PTPs, hydrogen peroxide also inhibits EGFR ubiquitination (127), which
presumably explains why it reduces ke. Pervanadate or DEP1 knockdown also failed to
promote EGF-mediated loss of EGFR from the cell surface as measured by flow
cytometry (Figure 3-2D and 2E). A lack of effect of pervanadate on ke was also observed
in three other cell lines (Figure S3-8A-C) and by immunofluorescence (Figure S3-8D and
E).
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Figure 3-2: Effects of phosphatases on EGFR phosphorylation and internalization.
(A) HeLa cells were treated with 10 ng/mL EGF with or without 100 μM pervanadate
(PV) for the indicated times. Lysates were analyzed by western blotting with antibodies
against indicated proteins (n=3). (B) HeLa cells transfected with control or DEP1targeting siRNA were treated with 10 ng/mL EGF for the indicated times. Lysates were
analyzed by western blotting with antibodies against indicated proteins (n=3). (C) The
rate constant for EGF-mediated EGFR endocytosis (ke) was measured in HeLa cells using
10 ng/mL 125I-EGF and reported as mean ± s.e.m. This was done for EGF alone at 37ºC,
with the addition of 100 μM pervanadate, with transfection of non-targeting control
siRNA, with transfection of DEP1-targeting siRNA, at 4°C, or with the addition of 1 mM
hydrogen peroxide (n=6 for all, except for 4ºC and hydrogen peroxide results where
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n=3). (D and E) HeLa cells were treated as in panels (A) or (B), respectively, except that
treatments were for 10 min. Relative EGFR levels were quantified by flow cytometry
(n=3).

It is unlikely that the absence of an effect of PTP inhibition or knockdown on ke
resulted from saturation of the clathrin-mediated endocytosis pathway, as pervanadate
also had no effect on ke measured using 1 ng/mL 125I-EGF (Figure S3-8F). Pretreatment
(as opposed to cotreatment) with pervanadate also failed to alter ke measured using 1 or
10 ng/mL

125

I-EGF (Figure S3-8F and S3-8G), as did treatment with sodium

orthovanadate (Figure S3-8H). Taken together, these data strongly suggest that PTPs
regulate EGFR phosphorylation at the cell surface without regulating EGFR endocytosis.
Model regression to experimental data. The model treats as unknowns the rate
constants

for

EGFR

dephosphorylation

at

the

cell

surface

(kdp,s),

EGFR

dephosphorylation in the cell interior (kdp,i), and translocation of GRB2-bound EGFR to
the pit compartment (kpit).

These parameters were determined by model regression

against quantitative measurements including: 1. our previous measurements of EGFR
phosphorylation response to an 8 min EGF pulse chased with 4 μM of the EGFR kinase
inhibitor gefitinib in parental HeLa cells (Figure 3-3A) and in HeLa cells expressing
dominant negative (K44A) dynamin (Figure 3-3B) (89); and 2. new measurements for the
effect of PTP inhibition on ke (Figure 3-2C). The best-fit parameters (Table 3-1) resulted
in good model recapitulation of the regression data (Figure 3-3A and 3-3B), including an
unchanged ke with PTP inhibition (Figure 3-3C). The best-fit model also accurately
predicted our previous data for the EGFR phosphorylation response to EGF (1 or 10
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ng/mL) or pervanadate (Figure 3-3D) for t < 20 min (89), which were not included in the
regression.

Figure 3-3: Assessment of model regression strategy.
To determine unknown model parameters, we considered data from our previous study
(89) in which (A) parental HeLa cells or (B) HeLa cells expressing K44A dynamin were
treated with the indicated EGF concentrations for 8 min and then chased with 4 μM
gefitinib. Times shown correspond to time after gefitinib addition. Best-fit results are
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shown as lines. (C) The best-fit parameters also allow the model to recapitulate the lack
of effect of pervanadate (PV) on ke measured with 10 ng/mL EGF (Figure 3-2C), which
was included in the regression. (D) Model predictions (lines) were compared to data for
the effect of EGF or 100 μM PV on EGFR phosphorylation (circles) from our previous
study (89). These data were not included in the model regression. (E) Model error was
calculated as a function of kdp,s and kpit with consideration of all regression data or all data
excluding that for the effect of PV on ke. Best-fit model parameters are shown as red
circles.

Model error. Plotting the model error as a function of kdp,s and kpit revealed that
kdp,s was well constrained by the regression but that only a lower limit of kpit was defined
by our approach (Figure 3-3E). Repeating this analysis with omission of data for the
effect of PTP inhibition on ke revealed that constraint of the lower bound of kpit was due
to our consideration of this data (Figure 3-3E).

The requirement that the model

recapitulate a ke = 0.146 min-1 also constrained kpit. In fact, unless kpit ≥ 1.5×100 min-1, pit
recruitment becomes rate-limiting and prevents recapitulation of experimentally
measured ke values.
Hypothesis for simultaneous EGFR dephosphorylation and internalization.
To understand the model’s ability to reconcile relatively rapid EGFR dephosphorylation
at the plasma membrane with a ke unchanged by PTP inhibition, we calculated
characteristic times for relevant EGFR processes (Figure 3-4A). The model suggests that
GRB2 binding, EGFR dephosphorylation, and EGFR pit recruitment all occur with
relatively small characteristic times (Figure 3-4A), consistent with the relatively short
residence time for receptors in the cell surface compartment.
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However, GRB2

association occurs with the highest maximum rate, followed by pit recruitment, and then
dephosphorylation (Figure 3-4A, inset), due to relatively rapid GRB2-EGFR association
(123). Comparison of compartmentalized EGFR dephosphorylation rates revealed that
nearly all dephosphorylation prior to internalization occurred for pit-localized receptors
(Figure 3-4B), suggesting that phosphorylated EGFR associates with GRB2 and moves to
the pit before substantial receptor dephosphorylation occurs.
receptors

internalize

regardless

of

phosphorylation

Because pit-associated

status,

as

demonstrated

experimentally (52) and as assumed by our model, EGFR dephosphorylation in the pit
does not influence ke. Consistent with this, the model predicted that PTP inhibition
would not significantly alter the characteristic times for EGFR phosphorylation prior to
pit recruitment, GRB2-EGFR binding prior to pit recruitment, EGFR recruitment to pits,
or EGFR internalization (Figure 3-4A). PTP inhibition was predicted to decrease the
characteristic times for phosphorylation in the pit and endosome because receptor
residence time in these compartments is sufficiently long for these characteristic times to
be influenced by phosphorylation/dephosphorylation cycling with normal PTP activity.
The model also suggests that large changes must be made to overcome the ability
of GRB2-EGFR binding to outcompete receptor dephosphorylation. Only when kdp,s is
increased by a factor ≥ 15 or when GRB2 concentration is reduced by a factor ≥ 10 is
PTP inhibition predicted to significantly increase ke (change of ~30% or more) (Figure 34C). In both scenarios, PTP-mediated control of ke can be eliminated by increasing kpit.
Model sensitivity analysis revealed that ke is insensitive to perturbations in kdp,s
and most sensitive to perturbations in ke,m, the model-determined internalization rate
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constant (Figure 3-4D). Conversely, model-predicted EGFR phosphorylation kinetics
during an EGF-inhibitor pulse-chase are sensitive to perturbations in numerous
parameters, including kdp,s and kdp,i (Figure 3-4E), supporting the notion that PTP activity
exerts control over EGFR phosphorylation at the plasma membrane without exerting
control over receptor endocytosis in the model.
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Figure 3-4: Model-based explanation for lack of effect of PTPs on EGFR
endocytosis.
(A) Characteristic times for various receptor processes were estimated from the model as
the time at which rates of the indicated processes were maximized in response to 10
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ng/mL EGF with (red) or without (black) simulated pervanadate (PV) treatment.
Maximum rates of a subset of processes are shown in the insert. (B) Using the model, the
rate of EGFR dephosphorylation within the indicated compartments was calculated as a
function of time after simulated addition of 10 ng/mL EGF. (C) The predicted fold
increase in the rate constant for EGF-mediated EGFR internalization with simulated PV
treatment (×ke) was calculated for variation in kpit and kdp,s or kpit and GRB2
concentration. Best-fit model parameters are shown as red circles. (D and E) The model
was used to quantify sensitivity of a simulated ke measurement or pulse-chase experiment
(as described for Figure 3-3A, with 10 ng/mL EGF) to the indicated perturbations in
model parameters.

Effects of PTP inhibition or knockdown on EGFR association with pit
proteins. By estimating time scales () for molecular processes based on the model
parameters, we find that the processes required for EGFR pit recruitment occur on time
scales (kG,f-1GRB2-1 = GRB2,on ~1 s and kpit-1 = pit ~1 s) that are smaller than the time scale
for EGFR dephosphorylation (kdp,s-1 = dp,s ~12 s). Thus, a testable model prediction is
that PTP inhibition affects GRB2-EGFR association for t > dp,s but without promoting
EGFR pit recruitment. To test this, we first measured the effect of PTP inhibition on
GRB2-EGFR association. Consistent with our predictions, PTP inhibition promoted
GRB2-EGFR association for times > dp,s (Figure 3-5A and 3-5B). We next measured
the effect of pervanadate on EGF-induced EGFR association with α-adaptin, a subunit of
the AP-2 complex which links EGFR to coated pits (129). EGF-induced α-adaptinEGFR association was unaffected by PTP inhibition, despite a pronounced effect on
EGFR phosphorylation (Figure 3-5C), in agreement with the model (Figure 3-5D and 377

5E). The model’s inability to quantitatively capture resting α-adaptin-EGFR association
is probably related to our method of estimation of this quantity (see Materials and
Methods).

We confirmed specificity of the α-adaptin antibody by siRNA-mediated

knockdown (Figure S3-9).

78

Figure 3-5: Effect of phosphatases on EGFR phosphorylation, adapter binding, and
pit recruitment.
(A) HeLa cells were treated with 10 ng/mL EGF either with or without 100 μM
pervanadate (PV) prior to lysis, GRB2 immunoprecipitation, and western blotting with
antibodies against indicated proteins (n=3). (B) Normalized data (circles) from (A) were
plotted versus model predictions (lines). (C) HeLa cells were treated with 10 ng/mL EGF
with or without 100 μM PV prior to lysis, EGFR/pEGFR immunoprecipitation, and
western blotting with antibodies against indicated proteins (n=3). (D and E) Normalized
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data (circles) from (C) for α-adaptin-EGFR association or EGFR phosphorylation are
shown with model predictions (lines). (F) HeLa cells transfected with control or DEP1targeted siRNA were treated with 10 ng/mL EGF prior to lysis, EGFR/pEGFR
immunoprecipitation, and western blotting with antibodies against indicated proteins
(n=4). (G) The model (lines) was fit to normalized data (circles) from (F) to determine a
new value for kdp,s. (H and I) The new value of kdp,s determined in (G) for DEP1
knockdown was used to simulate the effect of DEP1 knockdown on α-adaptin-EGFR
association with a comparison to normalized data (circles) and to predict the effect of
DEP1 knockdown on the rate constant for EGF-mediated EGFR internalization (ke).
Throughout the figure, data are normalized to the 5 min time point for EGF+PV or DEP1
knockdown and are shown as mean ± s.e.m.

We next tested the ability of specific PTPs to regulate EGFR pit recruitment by
knocking down DEP1 and assessing EGFR phosphorylation (Figure 3-5F), which model
regression determined was consistent with kdp,s = 2.4 min-1 (Figure 3-5G). For this kdp,s
versus the base value for control, the model predicted no change in α-adaptin-EGFR
association and no change in ke with DEP1 knockdown (Figure 3-5H and 3-5I,
respectively). We hypothesize that reduced induction of α-adaptin-EGFR association
compared to treatment with EGF alone was due to the siRNA transfection process.
Potential effects of PTP over-expression or intracellular competition between
SH2 domain-containing proteins on EGFR internalization. A previous study
identified suppressor of T-cell signaling 1 (STS1) as capable of dephosphorylating EGFR
and slowing EGFR internalizatio333n (130). To challenge our model, we first expressed
STS1 in HeLa cells (Figure 3-6A) and determined that the resulting reduction in
phosphorylation was consistent with kdp,s = 9.1 min-1 (Figure 3-6B). For this kdp,s versus
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the base value for control, the model predicted no change in ke, consistent with our
measurements (Figure 3-6C).

Raguz et al. (130) observed more substantial STS1-

mediated reduction in EGFR phosphorylation, which may explain why they observed
impaired EGFR internalization. Consistent with this notion, an ~10-fold reduction in
EGFR phosphorylation is predicted for a kdp,s = 687 min-1 (Figure 3-6B), and this kdp,s
results in a large predicted drop in ke (Figure 3-6C).

Figure 3-6: Potential effects of PTP over-expression or intracellular competition for
EGFR phosphotyrosines binding on EGFR endocytosis.
(A) Flag-tagged STS1 was stably expressed in HeLa cells. Control and STS1overexpressing HeLa cells were treated with 10 ng/mL EGF, and lysates were analyzed
by western blotting with antibodies against indicated proteins (n=7). (B) The model (red
line) was fit to data (circles) from (A) normalized to the 3 min time point for control to
determine a new value for kdp,s with STS1 expression. pEGFR was also predicted for a
kdp,s consistent with the data of Raguz et al. (green line) (130). (C) The values of kdp,s
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determined in (B) for our data (red bars) and the data of Raguz et al. (green bars) were
used to simulate the effect of STS1 expression on the EGF-mediated EGFR
internalization rate constant (ke) and compared to measurements of ke with 10 ng/mL 125IEGF (n=6). (D) The model was used to compute ke as a function of GRB2 expression and
kpit. The best-fit parameters are indicated by the red circle. (E) The effects of the
indicated expression levels of the GRB2-SH2 domain on ke and GRB2-EGFR association
(1 min after EGF addition) were predicted using the base model parameters for GRB2EGFR binding or with 100-fold reductions in the GRB2-EGFR on/off rate constants.

Competition for binding to EGFR phosphotyrosines between intracellular proteins
(e.g., STAT3 and GRB2 (131)) could also potentially regulate EGFR endocytosis by
antagonizing EGFR-GRB2 association. Since our model does not explicitly include a
GRB2-competitive species, we simulated the effect of one by reducing GRB2’s
concentration, which reduced ke (Figure 3-6D). This predicted sensitivity is reduced,
however, for increased kpit, which is important to consider given that our regression
constrains only the lower bound for kpit.
A previous study demonstrated that expression of the GRB2 SH2 domain (GRB2SH2) could reduce ke in HeLa cells by ~70% through competition with full-length GRB2
(28). According to the model, this would be consistent with a 90% reduction in GRB2EGFR association 1 min after EGF treatment. Even a 10% reduction in ke is predicted to
require a 40% decrease in GRB2-EGFR association.
competition between GRB2 (2.1×105 cell-1) and

Using a simple model of

GRB2-SH2, we estimated that

reductions of 40 or 90% in GRB2-EGFR association could be achieved by expression of
9.8×105 or 1.7×107 GRB2-SH2/cell, respectively (Figure 3-6E). EGFR internalization is
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able to remain relatively unchanged even in the presence of 5-fold higher GRB2-SH2
concentration because GRB2 and GRB2-SH2 on and off binding is so rapid that one of
the relatively rare endogenous GRB2 molecules binds EGFR within a relatively short
time after EGF addition and commits the receptor to pit recruitment. Consistent with
this, reducing the rate constants for GRB2-EGFR binding/unbinding by 100-fold without
changing GRB2-EGFR affinity, did not alter the predicted effect of GRB2-SH2
expression on GRB2-EGFR association, but significantly reduced the model-predicted ke
(Figure 3-6E).
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3-3 DISCUSSION
We sought to understand how EGFR is able to participate in multiple processes
that compete for the same EGFR phosphotyrosine in the first few minutes after
exogenous ligand addition. Our central finding is that EGFR multitasking is possible
because processes that depend upon the same phosphotyrosine occur with very different
time scales. We reached this conclusion by developing a novel computational model of
EGFR kinetics and using it to interpret our quantitative experimental measurements.
Of course, our computational model reflects an abstraction of EGFR biology
intended to capture the necessary regulatory aspects with sufficient resolution to answer
the question at hand. To minimize the number of model parameters, we did not explicitly
consider every process known to regulate EGFR endocytosis.

Rather, the model-

calculated rate of GRB2-bound EGFR pit recruitment encapsulates the known biological
processes that occur after EGFR-GRB2 binding, including EGFR-CBL association,
EGFR ubiquitination, and EGFR-pit protein binding (Figure 3-7A).

Assuming one

process is significantly slower than the others, that slowest process sets the pit
recruitment rate and determines kpit. Immunoprecipitation experiments in HeLa cells
demonstrate constitutive GRB2-CBL association (28), suggesting that GRB2-CBL
association is not rate-limiting. To our knowledge, the rate of CBL-mediated EGFR
ubiquitination has not been measured, but an upper bound time scale is suggested by the
measured EGFR-GRB2 dissociation rate (123).

Given that GRB2-mediated EGFR

association with CBL is important for EGFR internalization (31), CBL’s role in EGFR
internalization, which may be to mediate EGFR ubiquitination (132), must occur before
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GRB2 dissociates from EGFR. Thus, CBL-mediated EGFR ubiquitination would have to
occur on a time scale at least as small as the EGFR-GRB2 unbinding time scale (GRB2,off
= 0.1 s). This is significantly smaller than our estimate of the EGFR pit recruitment time
scale (pit ~1 s), suggesting that CBL-mediated EGFR ubiquitination also does not ratelimit EGFR pit recruitment. Thus, of the three biological processes coarse-grained by the
model pit recruitment step, we conclude that EGFR-pit protein association is rate-limiting
and that our estimate of kpit depends mainly upon the rate for this process.
Based on this conclusion and using time scales calculated from the model
parameters, we propose a timeline of the events that occur after initial tyrosine
phosphorylation for the average receptor (Figure 3-7B). Phosphorylated EGFR quickly
binds GRB2 (GRB2,on ~1 s), becomes ubiquitinated (ub < 0.1 s) and associated with a
coated pit (pit ~1 s) prior to dephosphorylation (dephos ~12 s).

Once EGFR is

ubiquitinated, EGFR dephosphorylation affects GRB2-EGFR association, but not pit
protein-EGFR association, as the latter does not require EGFR phosphorylation (33).
Based on these characteristic times, and an EGFR plasma membrane residence time of ~6
min (based on ke,m), a plasma membrane receptor cycles between phosphorylated and
unphosphorylated states > 18 times and GRB2-associated/unassociated states > 230 times
prior to internalization.
The best-fit model can also be used to predict the EGF-mediated compartmental
redistribution of total and phosphorylated EGFR versus time (Figure 3-7C and 3-7D). In
response to EGF, EGFR moves from the cell surface to the pit compartment within ~2
min, and becomes internalized with a time scale of ~5 min (Figure 3-7C). For the same
85

simulation and consistent with relatively rapid pit recruitment, phosphorylated EGFR
levels are higher in the pit compartment than in the cell surface compartment for t < 5
min, after which phosphorylated EGFR becomes concentrated in the cell interior (Figure
3-7D). These predictions are roughly consistent with observations of the distribution of
total or phosphorylated EGFR between the plasma membrane and the cell interior in
184A1 mammary epithelial cells (133).

With simulated PTP inhibition, EGFR

phosphorylation is increased without affecting total EGFR partitioning among
compartments (Figure 3-7C and 3-7D, respectively).
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Figure 3-7: Model coarse graining of pit recruitment process and model-based
inferences for EGFR multitasking.
(A) In living cells, EGF-EGFR binding promotes receptor dimerization, kinase (K)
activation, and phosphorylation (P) of cytoplasmic tyrosines (Y).

GRB2 mediates

EGFR-CBL association, leading to EGFR ubiquitination and association with pit
proteins. These processes are coarse-grained in the model such that phosphorylated
GRB2-bound EGFR translocates to the pit compartment in a process characterized by the
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rate constant kpit. (B) Using the model parameters, time scales for EGFR phosphorylation,
EGFR-GRB2 binding, and EGFR ubiquitination were estimated and used to construct an
approximate timeline of what happens to the typical EGFR after its first phosphorylation
in response to EGF binding. Durations of specific states (e.g., phosphorylation) were set
equal to the time scales for the appropriate reverse process (e.g., dephosphorylation), and
durations of various “off” states (shown in grey) were set equal to the time scale for the
appropriate forward process (e.g., phosphorylation). (C and D) The model was used to
calculate the amount of total EGFR or phospho-EGFR in the indicated cellular
compartments in response to 10 ng/mL EGF, with or without simulated pervanadate (PV)
treatment.

We note that our finding that DEP1 knockdown did not promote EGFR
internalization in HeLa cells conflicts with the findings of Tarcic et al. (51), despite our
repetition of their experimental method (Figure 3-2E). We have also previously noted
that the degree to which DEP1 knockdown appeared to promote EGFR internalization in
the experiments of Tarcic et al. would be consistent with an unusually large ke (89). One
potential explanation for this discrepancy is that the results of Tarcic et al. could have
been affected by disruption of antibody binding to activated EGFR, an effect for which
there is documented evidence (89).
Overall, our results emphasize the mechanistic importance of the emerging
paradigm that phosphorylation (and perhaps other post-translational modifications) and
protein-protein interactions cycle between “on” and “off” states with time scales that are
smaller than is generally appreciated.

For EGFR, and perhaps other receptors, this

enables the receptor to multitask by simultaneously initiating downstream signaling,
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internalizing, and being regulated by PTPs. Further study of this aspect of signaling
regulation would benefit greatly from improved techniques to measure events with
extremely small time scales.
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3-4 MATERIALS AND METHODS
Cell culture. HeLa cells (American Type Culture Collection, Manassas, Virginia,
USA) and 3T3 cells overexpressing PTP1B (Ben Neel, Ontario Cancer Institute) and
EGFR were cultured in DMEM. SKBR3 cells were cultured in RPMI. Media was
supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 μg/mL
streptomycin, and 1 mM L-glutamine (Life Technologies, Carlsbad, California, USA).
Prior to treatment with ligand, cells were serum-starved in media containing 0.1% FBS
for 15-20 hrs.
DEP1 knockdown. HeLa cells were transfected with SMARTpools of control or
DEP1-targetted siRNA (Dharmacon, Lafayette, CO, USA) using DharmaFECT1. For
internalization or immunoprecipitation experiments, 5 or 15 nM siRNA was used,
respectively, with the higher concentration for immunoprecipitation due to increased
plated cell density. DEP1 was efficiently knocked down in both cases (Figure S3-10).
STS1 expression. FLAG-tagged STS1 was amplified from a previously described
plasmid (Ivan Dikic, Institute of Biochemistry II) and inserted at the BamHI and NotI
sites of the pCDH vector. Lentiviral particles were prepared and target cells infected as
described previously (49). Cells were selected in 2 g/mL puromycin.
Radiolabeling and measurement of ke. Recombinant human EGF (Peprotech,
Rocky Hill, NJ, USA) was labeled with 125I (PerkinElmer, Waltham, MA, USA) and used
to measure EGF-mediated EGFR endocytosis rate constants (ke), as previously described
(48).
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Immunofluorescence. Immunofluorescence microscopy was performed as
described previously (2).
Flow cytometry for EGFR. Serum-starved cells were treated as indicated in
figures and removed from plates using cell dissociation buffer (Sigma-Aldrich, St Louis,
MO, USA), fixed in 2% paraformaldehyde, incubated with EGFR antibody overnight,
and incubated with Alexa Flour 488 conjugated secondary (Cell Signaling Technologies,
Danvers, MA, USA) for 30 min prior to analysis on a FACSCalibur cytometer. Data
were analyzed using FlowJo.
Western blotting. Cell lysates were prepared and analyzed by western blot as
described previously (89).
Immunoprecipitation. Immunoprecipitation (IP) of GRB2, EGFR, and pEGFR
was performed as previously described (89), with minor changes. For GRB2 IP, 30 μg of
total protein was used. For EGFR IP, lysis buffer was supplemented with 20 mM of the
deubiquitinase inhibitor N-ethylmaleimide to account for the possibility that
ubiquitination may influence EGFR-pit protein association (132). 100 μg of total protein
was added to beads that had been separately conjugated to EGFR or pEGFR Y1068
antibodies and pooled.
Other reagents. Antibodies were purchased against EGFR (NeoMarkers, #MS400-P0 (WB and IP), #MS-311-P0 (flow cytometry), Fremont, CA, USA), pEGFR
Y1068 (Epitomics, #1138 (IP) and #1727 (WB), Burlingame, CA, USA), ERK (Cell
Signaling Technologies, #4695 (WB)), DEP1 (R&D Systems, #MAB1934 (WB),
Minneapolis, MN, USA), α-adaptin1/2 (Santa Cruz Biotechnology, #SC10761) and
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GRB2 (Santa Cruz Biotechnology, #SC255). Infrared dye-conjugated secondary
antibodies were purchased from Rockland Immunochemicals (Gilbertsville, PA, USA).
Pervanadate was prepared as described previously (89).
Model topology and overview. The model considers three compartments for
EGFR: cell surface, endocytic pit, and endosome. In each compartment, reactions are
included for the binding of ligand, ATP, and kinase inhibitor to the receptor, receptor
dimerization, receptor phosphorylation, receptor dephosphorylation, and binding of the
phosphorylated receptor to GRB2 (Figure 3-1). A complete parameter list is provided in
Table 3-1. Differential equations describing the mass action kinetics of these processes
were solved using the Systems Biology Toolbox 2 (111).
EGFR dimers. To limit the number of species, we assumed that receptor
dimerization occurs only between identical monomers (e.g., ATP-bound EGFR only
dimerizes with ATP-bound EGFR), as we previously assumed (89). When applied to
ligand occupancy, this assumption led to irreconcilable differences in EGFR
phosphorylation between the model and data at early times. Thus, we included reactions
for the formation of dimers which were asymmetric in ligand occupancy, consistent with
recent experimental findings (134).
EGFR phosphorylation and dephosphorylation. EGFR phosphorylation within
ATP-bound dimers was assumed to occur at a single representative EGFR tyrosine that
controls GRB2 recruitment and endocytosis, as in our previous work (89).

EGFR

dephosphorylation was modeled as a first-order process with respect to phosphorylated
species not bound with GRB2 within cell surface and pit (kdp,s) and endosome
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compartments (kdp,i).

Note that EGFR dephosphorylation in coated pits has been

documented (52). Pervanadate treatment was simulated by setting kdp,s = kdp,i = 0 min-1.
EGFR trafficking. GRB2-bound EGFR species were modeled as entering the pit
compartment (28) in a first-order rate process characterized by kpit. All pit-localized
EGFR species were treated as capable of internalizing (52) in a first-order rate process
characterized by ke,m, which was determined iteratively as previously described (89), such
that the simulated experimentally determined ke = 0.146 min-1 (Figure 3-2C, “EGF
37°C”). EGFR degradation and recycling were incorporated as previously described
(97).
EGFR-adaptin association. To estimate α-adaptin-EGFR association, we
assumed that each receptor localized to the pit and endosomal compartments was
associated with an α-adaptin molecule, consistent with previous findings (129).
Parameter fitting. kdp,s, kdp,i, and kpit were determined using a simulated
annealing algorithm to minimize model error. Error at each time point was calculated as
the square of the difference between model and experimental values divided by the
experimental value. This calculation was made for all time points, and the sum was
normalized by the number of time points. Error associated with EGFR internalization
data was weighted more heavily than the individual errors associated with pulse-chase
kinetics because more conditions were explored for the pulse-chase experiments. The
model was fit to the data 25 times. For the 16 fits with the smallest error, there were only
small variations in kdp,s, kdp,i, and kpit. We selected the parameter set with the lowest kpit,
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in recognition of the fact that the model error structure provided only a lower bound for
kpit (Figure 3-3E).
Sensitivity. Model sensitivity to perturbations in parameters was computed as
described previously (89).
Representative HeLa cell. Simulations assumed 5×104 EGFR/cell (110), 2.1×105
GRB2/cell (85), and 1 mM ATP (102), unless noted otherwise.
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3-6 SUPPLEMENTAL MATERIAL

Figure S3-8: Effects of PTP inhibitors on EGF-mediated EGFR internalization.
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The rate constant for EGF-mediated EGFR endocytosis (ke) was measured using 10
ng/mL

125

I-EGF alone or with 100 μM pervanadate (PV) in (A) H3255 cells (n=3), (B)

SKBR3 cells (n=3), or (C) 3T3 cells (n=3). (D) 3T3 cells were left untreated, treated with
10 ng/mL EGF for 15 min, or treated with 10 ng/mL EGF and 100 μM PV for 15 min
before cells were fixed and prepared for immunofluorescence measurements with
staining against indicated targets. (E) HeLa cells were left untreated, treated with 10
ng/mL EGF for 20 min, or treated with 10 ng/mL EGF and 100 μM PV for 20 min before
EGFR and DNA were visualized by immunofluorescence. (F) ke was measured in HeLa
cells using 1 ng/mL 125I-EGF alone, with 100 μM PV, or with 100 μM PV after a 5 min
100 μM PV pretreatment (n=3). (G) ke was measured in HeLa cells using 10 ng/mL 125IEGF after a 20 min pretreatment with serum free media (SFM) or using 10 ng/mL

125

I-

EGF with 100 μM PV after a 20 min pretreatment with 100 μM PV. (H) ke was measured
using 10 ng/mL

125

I-EGF with or without 1 mM sodium orthovanadate (SOV). All ke

values are shown as mean ± s.e.m.
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Figure S3-9: α-adaptin antibody validation.
HeLa cells were transfected with control or α-adaptin-targeted siRNA, transfected again
24 hrs later, and then treated 48 hrs after the second transfection with 100 ng/mL EGF for
15 min before lysis and immunoprecipitation (IP) of EGFR/pEGFR.

Lysates were

analyzed by western blotting with antibodies against indicated proteins (n=3).
Knockdown of α-adaptin was verified in whole cell lysates (WCL), EGFR/pEGFR
immunoprecipitations (IP: EGFR/pEGFR) and immunoprecipitation supernatants (IP
Sup.).

Figure S3-10: siRNA-mediated DEP1 knockdown.
HeLa cells were transfected with (A) 15 nM or (B) 5 nM of control or DEP1-targeted
siRNA 48 hrs prior to analysis by western blotting with antibodies against indicated
proteins (n=3).
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Chapter 4 : Identification of Determinants of EGFR-Targeted
Therapeutic Efficacy Using Computational Modeling

4-1 ABSTRACT
For decades, clinicians have attempted to antagonize aberrant growth factor
receptor-mediated signaling in cancer using antibodies and small-molecule inhibitors.
Significant dose-response variability is observed for these drugs among cells and tumors
even in the absence of receptor mutations, but the basis for this is not fully understood.
Using the epidermal growth factor receptor (EGFR) as a model system, we implemented
a computational analysis of EGFR tyrosine phosphorylation dynamics to identify factors
that determine the efficacy of the EGFR-targeted kinase inhibitor gefitinib and the ligandcompetitive monoclonal antibody cetuximab. Our results: 1. identify different kinetic
processes as preferentially controlling the efficacy of gefitinib versus cetuximab; 2.
suggest that the efficacy of gefitinib and cetuximab may be favored by the expression of
certain naturally expressed EGFR ligands versus others; and 3. suggest new therapeutic
design principles.

For example, the model predicts that

gefitinib efficacy is

preferentially sensitive to perturbations in the activity of protein tyrosine phosphatases
(PTPs) regulating EGFR, but that cetuximab efficacy is preferentially sensitive to
perturbations in ligand binding kinetics, suggesting that cell-to-cell variation in PTP or
ligand expression could underlie heterogeneous cellular responses to

gefitinib or

cetuximab, respectively. Our results also highlight that kinetic considerations beyond
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those reflected by equilibrium affinities determine therapeutic efficacy. For constant
gefitinib binding affinity, decreasing rates of gefitinib binding and unbinding is predicted
to promote efficacy by increasing the time scale for which the receptor must remain
unphosphorylated.

Conversely, for constant cetuximab binding affinity, decreasing

antibody binding and unbinding rates impairs efficacy as cetuximab is increasingly outcompeted by ligand.

By integrating these considerations, the model also identifies

minimum concentrations of gefitinib and cetuximab that can be combined to maximally
reduce receptor phosphorylation.
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4-2 INTRODUCTION
In many cancers, aberrant signaling initiated by receptor tyrosine kinases (RTKs)
such as the epidermal growth factor receptor (EGFR) is a key driver of disease. For
several decades, oncologists have tried to leverage this knowledge by treating patients
with small molecule inhibitors or monoclonal antibodies that antagonize RTK
phosphorylation by interfering with specific mechanistic steps in RTK function or simply
promote down-regulation of RTK expression.

For EGFR, the well-known kinase

inhibitors gefitinib and erlotinib compete with ATP for binding to the receptor and are
approved for the treatment of non-small cell lung carcinoma (NSCLC) and NSCLC and
pancreatic cancers, respectively (12, 135). The monoclonal antibody cetuximab, which
interferes with EGFR’s ability to bind ligands and dimerize, is approved for the treatment
of head and neck and colorectal cancers (136). Multiple trials are currently underway for
combining cetuximab and erlotinib for treating gastrointestinal, head and neck, non-small
cell lung, and colorectal cancers.
Substantial evidence from cell culture and patient data suggests that EGFRtargeted therapeutics are not uniformly effective. For example, one study demonstrated
that the amount of gefitinib, erlotinib, or cetuximab required to reduce EGFR
phosphorylation to basal levels varied by about 10-fold between the wild-type EGFRexpressing H1819 and H1299 cells (137).

Another study demonstrated that the

concentration of cetuximab or gefitinib required to reduce phosphorylated EGFR to basal
levels differed by roughly 5-fold in wild-type EGFR-expressing DiFi and A431 cells
(138). Neither study was able to conclude why this variation existed. Consistent with
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this, the inhibitor concentration required to reduce EGFR phosphorylation to halfmaximal (IC50) varied between ~2×101 nM in NR6 cells expressing relatively low and
relatively high amounts of EGFR (105) and ~7×101 nM in NIH3T3 cells over-expressing
EGFR (139). A fourth study identified expression of EGFR ligands as a predictor of
variations of at least roughly 10-fold in the concentrations of gefitinib and cetuximab
required to half-maximally inhibit cellular proliferation among wild-type EGFRexpressing NSCLC cells (140). Similar variations in response to therapeutics are also
seen in the clinic as indicated by a 17.2% response rate for erlotinib in EGFR mutation
negative NSCLC patients (11). Thus, experimental studies in general suggest that
processes other than EGFR mutational status may affect the efficacy of EGFR-targeted
therapeutics.
Computational modeling represents a useful approach for identifying processes
that may account for the differential therapeutic efficacy that can be observed. In fact,
multiple studies have employed these approaches to understand the cellular contexts
where EGFR-targeted therapeutics work and their mechanisms of action. For example,
mechanistic models concentrating on signaling processes downstream of EGFR have
explored the role of EGFR internalization (50), dual inhibition of EGFR and proteins
such as PLCγ (141), and basal phosphorylated AKT levels (142) in the efficacy of
EGFR-targeted therapeutics. Other computational studies have focused on processes that
directly involve EGFR, such as enzyme-inhibitor binding (143), MIG6-mediated
feedback regulation (144), and phosphorylation of multiple EGFR tyrosines (99), and
how these processes might influence targeted therapeutic efficacy. None of these studies
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have sought to quantitatively delineate the processes most important to the ability of a
therapeutic to mediate a reduction in EGFR phosphorylation. Identification and
exploration of these processes is paramount because their variation might account for the
differential effect of EGFR-targeted therapeutics observed in cell lines and in the clinic.
One candidate process is receptor dephosphorylation, which therapeutics rely upon to
remove EGFR phosphorylation and which we have shown occurs more rapidly than
previously assumed (89). A role for EGFR dephosphorylation in therapeutic efficacy is
supported by a review that argues for its importance in the context of kinase inhibitors
(90) and an experimental study which demonstrated that reduced expression of the
phosphatase PTPRS correlates with increased EGFR phosphorylation and reduced
EGFR-targeted therapeutic efficacy in head and neck squamous cell carcinoma (HNSCC)
patients (82).

EGFR internalization also influences the efficacy of EGFR-targeted

therapeutics (48, 145). Thus, multiple processes that involve EGFR directly have been
shown to influence therapeutic efficacy, arguing for more focused study of upstream
processes in the context of targeted therapeutics.
Here, we used a previously developed model of EGFR phosphorylation,
dephosphorylation and internalization to predict the efficacy of EGFR-targeted
therapeutics in mediating a reduction in EGFR phosphorylation.

We then used a

sensitivity analysis-based approach to quantify the relative contributions of receptor-level
processes to therapeutic efficacy at steady-state and as a function of time. We performed
our analysis for two EGFR-targeted therapeutics (gefitinib and cetuximab) and two
EGFR ligands (epidermal growth factor (EGF) and amphiregulin (AR)). We found that
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the processes that determine EGFR-targeted therapeutic efficacy vary between
therapeutic/ligand pairs and extend beyond processes involved in the competitive binding
of therapeutics to EGFR. For example, increased therapeutic concentrations are required
to reduce receptor phosphorylation in the context of EGF compared to AR due to the
slower ligand-receptor dissociation rate for EGF. Our steady-state sensitivity analyses
revealed that EGFR phosphorylation and dephosphorylation were preferentially
important determinants of gefitinib efficacy while EGFR trafficking processes were
preferentially important determinants of cetuximab efficacy. Our dynamic sensitivity
analyses identified EGFR dephosphorylation as an important process in the context of
both gefitinib and cetuximab. Lastly, our model predicts that co-treatment with gefitinib
and cetuximab would additively, but not synergistically, reduce EGFR phosphorylation in
the context of either EGFR ligand. We conclude that for each therapeutic/ligand pair
EGFR-targeted therapeutic efficacy is determined by processes in addition to those that
control competitive therapeutic binding to EGFR. Based on this, we hypothesize that
variation in the clinical response to cancer therapeutics may be at least partially explained
by variation in the EGFR-level processes identified by this study.
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Figure 4-1: Model topology of processes leading to EGFR phosphorylation and
therapeutic inhibition of this process.
(A) Ligand (L) and cetuximab (C) compete for binding to the EGFR extracellular domain
while ATP (A) and gefitinib (G) compete for binding to the EGFR kinase domain (K).
Ligand binding promotes EGFR dimerization and ATP-dependent phosphorylation of
cytoplasmic tyrosines (Y) which link the receptor to adapter proteins. EGFR-adapter
binding permits recruitment of EGFR to coated pits from which EGFR is internalized.
(B) From a dimerized phosphorylated state, gefitinib and cetuximab mediate reductions
in EGFR phosphorylation through different mechanisms. Gefitinib competes for binding
to EGFR with ATP, which interrupts phosphorylation. Conversely, cetuximab cannot
bind phosphorylated receptors until they uncouple and dissociate from their ligands, at
which point cetuximab binding prevents ligand binding and dimerization.
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Table 4-1: Model parameters.
parameter

description

-1

-1

kL,fs (μM ·min )

ligand binding to EGFR, forward, surface/pit

-1

kL,rs (min )*

ligand binding to EGFR, reverse, surface/pit
-1

kL,fi (endosome∙min )
-1

kL,ri (min )*
-1

kA,f (μM ·min )

ATP binding to EGFR, forward

-1

kA,r (min )

ATP binding to EGFR, reverse
-1

kg,f (μM ·min )

gefitinib binding to EGFR, forward

-1

kg,r (min )
-1

gefitinib binding to EGFR, reverse
-1

kc,f (μM ·min )

cetuximab binding to EGFR, forward

-1

kc,r (min )

cetuximab binding to EGFR, reverse
-1

kG2,f (cell·min )

GRB2 binding to EGFR, forward

-1

kG2,r (min )

GRB2 binding to EGFR, reverse
-1

kd,fs (cell·min )

EGFR dimerization, forward, surface/pit
-1

kd,fi (endosome·min )
-1

kd,r (min )
-1

kd,rL (min )
-1

kp (min )
-1

kp,L (min )
-1

kdp,s (min )
-1

kdp,i (min )

EGFR dimerization, reverse, unoccupied
EGFR dimerization, reverse, ligand-occupied
phosphorylation, unoccupied dimer
phosphorylation, ligand-occupied dimer
dephosphorylation, surface/pit
dephosphorylation, endosome

3.1×10

(125)

8.0×10

-1

KD (100)

3.1×10

-4

(100)

6.6×10

-1

(100)

1.0×10

5

(89)

1.1×10

7

(89)

1.0×10

5

(89)

2.1×10

2

(89)

1.3×10

1

(146)

6.6×10

-2

(146)

3.8×10

-4

(123)

4.6×10

2

(123)

6.7×10

-4

calculated (89)

2.7×10

-3

calculated (89)

1.0×10

4

KD (126)

1.0×10

-1

(87)

2.7×10

0

(101)

1.3×10

1

(101)

4.9×10

0

fit

2.2×10

0

fit

1

fit

EGFR recruitment to pit compartment

4.4×10

-1

EGFR internalization

varies

ki (min )
-1

kx (min )
fr

EGFR dimerization, forward, endosome

endosomal exit
recycle fraction, EGF-occupied
recycle fraction, unoccupied

source
2

-1

kp (min )

frE

ligand binding to EGFR, forward, endosome
ligand binding to EGF, reverse, endosome

-1

-1

value

calculated (89)

4.0×10

-2

(97)

5.0×10

-1

(97)

8.0×10

-1

(97)

*Values for EGF are shown. Dissociation rate constants for AR were equal to these values multiplied by
100.
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4-3 METHODS
Model topology. The computational model of EGFR phosphorylation,
dephosphorylation and internalization used in this study was described previously
(Monast and Lazzara, 2013), with the exception that kinetics for the binding of the
therapeutic antibody cetuximab to EGFR were added as described below. The model
considers three compartments (Figure 4-1A): 1. cell surface, 2. pit, and 3. endosome. In
each compartment, EGFR is permitted to reversibly bind ligand, ATP, gefitinib, and
another EGFR monomer (dimerization). Reversible EGFR-cetuximab binding occurs
only in the cell surface and pit compartments (discussed below). Receptor dimers may
bind and unbind ligand, ATP, and gefitinib. Dimerized, ATP-bound receptors undergo
receptor phosphorylation characterized by rate constants kp and kp,L depending on whether
the receptor dimer is unoccupied or occupied by ligand, respectively. Phosphorylated
receptors may be dephosphorylated or bind the adapter protein GRB2, which was
considered because of its role in initiating both signaling and internalization processes
(28, 119). Dephosphorylation occurs with different rate constants for EGFR in the cell
surface and pit compartments (kdp,s) compared to EGFR in the endosome compartment
(kdp,i).

Both rate constants take into account our recent finding that EGFR

dephosphorylation occurs with a time scale of < 1 min regardless of receptor localization
(89). GRB2-bound receptors in the cell surface compartment irreversibly translocate to
the pit compartment and all receptors in the pit compartment irreversibly translocate to
the endosome compartment regardless of phosphorylation status, consistent with
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experimental findings (28, 52). Model parameters describing these processes, and others
to be described below, are given in Table 1.
EGF and amphiregulin. EGF-EGFR binding constants were based on
experimental measurements (100, 147).

Amphiregulin was assumed to have a rate

constant for ligand dissociation from EGFR that was 100-fold higher than that for EGF
dissociation from EGFR, consistent with studies suggesting that AR compared to EGF: 1.
has a higher value of the ligand-receptor dissociation constant (KD) for binding to EGFR
(148); 2. is 50-300 times less potent in cellular growth assays (149), and 3. is less
efficient on a molar basis at promoting ligand-mediated EGFR phosphorylation,
ubiquitination, and association with CBL (150). The 100-fold increase in the ligand
dissociation rate constants was applied to ligand-receptor binding in the cell surface/pit
compartments and in the endosome compartment (kL,rs and kL,ri, respectively). LigandEGFR binding at these different cellular locations is characterized by different binding
parameters due to differences in pH (44, 45).
To compare EGF and AR, we considered: 1. a base EGF concentration (1.6 nM or
10 ng/mL), 2. an equimolar AR concentration (1.6 nM) and 3. an AR concentration
increased by 100-fold to correct for the assumed difference in ligand-receptor binding KD
between EGF and AR (160 nM).

Comparison on the basis of equimolar ligand

concentrations (1.6 nM EGF and AR) ensures similar ligand-EGFR association time
scales for the two ligands, but allows for receptor occupancy by ligand to vary due to the
difference in ligand-receptor KD. Comparison of the same EGF concentration with an
increased AR concentration corrects for the difference in ligand-receptor KD (1.6 nM
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EGF and 160 nM AR) between EGF and AR. However, this approach leads to more
rapid ligand-EGFR association in the context of AR compared to EGF.
Gefitinib and cetuximab. Gefitinib was assumed to be cell permeable and was
permitted to compete with ATP for EGFR binding regardless of EGFR localization. This
assumption is consistent with our published results demonstrating that gefitinib can
mediate a reduction in EGFR phosphorylation even after an 8 min, 1.6 nM EGF treatment
of HeLa cells which results in localization of roughly 50% of cellular EGFR to the cell
interior (89). In contrast, the monoclonal antibody cetuximab was assumed to bind only
EGFR monomers that were not ligand-bound and that were localized to the cell surface or
pit compartments. The assumption that cetuximab binds to EGFR monomers that are not
ligand-bound is based on a study suggesting that cetuximab binding to EGFR competes
with EGFR-ligand binding and EGFR dimerization (136). In the model, cetuximab-bound
species were permitted to internalize. However, cetuximab-EGFR dissociation was not
permitted in the cell interior due to issues with the ODE solver. Given that the EGFRcetuximab dissociation rate constant and the endosomal exit rate constant are similar in
magnitude (Table 1), this assumption should not significantly affect simulations. EGFRtherapeutic binding is summarized in Figure 4-1.
Comparing therapeutics. For comparisons of gefitinib and cetuximab that
required a fixed drug concentration, we assumed concentrations of 1 μM for both. This is
an appropriate basis for comparison because these concentrations are significantly greater
than the therapeutic-EGFR binding KD values, which are similar in magnitude (2.1 nM
for gefitinib, 5.2 nM for cetuximab (12, 146)).
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This eliminates the possibility of

differential therapeutic-receptor occupancy between cetuximab and gefitinib.

A

concentration of 1 μM is also consistent with achievable levels for both therapeutics in
vivo (7, 151, 152).
Inhibition curves and IC50 calculation. To quantify the ability of a therapeutic
to mediate a reduction in EGFR phosphorylation at steady-state, inhibition curves were
simulated by computing steady-state EGFR phosphorylation in the presence of ligand
over a range of therapeutic concentrations. EGFR degradation was not permitted in these
simulations because our model does not consider receptor synthesis and so this alteration
was necessary to reach a steady-state.

We defined the IC50 as the therapeutic

concentration at which steady EGFR phosphorylation was reduced to 50% of its value at
the lowest therapeutic concentration. Similar approaches have been used in experimental
studies (105). Note that there is at least one other definition for IC50. In classical enzyme
kinetics, IC50 is defined as the therapeutic concentration required to reduce the maximal
enzyme-mediated product formation rate by half (143).
Pulse-chase curves and t50 calculation. To quantify the ability of a therapeutic to
mediate a reduction in EGFR phosphorylation as a function of time, we performed
calculations in which we simulated a 5 min treatment of cells with ligands followed by a
chase with 1 μM therapeutic. We defined t50 as the time at which receptor
phosphorylation was reduced to 50% of the observed decrease between the time of
therapeutic addition and steady-state. Again, EGFR degradation was not permitted in
these simulations in order to reach a steady state.
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Local parameter sensitivity. To quantify the relative contributions of receptor
level processes to IC50 and t50 values, we computed the sensitivity of IC50 and t50 to
perturbations in most model parameters. The excess ligand approximation was applied
for concentrations of extracellular ligand (EGF or AR), therapeutic (cetuximab or
gefitinib), and ATP. Thus, these concentrations are constants and so could be included in
our sensitivity analysis.

However, perturbations in a particular concentration is

mathematically identical to perturbations in the respective rate constant for association
with EGFR, so these concentrations were not included separately in the sensitivity
analysis. Sensitivity was defined as the absolute value of the difference in the logarithm
of IC50 or t50 values between the perturbed and base parameter values, summed over all
perturbations. Perturbations in parameters were 10-fold and 0.1-fold.
Representative cell. Cells were assumed to express 5×104 EGFR (110), 2.1×105
GRB2 (85), and to internalize EGFR at a rate consistent with a measured EGFR
internalization rate constant of 0.146 min-1 (Chapter 3).

Consistency with this

internalization rate was enforced as described previously (89). The model was brought to
steady state in the absence of receptor degradation before the simulated addition of ligand
or therapeutic, as described previously (Chapter 3).
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4-4 RESULTS
Model-predicted inhibition of receptor phosphorylation by gefitinib or
cetuximab. We used the model to predict dose-response relationships for EGFR
phosphorylation as a function of gefitinib or cetuximab concentration (Figure 4-2). For
1.6 nM EGF, which corresponds to the commonly utilized experimental EGF
concentration of 10 ng/mL, or 1.6 nM AR, we simulated inhibition curves for each
ligand/drug pair by computing steady-state EGFR phosphorylation for the indicated range
of therapeutic concentrations (Figure 4-2A).

As shown in Figure 4-2B, for both

cetuximab and erlotinib, the predicted IC50 in the presence of EGF exceeds that for AR
by an order of magnitude. This occurs, in part, because for ligand concentrations of 1.6
nM the occupancy of receptors by EGF greatly exceeds that by AR due to the large
difference in KD. This reduces the driving force for dimerization (which has secondorder dependence on occupied receptors) and therefore reduces the IC50. For either
ligand, the predicted IC50 is significantly larger for gefitinib than cetuximab. This occurs,
in part, because gefitinib competes with abundant ATP (1 mM (102)), while cetuximab
competes with a much less abundant ligand. Additional factors contribute to these IC50
differences, as will be discussed.

To account for the difference in ligand-receptor

affinities, we repeated the previous analysis with a 100-fold increase in AR concentration
and the same EGF concentration (Figure 4-2C). That reduces, but does not eliminate, the
IC50 difference predicted for the two ligands.

Thus, additional factors beyond the

receptor occupancy by ligand explain the IC50 differences observed for EGF versus AR.
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Figure 4-2: Predicted therapeutic IC50 values.
(A) The amount of phosphorylated EGFR (pEGFR) was computed and normalized to the
maximum value for a range of therapeutic concentrations and the indicated
ligand/therapeutic pairs for 1.6 nM EGF or AR. (B) The drug concentration at which
steady-state receptor phosphorylation was reduced to half-maximal (IC50) was quantified
for each ligand/therapeutic pair in (A). (C and D) The calculations in (A) and (B),
respectively, were repeated for an 160 nM AR and compared to results for 1.6 nM EGF.

Effect of ligand and therapeutic binding kinetics on predicted IC50 values for
gefitinib and cetuximab. Given that differences in receptor occupancy by ligand do not
fully explain predicted differences in IC50 values of drugs with different ligands, we
hypothesized an IC50 dependence on kinetic factors beyond those reflected by
equilibrium binding affinities. We thus performed an analysis assuming constant binding
affinities of ligand (based on EGF) and drug (gefitinib or cetuximab) for the receptor, but
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varying the rate at which ligand and drug cycle on and off the receptor by multiplying the
rate constants for binding and unbinding by an equal “cycling factor” over a broad range
(Figure 4-3A and 4-3B). Faster cycling of ligand on and off the receptor is predicted to
decrease gefitinib and cetuximab IC50. For example, an increase in EGF cycling of 10fold reduces gefitinib or cetuximab IC50 by ~25% or 40%, respectively. This occurs
because of an effective reduction in the driving force for receptor phosphorylation as the
time scale for receptor occupancy by ligand becomes similar or small compared to the
time required for a ligand bound receptor to become phosphorylated. This is reflected in
the decrease in steady EGFR phosphorylation levels observed in the absence of any drug
with increasing ligand cycling factor (see the vertical bars at left in each panel in Figure
4-3). This allows the process of receptor dephosphorylation to play a more substantial
role and decreases the concentration of drug required to reduce receptor phosphorylation.
We note as well that the predicted sensitivity of IC50 to changes in the ligand cycling
factor is greater for cetuximab than for gefitinib. This occurs because of a generally
greater sensitivity of cetuximab’s efficacy to ligand binding kinetics, which will be
discussed further later. Note that IC50 values corresponding to 1.6 nM EGF and 160 nM
AR are shown in Figure 4-3 panels. 160 nM AR is equivalent to 1.6 nM EGF with a
ligand cycling factor of 102 because AR is modeled as having a dissociation constant
100-times larger than that of EGF and the 100-fold greater concentration of AR
compared to EGF leads to a 100-fold increase in AR’s association relative to EGF (since
both ligands are assumed to associate with EGFR with equally rapid kinetics).
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Figure 4-3: Effects of the rates of cycling of ligand or therapeutic binding and
unbinding.
(A-D) The logarithm of the drug concentration at which steady-state receptor
phosphorylation was reduced to half-maximal (IC50) was calculated for the indicated
fold-change in ligand or therapeutic cycling. Cycling was altered by multiplying ligandreceptor association and dissociation rate constants or drug-receptor association and
dissociation rate constants by the indicated ligand or therapeutic cycling factors,
respectively. These alterations did not affect the values of the appropriate dissociation
constant (KD). Ligand cycling rates corresponding to 1.6 nM EGF (filled yellow circle)
and 160 nM AR (filled white circle) are shown for no change in the therapeutic binding
parameters. This analysis was performed for (A) gefitinib and (B) cetuximab with the
base parameters. (C and D) The simulations in (A) and (B) were repeated but with (C) the
rate

constants

for

phosphorylation

within

ligand-bound

dimers

(kp,L)

and

dephosphorylation at the cell surface and in the cell interior (kdp,s and kdp,i, respectively)
reduced by 102-fold and (D) the rate constants for receptor dimerization at the cell surface
and in the cell interior (kd,fs and kd,fi, respectively) and uncoupling of ligand-bound
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receptor dimers (kd,rL) reduced by 103-fold, respectively. For (A-D), the percent of
phosphorylated EGFR (pEGFR) is shown in the bar to the left of each plot as a function
of the ligand cycling factor but in the absence of therapeutic.

Figures 4-3A and 4-3B also show predicted effects of changing cycling rates of
gefitinib or cetuximab, again for constant binding affinities. Sufficient decreases in
gefitinib cycling are predicted to augment gefitinib efficacy (Figure 4-3A), which is
qualitatively consistent with the observation that irreversible EGFR tyrosine kinase
inhibitors tend to be more effective than gefitinib (153). This effect arises because the
receptor is increasingly less likely to rephosphorylate as the time scale with which it
remains bound by gefitinib increases. In support of this reasoning, we find that the
sensitivity of IC50 to gefitinib cycling is reduced as the cycling of EGFR tyrosines
through phosphorylated and unphosphorylated states decreases (Figure 4-3C). In contrast
to gefitinib, the model predicts that cetuximab efficacy can be augmented by increasing
its cycling for a constant affinity (Figure 4-3B). This is observed because cetuximabEGFR binding occurs slowly relative to ligand-EGFR binding and EGFR dimerization.
Thus, increased rates of cetuximab cycling on and off the receptor allow cetuximabEGFR binding to occur before a receptor monomer becomes ligand-bound or dimerized.
Consistent with this reasoning, reducing the rate of ligand cycling reduces the predicted
effect of cetuximab cycling rate on cetuximab IC50 (Figure 4-3B). Furthermore, reducing
the rate constants for receptor dimerization and receptor uncoupling, which does not alter
the KD for receptor dimerization, virtually eliminated the ability of faster cetuximab
cycling to reduce IC50 (Figure 4-3D). This occurs because relatively slow dimerization
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and receptor uncoupling reduces the ability of ligand bound monomers to sequester
monomers that are not occupied by ligand into receptor dimers which are asymmetric in
the receptor ligand occupancy. Thus, this alteration generates increased unoccupied
receptor monomers, which are free to bind cetuximab efficiently without any alteration to
the cetuximab cycling rate.
IC50 sensitivity analysis. To identify other processes that determine therapeutic
efficacy, we repeated our IC50 calculations for a series of perturbations to individual
model parameters. This sensitivity analysis suggests that the IC50 for gefitinib in the
E ,g
presence of 1.6 nM EGF ( IC50
) is most sensitive to perturbations in the parameters for

ATP binding (kA,f and kA,r), gefitinib binding (kg,f and kg,r), EGFR phosphorylation within
ligand-bound dimers (kp,L), and EGFR dephosphorylation in the cell interior (kdp,i) (Figure
4-4A). Sensitivity to perturbations in ATP and gefitinib binding parameters is anticipated
because these parameters directly control the competition between ATP and gefitinib.
Sensitivity to kdp,i and kp,L arises because of the importance of cycles of receptor
dephosphorylation and rephosphorylation in setting steady receptor phosphorylation
levels. The relative insensitivity to perturbations in dephosphorylation of EGFR at the
cell surface (kdp,s) is observed because at steady-state and in the presence of 1.6 nM EGF
the model predicts that most phosphorylated EGFR is localized to the cell interior.
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Figure 4-4: Local sensitivity analysis to identify determinants of IC50 values for
gefitinib and cetuximab.
(A and B) Sensitivity of the therapeutic concentration at which steady-state receptor
phosphorylation is reduced to half-maximal (IC50) to perturbations of 10-fold in each of
the model parameters was computed for (A) gefitinib or (B) cetuximab. Sensitivities
were reported as the absolute value of the difference in the logarithm of the base IC50 and
the perturbed IC50 values and then normalized to the maximum. This analysis was
performed for 1.6 nM EGF, 1.6 nM AR, and 160 nM AR.

Repeating our analysis for 1.6 nM AR revealed that the gefitinib IC50 for that case
( IC50A, g ) is predicted to be sensitive to perturbations in the binding constants of ATP and
gefitinib but relatively insensitive to perturbations in kp,L and kdp,i. Relative to EGF, AR
reduces the driving force for dimer formation by reducing receptor occupancy. This
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impairs phosphate cycling which decreases sensitivity of IC50A, g to kp,L and kdp,i.
Increasing the AR concentration to 160 nM increases sensitivity of IC50A, g to perturbations
in the rate constants for ligand-receptor association and dissociation (kL,f and kL,r,
respectively), kp,L and kdp,i (Figure 4-4A), because this change increases dimer formation
by roughly 30-fold.
E ,c
The IC50 for cetuximab in the presence of 1.6 nM EGF ( IC50
) is predicted to be

most sensitive to perturbations in kL,f and kL,r, the rate constants for EGFR-cetuximab
binding (kc,f and kc,r), and the rate constant for EGFR internalization (ki) (Figure 4-4B).
Cetuximab competition with ligand for binding to EGFR results in sensitivity to
E ,c
cetuximab-EGFR and EGF-EGFR binding parameters. IC50
is sensitive to ki because

this parameter controls EGFR distribution between the cell surface and the cell interior
E ,g
E ,c
and cetuximab may only bind EGFR at the cell surface. Unlike IC50
, IC50
is not

sensitive to perturbations in kp,L, kdp,s or kdp,i due to the mechanisms by which gefitinib or
cetuximab reduce or prevent EGFR phosphorylation.

Gefitinib antagonizes EGFR

phosphorylation by directly interrupting phosphate cycling within dimers, while
cetuximab antagonizes EGFR phosphorylation by preventing receptor from even forming
E ,c
dimers (Figure 4-1B). IC50
is insensitive to kp,L, kdp,s and kdp,i because cetuximab can

only indirectly disrupt dimer-mediated phosphate cycling by preventing receptor
monomers from binding ligand and dimerizing. Thus, relatively slow dephosphorylation
process is sufficient to reduce receptor phosphorylation in this context.
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For 1.6 nM AR ( IC50A,c ), we observe sensitivity only to the cetuximab binding
parameters (Figure 4-4B). Relative insensitivity of IC50A,c to AR binding parameters is
because EGFR occupancy by AR is so low that perturbations in AR-receptor binding
E ,c
constants cannot promote AR-cetuximab competition for binding to EGFR. Unlike IC50

, IC50A,c is relatively insensitive to perturbations in ki, because impaired occupancy in the
context of this AR concentration promotes less EGFR internalization compared to EGF.
Increasing the AR concentration sensitizes IC50A,c to ligand binding and trafficking
E ,c
parameters, such that the sensitivity profiles for IC50A,c and IC50
were nearly identical

(Figure 4-4B), because this change increases receptor occupancy (which promotes ARcetuximab competition) and increases receptor dimer formation and phosphorylation
(which promotes receptor internalization).
Kinetics of therapeutic-mediated reduction in EGFR phosphorylation. As is
suggested by some of the results already discussed (e.g., Figure 4-3C), many of the
differences in the IC50 determinants between gefitinib and cetuximab arise because the
kinetics with which phosphorylated receptors become dephosphorylated (and then
eventually rephosphorylated) in the presence of the drugs directly influences IC50. At
least part of these differences are due to the differential abilities of these drugs to
antagonize the phosphorylation of receptors that have already bound ligand and become
phosphorylated.

The general dependence on these kinetics arises because of the

smallness of time scales for the reversible processes considered here relative to other
process time scales for the receptor (e.g., time scales for trafficking). Differences in
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those kinetics, which again give rise to differential IC50 behaviors for the two drugs, can
be observed in certain calculations of the kinetic response of EGFR phosphorylation to
specific perturbations. For example, the relative insensitivity of cetuximab IC50 to the
rate of dephosphorylation can be further understood by using the model to predict the
kinetics of receptor dephosphorylation that would be observed if cells were treated with
gefitinib or cetuximab after an initial pulse of EGFR ligand.

Figure 4-5: Predicted dynamics of ligand-therapeutic pulse-chase.
(A-D) The model was used to predict the percent of phosphorylated EGFR (pEGFR)
observed in response to a 5 min treatment with (A) 1.6 nM EGF, (B) 1.6 nM EGF, (C)
1.6 nM AR, or (D) 160 nM AR, followed by a chase with 1 μM gefitinib or cetuximab.
For (B), the internalization rate constant (ki) was set to zero at t = 0 min for all conditions
and the rate constants for ligand-receptor association and dissociation (kL,f and kL,r,
respectively) were increased by 102 for the cetuximab condition at t = 5 min.
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We thus simulated a 5 min pulse of EGF chased with 1 μM gefitinib or cetuximab
(Figure 4-5A). Gefitinib produces a much more rapid reduction in EGFR phosphorylation
than cetuximab as indicated by the time scales for gefitinib- and cetuximab-mediated
reduction in phosphorylated EGFR (t50), which we calculated to be 0.2 and 11 min,
respectively. These differences are explained by the notion that, in the presence of EGF,
cetuximab functions by locking the receptor into a state that is multiple mechanistic steps
away from EGFR phosphorylation and is in competition with the relatively slow
processes of dimer uncoupling and ligand dissociation (Figure 4-1B).

In contrast,

gefitinib locks the receptor into a state that is fewer mechanistic steps away from
phosphorylation and is only in competition with the relatively fast process of ATP
dissociation (Figure 4-1B). Thus, competition with slower processes that are additional
mechanistic steps away from phosphorylation results in slower cetuximab-mediated
reductions in phosphorylated EGFR compared to gefitinib. Consistent with this, reducing
EGFR internalization, to ensure access of EGFR to cetuximab, and increasing ligand
cycling, which also promotes dimer uncoupling, results in nearly identical t50 values
between gefitinib and cetuximab (Figure 4-5B).
For equimolar AR compared to EGF, receptor phosphorylation is significantly
lower prior to simulated addition of therapeutic due to decreased receptor occupancy by
ligand. However, the time scales for therapeutic-mediated reduction in EGFR
phosphorylation were similar for both therapeutics because AR cycles more rapidly
compared to EGF (Figure 4-5C). To account for differential occupancy, we repeated the
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pulse-chase simulation with 160 AR which increased receptor phosphorylation prior to
addition of therapeutic. Interestingly, time scales for therapeutic-mediated reduction in
EGFR phosphorylation remained similar due to the rapid ligand cycling in the context of
AR (Figure 4-5D). The reduction in EGFR phosphorylation is not complete in this
context because some receptors were internalized, and therefore unable to bind cetuximab
consistent with the need to impair internalization in order to force similarity in the t50
values (Figure 4-5B).
t50 sensitivity analysis.

In some cancer cells, mutated or over-expressed

oncoproteins may promote both pro- and anti-apoptotic signaling. According to the
theory of “oncogenic shock,” treatment of these cells with targeted therapeutics induces
cell death especially well in cases where apoptotic signaling persists longer than survival
signaling in response to therapeutic administration (154, 155). Thus, in addition to an
ability to reduce receptor phosphorylation at steady state, the functional ability of a
therapeutic to kill cancer cells may depend upon the time scale with which a therapeutic
reduces receptor phosphorylation. To identify the processes that influence this time
scale, we examined the sensitivity of t50 to perturbations in model parameters (Figure 46). For the sake of simplicity we will not discuss processes that have already been
discussed in the context of our steady-state sensitivity analysis because these processes
control dynamics for similar reasons.
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Figure 4-6: Local sensitivity analysis to identify determinants of the time scale with
which therapeutics lead to EGFR dephosphorylation.
(A and B) Sensitivity of the time after simulated therapeutic addition at which receptor
phosphorylation was reduced to half-maximal (t50) to perturbations of 10-fold in each of
the model parameters was computed for (A) gefitinib or (B) cetuximab. Sensitivities
were reported as the absolute value of the difference in the logarithm of the base t50 and
the perturbed t50 and then normalized to the maximum. This analysis was performed for
1.6 nM EGF, 1.6 nM AR, and 160 nM AR.

E ,g
For 1.6 nM EGF and gefitinib, t50 ( t50
) is sensitive to perturbations in kdp,s and

kdp,i, kp,L, kA,f and kA,r, kg,f and kg,r, ki, and parameters for GRB2-EGFR binding (kG2,f and
E ,g
kG2,r) (Figure 4-6A). t50
sensitivity to GRB2 binding and internalization parameters is

observed because GRB2 binding protects phosphotyrosines from dephosphorylation and
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the endosome compartment is characterized by different kinetics for processes involved
in receptor phosphorylation, respectively.

With 1.6 nM AR, gefitinib t50 ( t50A, g ) is

sensitive to kdp,s, kdp,i and kG2,f and kG2,r (Figure 4-6A).

E ,g
Compared to t50
, t50A, g is

insensitive to perturbations in kp,L because of impaired dimer formation. For 160 nM AR,
t50A, g is sensitive to perturbations to kdp,s, kA,f, kA,r, kg,f, and kg,r (Figure 4-6A). Even for

increased AR, dimer formation is impaired compared to EGF due to more rapid EGFRAR

dissociation. This leads

to

reduced

sensitivity to

phosphorylation

and

dephosphorylation processes because these processes are most important in the context of
phosphate cycling within receptors dimers.
E ,c
For cetuximab and 1.6 nM EGF, t50 ( t50
) is sensitive to kL,f and kL,r, kdp,s and kdp,i,

ki, and the rate constant for EGFR exit from the endosome compartment (kx) (Figure 4E ,c
E ,c
6B). Unlike IC50
, t50
is sensitive to perturbations in dephosphorylation parameters

because this process directly controls the rate at which cetuximab-mediated reduction in
EGFR phosphorylation occurs. Thus, in the context of oncogenic shock, kdp,s and kdp,i
E ,c
may be important determinants of cetuximab efficacy despite insensitivity of IC50
to

E ,c
perturbations in these parameters. t50
is sensitive to perturbations in ki and kx because

these parameters control EGFR distribution between the cell interior and cell surface,
where EGFR-cetuximab binding occurs. For 1.6 nM AR, cetuximab t50 ( t50A,c ) is sensitive
to kdp,s kc,f, kg,f, kg,r, the rate constant for EGFR dimerization in the cell interior (kd,fi), and
kdp,i (Figure 4-6B). Since AR-EGFR dissociation is more rapid than EGF-EGFR,
dephosphorylation instead of ligand dissociation rate-limits cetuximab-mediated
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reduction in EGFR phosphorylation. Sensitivity to perturbations in parameters that
influence unoccupied dimer phosphorylation (kd,fi and kdp,i) is because ligand-mediated
EGFR phosphorylation accounts for a smaller fraction of total EGFR phosphorylation.
Increasing the AR concentration to 160 nM leads to sensitivity of t50A,c to perturbations in
ligand-receptor

binding

parameters,

kc,f,

GRB2

binding

parameters,

kd,fi,

dephosphorylation parameters and ki. Increasing the AR concentration promotes receptor
internalization, which protects EGFR from cetuximab binding and increases the
importance of ki and kdp,i. Since 160 nM AR compared to 1.6 nM EGF promotes dimer
E ,c
uncoupling, t50A,c compared to t50
is more sensitive to kd,fi and kL,fi and kL,ri.

Predicted effects of gefitinib and cetuximab in combination. Results from the
IC50 and t50 sensitivity analyses clearly support the notion that gefitinib- and cetuximabmediated reductions in EGFR phosphorylation are achieved through different
mechanisms and controlled by different processes, suggesting that co-treatment might be
more effective than treatment with either therapeutic alone. To test this, we simulated
steady EGFR phosphorylation in the presence of varying concentrations of both
therapeutics. The model predicted that for a particular concentration of cetuximab or
gefitinib, addition of increasing concentrations of the other therapeutic further decreased
steady EGFR phosphorylation in the presence of 1.6 nM EGF, 1.6 nM AR, or 160 nM
AR (Figure 4-7A-C).
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Figure 4-7: Effects of gefitinib and cetuximab co-treatment.
(A-C) The model was used to predict the steady-state percent of phosphorylated EGFR
(pEGFR) as a function of cetuximab and gefitinib concentrations for (A) 1.6 nM EGF,
(B) 1.6 nM AR, or (C) 160 nM AR. (D-F) Synergy, defined as the reduction in receptor
phosphorylation resulting from co-treatment minus the reductions in receptor
phosphorylation following treatment with each therapeutic alone, was calculated as a
function of cetuximab and gefitinib concentrations for the same ligand concentrations as
in (A-C). (G-I) To estimate therapeutic efficiency, pEGFR (A-C), synergy (D-F) and the
logarithm of the sum of the drug concentrations were scaled to each range between 0 and
1 and then summed for all drug combinations. Based on this definition, therapeutic
efficiency is highest for low pEGFR, high synergy, and low amount of drug.
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To explore the possibility that co-treatment could produce synergistic effects, we
calculated the difference between the reduction in receptor phosphorylation resulting
from co-treatment and the sum of the reductions in phosphorylation achieved using each
therapeutic alone (Figure 4-7D-F). Co-treatment is not predicted to be synergistic, as
indicated by negative values for each therapeutic concentration combination. Negative
values result from at least some receptors being bound by both therapeutics. As expected,
our estimates of therapeutic synergy were highest for the lowest concentrations of
therapeutic, where the likelihood that a single EGFR species would be bound by both
therapeutics is lowest. The optimal co-treatment concentrations of each therapeutic would
be those that maximize synergy and minimize receptor phosphorylation while using the
least amount of drug. We estimated these regimes (Figure 4-7G-I) by scaling pEGFR
(Figure 4-7A-C), synergy (Figure 4-7D-F) and the logarithm of the total amount of drug
to range between 0 and 1 and then summing these quantities for each combination of
therapeutic. Based on this metric, therapeutic efficiency is highest for low phosphorylated
EGFR, high synergy, and low drug amount. For 1.6 nM EGF, therapeutic efficiency is
highest for ~103 nM cetuximab and an arbitrarily low concentration of gefitinib because
E ,c
E ,g
< IC50
(Figure 4-2A and 4-2B). Treatment with AR compared to EGF results in
IC50

larger maxima in therapeutic efficiency due to lower IC50s in this context (Figure 4-2A
and 4-2B). For all three ligand conditions, more therapeutic combinations that involve
E ,c
higher cetuximab than gefitinib concentrations exhibit high efficiency due to IC50
<

E ,g
and IC50A,c < IC50A, g (Figure 4-2).
IC50
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4-5 DISCUSSION
We quantified the receptor-level processes that contribute to the efficacy of the
EGFR-targeted therapeutics gefitinib and cetuximab in mediating reductions in EGFR
phosphorylation in the presence of the EGFR ligands EGF and AR. A key conclusion of
our study is that the antagonism of EGFR phosphorylation achieved by these therapeutics
is influenced not only by equilibrium considerations related to the binding affinities of
EGFR-targeted therapeutics and the molecules with which they compete, but also by
relative magnitudes of time scales of kinetic processes which compete with one another
to determine the ability of these therapeutics to reduce EGFR phosphorylation levels.
Several studies have noted differences among cell lines expressing wild-type
EGFR in the efficacy of EGFR-targeted therapeutics. For example, an IC50 based on a
metabolic assay performed after 3 days of treatment with gefitinib varied nearly 3 orders
of magnitude among head and neck squamous cell carcinoma (HNSCC) cell lines (156).
This study goes on to demonstrate that neither variation in the levels of proteins including
EGFR, AKT, and ERK nor the mutational status of EGFR correlated with variations in
IC50. Our results suggest that differential expression of other proteins might account for
this variation, including phosphatases and/or EGFR ligands. For IC50 measured in the
same way (except for a gefitinib treatment of 6 days), another study used microarray data
to determine a genetic signature for gefitinib sensitivity or resistance using a panel of 11
EGFR wild-type expressing NSCLC cell lines that varied in IC50 by 2 orders of
magnitude (157). Many genes were identified in this analysis. Notably, the phosphatase
PTPRG was upregulated in the context of resistance, which is consistent with our
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repeated identification of EGFR dephosphorylation as an important determinant of
gefitinib efficacy. While, to our knowledge, there has not been a study that examines the
ability of PTPRG to dephosphorylate EGFR, the general notion that phosphatases are
perturbed in multiple cancers is supported by numerous studies (15).

Interestingly,

another study demonstrates that the cell growth response to separate gefitinib and
cetuximab treatments varied by nearly an order of magnitude among cell lines expressing
wild-type EGFR in a manner that correlated with expression of AR (140). Consistent
with this, our analysis of determinants of gefitinib IC50 identified EGFR-AR association
(Figure 4-4A), which can be modulated by variation in AR concentration. It should be
noted that variability in EGFR phosphorylation after drug treatment has also been
observed among cell lines expressing wild-type EGFR, which is more applicable to our
simulated IC50s for reduction in EGFR phosphorylation. For example, the amount of
gefitinib and cetuximab, separately, required to reduce EGFR phosphorylation can vary
as much as 10-fold between H1819 and H1299 cells (137) and 5-fold in DiFi and A431
cells (138). While the processes that account for this variation have not been identified,
our work provides strong evidence for multiple candidates.
In addition to the processes already mentioned above, our study suggests that
variation in therapeutic-receptor binding and EGFR internalization can affect therapeutic
efficacy. Interestingly, perturbation of these processes in cells has been observed in the
context of drug resistance. For example, EGFRT790M confers cellular resistance to
gefitinib treatment and is characterized by decreased gefitinib-receptor binding and
increased ATP-receptor binding (158). Gefitinib-EGFR binding also could vary among
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cell lines that express wild-type EGFR via differential action of drug transporters, which
regulate the intracellular concentration of small-molecule therapeutics (159). CetuximabEGFR binding can be perturbed via mutation of the EGFR extracellular domain which
can also confer cetuximab resistance (160). In a previous study, we elucidated a
resistance mechanism in which cells characterized by increased EGFR internalization
were also characterized by a roughly 10-fold higher irreversible EGFR kinase inhibitor
IC50 for reducing EGFR phosphorylation (145). While it is unknown how these two
observations relate mechanistically, these findings are consistent with our identification
of EGFR internalization as an important determinant of therapeutic efficacy. Similarly,
resistance to cetuximab has been shown to correlate with increased EGFR ubiquitination
(161), which might also be related to an increase in EGFR internalization (36). In
contrast, another study reported that cetuximab-resistant cells are characterized by
impaired EGFR internalization which is inconsistent with our model (162).
Our

sensitivity

analyses

generally

identified

the

kinetics

of

EGFR

dephosphorylation as important in determining gefitinib- and cetuximab-mediated
reduction in EGFR phosphorylation (Figure 4-6). This finding is consistent with the
understanding that neither gefitinib nor cetuximab can directly reverse EGFR tyrosine
phosphorylation. Rather, these therapeutics function by disrupting EGFR phosphorylation
processes, which tips the balance toward dephosphorylation and a reduction in
phosphorylated EGFR. Therapeutic efficacy is predicted to be sensitive to the kinetics of
this process because these drugs do more than just sequester free, unphosphorylated
receptor away from the process that leads to receptor phosphorylation. Due to the
131

reversibility of all steps considered here, an important aspect of how these drugs work is
to antagonize the phosphorylation of receptors which have already been phosphorylated.
Interestingly, multiple protein tyrosine phosphatases (PTPs) have been shown to be
altered in ways that either positively or negatively affect PTP activity in the context of
different cancers (15). Some of these PTPs have been shown to dephosphorylate EGFR,
including: LRP (64), LAR (64), DEP1 (71), PTPRK (63), PTPRS (62), PTP1B (57),
TCPTP (68), SHP1 (66), and PTP-PEST (72). Of particular significance, PTPRS was
recently shown to be deleted in 26% of tumor samples from a cohort of HNSCC patients
(82). Tumor samples characterized by PTPRS deletion were also characterized by
increased EGFR and AKT phosphorylation compared to normal tissue. Furthermore,
PTPRS knockdown promoted ligand-independent EGFR phosphorylation in HNSCC cell
lines (MDA-584 and FaDu) and increased the resistance of cells to treatment with the
EGFR TKI erlotinib in HNSCC and NSCLC cell lines (HCC827 and H3255,
respectively). Low PTPRS expression was also predictive of poor prognosis in lung
adenocarcinoma patients with TKI-sensitizing EGFR mutations. Taken together, these
results support our finding that EGFR dephosphorylation is an important process in the
context of EGFR-targeted therapeutics and that perturbation to EGFR dephosphorylation
can affect EGFR-targeted therapeutic efficacy. Going forward, mechanistic studies
should address whether the correlations between PTPRS expression and therapeutic
efficacy are indeed due to reduced EGFR dephosphorylation rates and their effect on
AKT phosphorylation or PTPRS-mediated dephosphorylation of another protein target.
To do this, it would be important to first demonstrate that overexpression of PTPRS can
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reduce EGFR-mediated AKT signaling and increase cellular sensitivity to EGFR-targeted
therapeutics. In the same cells, expression of a constitutively active kinase upstream of
AKT but downstream of EGFR, such as PI3 kinase, should reduce the ability of PTPRS
expression to affect AKT phosphorylation and cellular sensitivity.
In general, our findings suggest that the efficacy of cetuximab, more so than
gefitinib, is a function of the identity and concentration of available ligands since
cetuximab competes with ligand for EGFR binding. Interestingly, the relative levels of
mRNA encoding the EGFR ligands AR, betacellulin, epigen, epiregulin, EGF, heparinbinding EGF-like growth factor, and transforming growth factor alpha were shown to
vary within a panel of gastric and colon cancer cell lines (163). This supports the
possibility that variability in the response to cetuximab among patients could be
explained by differential expression of EGFR ligands. This hypothesis is generally
consistent with the observation that overexpression of ErbB ligands correlates with
cellular resistance to cetuximab (164). However, this effect was attributed to EGFR
nuclear localization and not increased competition of cetuximab with EGFR ligands for
EGFR binding as our simulations suggest. Additional experimental study is needed to
explore the degree to which different EGFR ligands influence the efficacy of EGFRtargeted therapeutics.
We predicted that gefitinib and cetuximab co-treatment could be efficacious
(Figure 4-7) due to the difference in the mechanism by which these therapeutics reduce
EGFR phosphorylation (Figure 4-1B).

This finding is consistent with experimental

results demonstrating that co-treatment of A431 cells with gefitinib and cetuximab
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further reduces EGFR phosphorylation compared to treatment with either therapeutic
alone (165). In addition, cetuximab was found to benefit NSCLC patients for whom
gefitinib treatment had not been effective (166). Lastly, an analysis of a panel of NSCLC
cell lines revealed that some cell lines characterized by sensitivity to gefitinib were not
sensitive to treatment with cetuximab (152). These experimental findings are consistent
with our conclusion that different receptor-level processes determine gefitinib and
cetuximab therapeutic efficacy. Perhaps the most striking difference between gefitinib
and cetuximab in our simulations is the time scales with which the therapeutics mediate a
reduction in EGFR phosphorylation in the context of EGF (Figure 4-5A). Thus, one
explanation for the experimental observation of differential sensitivity to gefitinib and
cetuximab is that a relatively rapid reduction in EGFR phosphorylation is required to
induce the imbalance between pro-apoptotic and pro-survival signaling known as
“oncogenic shock” (155). This would make gefitinib more effective than cetuximab at
inducing apoptosis in cells dependent upon EGFR signaling.
In general, our analysis suggests that therapeutic efficacy is determined by a
variety of receptor-level processes, making it inaccurate to assume that a therapeutic will
be effective in a cellular context simply because it is characterized by a relatively low KD
for its protein target. The notion that IC50 values may be determined by different
processes in the context of different ligand/therapeutic pairs argues for the study of
EGFR-targeted therapeutics in the context of multiple EGFR ligands, rather than the
predominantly-used EGF. More broadly, this work suggests that variation in any of the
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processes identified herein as determinants of IC50 or t50 may account for variation in the
response of cancer patients to EGFR-targeted therapeutics.
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Chapter 5 : Diversity in Dimerization Topologies Enables
Differential Control of Receptor Tyrosine Kinase
Phosphorylation Dynamics

5-1 ABSTRACT
Within the receptor tyrosine kinase (RTK) super-family there is natural diversity
in mechanisms leading to RTK dimerization, but the impact on receptor-mediated
signaling is not well understood. Using parameters from studies of epidermal growth
factor receptor (EGFR) and considering effects of ligand binding, receptor dimerization,
and receptor phosphorylation and dephosphorylation, we developed computational
models to compare the effects of dimerization through direct extracellular receptorreceptor contacts (receptor-mediated dimerization, RMD) or through indirect receptorreceptor interactions facilitated by an interposed bivalent ligand (ligand-mediated
dimerization, LMD). We found that the LMD topology enables different and complex
regulatory modes of signaling versus RMD, and that this complexity depends upon
differences

in

time

dephosphorylation.

scales

for

ligand

binding,

dimerization,

and

receptor

Versus RMD, the LMD topology: 1. enables non-monotonic

phosphorylation dynamic response to ligand binding; 2. favors an amplification process
wherein a single receptor-ligand binding event produces more than two phosphorylated
receptors within the time scale for receptor dephosphorylation; and 3. generates greater
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phosphorylation sensitivity to changes in receptor expression at sub-saturating ligand
concentrations and to changes in preformed receptor dimer abundance. Thus, different
dimerization mechanisms may allow RTKs to initiate signaling in very different ways,
and our models provide a framework for exploring this complexity.
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5-2 INTRODUCTION
Ligand binding to the extracellular domains of some receptor tyrosine kinases
(RTKs) promotes RTK oligomerization (3). Receptors may oligomerize as dimers, as in
the case of the fibroblast growth factor receptor and epidermal growth factor receptor
(EGFR), or as higher order complexes, as has been suggested for receptors such as TIE2
and Eph receptor (25, 167-171). For TIE2, for example, the multimeric and multivalent
receptor ligand angiopoietin-1 may promote the formation of tetrameric TIE2 (169, 170).
Ultimately, these oligomerization processes promote the phosphorylation of cytoplasmic
receptor tyrosines that bind intracellular adapter proteins and thereby couple receptors to
intracellular signaling pathways (1).

Structural studies have revealed that RTK

oligomerization is generally mediated by: direct contacts between receptors; indirect
receptor-receptor interaction facilitated by interposed multivalent ligands; or a
combination of these mechanisms (3). While many aspects of RTK-mediated signaling
have been studied in detail, the extent to which these different oligomerization
mechanisms may account for differences in receptor-mediated signaling dynamics among
RTKs remains unclear.
Perhaps the most common form of receptor oligomerization is dimerization. The
well-studied RTKs EGFR and tropomyosin-related kinase A (TrkA) exemplify two
mechanistic extremes of this process (Figure 5-1) (3). EGFR undergoes a receptormediated dimerization (RMD) process in which direct contacts occur between receptor
domains that become preferentially accessible after monovalent ligand binding (25, 168).
Conversely, TrkA undergoes a ligand-mediated dimerization (LMD) process wherein
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receptors do not form direct extracellular receptor-receptor contacts but instead dimerize
around the bivalent ligand nerve growth factor (NGF) (3, 172, 173). Interestingly, EGFR
dimers have been identified at the cell surface in the absence of ligand in Ba/F3 (174) and
NIH3T3 cells (175). Similarly, TrkA dimers have been observed in the absence of
ligand in PC12 cells (176), and pre-formed oligomers containing at least two TrkA
receptors have been observed in xenopus oocytes (177). How these dimers arise and
what role they play in receptor-mediated signaling is unclear.
Numerous computational models of receptors characterized by RMD have been
developed to dissect the dynamics of receptor-mediated signaling.

EGFR has been

particularly well-studied, including focused investigation of the roles of receptor
dephosphorylation (89), receptor internalization (97), signal-branching (99), and
activation of downstream pathways (98), Receptors characterized by LMD have not been
the focus of similarly extensive computational efforts. The relatively few available
computational models for TrkA have focused on downstream signaling (e.g., (178))
without considering the mechanistic details of LMD.

Perhaps the model that most

thoroughly explores the implications of LMD is the general bivalent ligand/monovalent
receptor model developed by Perelson and coworkers (179), which showed that ligand
binding promotes receptor dimerization at sub-saturating ligand concentrations but
reduces the number of receptor dimers at saturating ligand concentrations. This model
focuses solely on dimer formation, without consideration of how LMD might exert
unique control over receptor phosphorylation.
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To investigate the consequences of RMD versus LMD for receptor
phosphorylation, we developed two mechanistic models of receptor phosphorylation
dynamics that differ only in receptor dimerization mechanism and additionally consider
the effects of ligand binding, receptor dimerization, and receptor phosphorylation and
dephosphorylation. The models use identical parameters based on studies of EGFR,
including our recent model-based quantitation of EGFR tyrosine dephosphorylation,
which occurs with a time scale of less than one minute (89). For the LMD model,
differences among the time scales for ligand binding, receptor dimerization, and receptor
dephosphorylation allow for a competition between ligand binding and dimerization to
arise which can antagonize steady receptor phosphorylation and produce nonmonotonicity in dynamic phosphorylation response to ligand binding.

Differences

among these time scales also preferentially enable the LMD system to amplify the effects
of a single ligand-receptor binding event to produce more than two phosphorylated
receptors within the time scale for receptor dephosphorylation. Furthermore, the LMD
model demonstrates a greater degree of receptor phosphorylation sensitivity to changes in
receptor expression at sub-saturating ligand concentrations and greater sensitivity to the
presence of preformed receptor dimers. Thus, our study points to the possibility that
diversity in dimerization mechanisms may generate important differences in signaling
initiation capacity among different RTKs and provides a basis for developing testable
predictions to explore this possibility.

140

Figure 5-1: Receptor-mediated dimerization (RMD) and ligand-mediated
dimerization (LMD) model topologies
RMD occurs through direct extracellular receptor-receptor interactions that are stabilized
by the binding of monovalent ligand to receptors. LMD occurs through indirect receptorreceptor interactions facilitated by an interposed bivalent ligand, around which the
receptors dimerize. In both cases, receptor dimerization promotes phosphorylation (P) of
a representative tyrosine (Y) present in the cytoplasmic tail of the receptor. Symbols for
parameters describing various receptor processes are indicated in the figure and are
defined in Table 1.

Table 5-1: Model parameters.
parameter
kL,f
kL,r
kd,f
kd,r
kcat
kdp

description

value
2

reference
-1

-1

1×10 μM ·min

ligand association

-1

ligand dissociation

-1

1×10 min
-3

receptor coupling

KD (100)
-1

1×10 cell·min

receptor uncoupling

-1

(85)

1

-1

(101)

0

-1

(89)

1×10 min

dephosphorylation

1×10 min
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(89)

1

1×10 min

phosphorylation

(125)

5-3 METHODS
Model topology and scope. The RMD and LMD models are comprised of sets of
coupled ordinary differential equations to describe the kinetics of reversible reactions for
ligand-receptor binding, receptor dimerization, and receptor tyrosine phosphorylation and
dephosphorylation, based upon mass-action assumptions. Phosphorylation at a single
representative

tyrosine

is

assumed

to

occur

within

ligand-bound

dimers.

Dephosphorylation is treated as a first order process with respect to phosphorylated
receptor species that occurs with the kinetics we previously measured for EGFR (89).
The sole difference between the models is the mechanism for receptor dimerization
(Figure 5-1). In the RMD model, two ligand-bound receptors are required to form a
single receptor dimer via direct receptor-receptor contacts.

In the LMD model,

dimerization requires one receptor bound to a dimeric ligand and one empty receptor.
Models were solved using MATLAB with SBToolBox2 (111).
Simplifying assumptions. To minimize the number of differential equations in
each model, we assumed that: 1. the soluble ligand concentration was constant; 2. ligand
could not dissociate from ligand-bound dimers without the dimers first uncoupling; and
3. all receptor species were ready to participate in a phosphorylation reaction once
dimerized (i.e., ATP and its binding to receptors was not explicitly considered). To
further simplify the models, receptor trafficking and binding of intracellular adapter
proteins to receptors were not considered.
Model parameters. Parameters were based on order-of-magnitude estimates from
previous studies for EGFR, as summarized in Table 1. The value of the rate constant for
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dephosphorylation of EGFR (kdp) is taken from a previous publication in which we
quantified the rate at which EGFR Y1068 cycles between phosphorylated and
unphosphorylated states (~1 min-1) (89). Thus, the RMD and LMD models take into
account experimental evidence for cycling of RTK phosphotyrosines between
phosphorylated and unphosphorylated states over time scales smaller than commonly
assumed. The speed of this process relative to other receptor processes produces some of
the interesting complexity discussed herein. The same set of parameters was used for
both models so that the source of model output differences could only be attributed to
differences in the dimerization topology. Unless otherwise noted, receptor expression
was assumed to be 100,000 cell-1.
Receptor coupling and uncoupling. In the RMD model, receptor coupling
(dimerization) and uncoupling parameters describe the reversible association between
two ligand-bound receptors via receptor-receptor contact. In the LMD model, the same
receptor coupling and uncoupling parameters describe the reversible association between
one ligand-bound and one empty receptor with contacts occurring only between receptors
and the interposed ligand. Thus, for comparisons using identical parameters, there is an
inherent assumption that the interaction between a ligand-bound receptor and a free
receptor in the LMD model occurs with the same kinetics as the interaction between two
ligand-bound receptors in the RMD model.
Calculation of R50. To quantify the sensitivity of steady-state ligand-initiated
receptor phosphorylation to changes in receptor expression levels, we computed the
receptor expression level for which 50% of maximum steady-state receptor
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phosphorylation was achieved for a specific ligand concentration.

This receptor

expression level is defined as the R50.
Preformed receptor dimers. In both models, preformed receptor dimers were
treated as dimeric complexes that could not dissociate into monomers. As with other
receptor species, these complexes were permitted to bind ligand reversibly, become
phosphorylated, and be dephosphorylated.
Sensitivity analysis. The sensitivity of predicted receptor phosphorylation
response to ligand addition to changes in model parameters was calculated by computing
the fold-change in model output for 10-fold perturbations to individual parameter values,
with summation over 0 ≤ t ≤ 10 min. Sensitivity was reported as the sum of the fold
change in model output for a 10-fold increase and a 10-fold decrease in that parameter.
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5-4 RESULTS
Dynamics and steady-states of ligand-mediated receptor phosphorylation.
For calculations shown as a function of time, it is convenient to show results for a limited
number of ligand concentrations (L). We will thus define three values of L relative to the
dissociation constant for ligand binding to the receptor (KD). “Low,” “medium,” or
“high” L is defined as L/KD = 10-2, L/KD = 100, or L/KD = 102, respectively. As expected
for the RMD model and as generally described elsewhere, receptor phosphorylation rates
and phosphorylation levels increase with L due to increased rate of ligand binding and
increased receptor occupancy (Figure 5-2A). For LMD, initial receptor phosphorylation
rates uniformly increase with increasing L, but at high L a non-monotonic dynamic
response of receptor phosphorylation to ligand is observed which results in an eventual
antagonism of receptor phosphorylation versus medium L (Figure 5-2B). This nonmonotonicity in receptor phosphorylation versus time for LMD does not require an L as
high as 100-fold in excess of Kd, and the factors that contribute to this effect are
discussed in detail later. For now, it suffices to comment that this occurs because
sufficiently high L antagonizes dimerization in the LMD model.

This notion is

qualitatively consistent with previous models of receptor complex formation for bivalent
ligands (179).
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Figure 5-2: Dynamic and steady-state receptor phosphorylation.
(A and B) The percent of total receptor that is phosphorylated (pR) was calculated as a
function of time for the indicated ligand concentrations (L) with the (A) receptormediated dimerization (RMD) and (B) ligand-mediated dimerization (LMD) models. (C)
The steady-state percentage of total receptor that is phosphorylated (solid lines) or ligandbound (dashed lines) was calculated as a function of L. The value of the dissociation
constant for ligand binding to the receptor (KD) is shown by the dashed vertical line.

Differences between RMD and LMD can also be explored by comparing steady
receptor phosphorylation and ligand-occupancy as a function of L. For RMD, steadystate levels of phosphorylation and occupancy increase monotonically with L (Figure 52C), as expected. The percentages of total receptor occupied by ligand or phosphorylated
are roughly equal until L ≈ KD. At this point, receptor phosphorylation reaches a plateau,
and ligand binding continues to occur.

The difference between the two plateaued

percentages of ligand-bound and phosphorylated receptors is a result of the
dephosphorylation kinetics considered in our model. While not easily seen in Figure 52C, the dephosphorylation process maintains an excess of ligand-bound compared to
phosphorylated receptors of at least ~15% for all L for RMD. For LMD, the percentage
of total receptor phosphorylated increases up to L = KD, but decreases beyond that point
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as occupancy continues to increase (Figure 5-2C). Interestingly, for LMD, the percent of
receptor phosphorylated is greater than the percent occupied for low L, for reasons
discussed later.

As L increases above KD and receptor occupancy exceeds ~80%,

receptor phosphorylation decreases. This is because ligand binds receptors uncoupling
from dimers, which antagonizes dimerization as free receptors become limiting thereby
slowing the phosphorylation rate.

L = KD represents a maximum in receptor

phosphorylation because this L results in 50% occupancy of the receptor monomers not
incorporated into receptor dimers, which maximizes dimer formation rate. Note that
receptor occupancy is > 50% for L = KD due to our assumption that ligand only
dissociates from receptor monomers.
Amplification of phosphorylation. In Figure 5-2C, we noted that LMD allows
for the percent of phosphorylated receptor to exceed that for occupied receptor at
sufficiently low L. This occurs because of a process of “amplification,” which we define
as the ability of the minimum number of ligands required to form a dimer (two for RMD,
one for LMD) to induce steady phosphorylation of more than two receptors. For LMD,
this can occur if a single ligand-bound monomer dimerizes with and phosphorylates
multiple empty receptors within the time scale for dephosphorylation (Figure 5-3A). For
RMD, this can occur if a phosphorylated dimer uncouples, ligands dissociate, and
dissociated ligands bind to and induce the phosphorylation of two other receptors before
the original receptors are dephosphorylated (Figure 5-3A). To determine the extent of
amplification, we computed the amount of phosphorylated receptor (pR) per bound ligand
(Lb) at steady-state for both models over a range of L (Figure 5-3B). According to our
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definition, amplification occurs if pR/Lb > 2 for LMD (two phosphorylated receptors per
bound ligand) or if pR/Lb > 1 for RMD (two phosphorylated receptors per two bound
ligands). For LMD, amplification is promoted by lower L because the process depends
upon a relative abundance of free receptors. For the base model parameters and LMD,
pR/Lb increases to a maximum of ~7 as L decreases (Figure 5-3B). We note that the
degree to which receptor phosphorylation exceeds occupancy in Figure 5-2C may appear
inconsistent with a pR/Lb as high as ~7. This apparent discrepancy is explained by
recalling that an LMD dimer consists of two occupied receptors and one bound ligand.
Thus, the ratio of phosphorylated receptor to occupied receptor for LMD (which can be
estimated from data shown in Figure 5-2C) is two-fold lower than pR/Lb for the same
conditions.

For RMD, amplification does not occur for the base model parameters

(although it is possible for it to occur), as indicated by a pR/Lb that increases with L but
does not exceed unity (Figure 5-3B). Amplification is not observed here because by the
time ligand dissociates from one uncoupled dimer and induces dimerization and
phosphorylation of two other receptors, the initially-phosphorylated receptors are
dephosphorylated. This limitation does not affect amplification in the context of LMD
because LMD amplification is not dependent upon ligand-receptor unbinding and
rebinding.
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Figure 5-3: Phosphorylation amplification.
(A) For ligand-mediated dimerization (LMD), amplification occurs when a ligand-bound
receptor dimerizes with and phosphorylates multiple empty receptors within the time
scale for receptor dephosphorylation.

For receptor-mediated dimerization (RMD),

amplification occurs when a phosphorylated dimer uncouples, ligands dissociate, and
dissociated ligands bind to and induce the phosphorylation of two other receptors before
the original receptors are dephosphorylated. (B) The steady-state ratio of the number of
phosphorylated receptors to the number of bound ligands (pR/Lb) was calculated as a
function of ligand concentration (L) for the base model parameters (solid lines) or for a
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105-fold reduction (relative to the base parameters) in the receptor dimer uncoupling rate
constant (kd,r) (dashed lines). (C and D) pR/Lb was calculated with the (C) LMD and (D)
RMD models as a function of ligand concentration and for the indicated values of the rate
constant for receptor dephosphorylation (kdp).

Based on the preceding discussion, it is clear that dimer uncoupling and
dephosphorylation exert control over amplification. Consistent with this, dramatically
decreasing the rate constant for dimer uncoupling (kd,r) by a factor of 105 relative to the
base parameter value in Table 1 eliminates amplification in the LMD model, as indicated
by pR/Lb < 2 for all L (Figure 5-3B). By promoting dimerization, decreased kd,r also
increases pR/Lb at a lower L with the RMD model compared to the base parameters, but
the maximum pR/Lb is unchanged. Also consistent with our discussion, reducing the rate
constant for receptor dephosphorylation (kdp) increases the extent of amplification
observed for LMD (Figure 5-3C). A sufficiently small kdp also permits amplification
over a short range of low L in the RMD model, as indicated by pR/Lb > 1 (Figure 5-3D).
Even with decreased kdp, amplification disappears with increasing L in the RMD model as
receptors become saturated and pR/Lb > 1 becomes increasingly difficult to achieve. We
note finally that if amplification occurs as described above, a reduced kdp should not
promote amplification if dimer uncoupling is impaired. Indeed, reducing kd,r by a factor
of 105 relative to the base parameters eliminates amplification in both models regardless
of the value of kdp (Figure S5-8A and S5-8B, respectively).
Peak formation in receptor phosphorylation dynamics. To explain the
formation of peaks in receptor phosphorylation versus time with LMD (as observed in
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Figure 5-2B), we propose the model shown schematically in Figure 5-4A. Upon ligand
addition, dimers begin to form and receptor phosphorylation is induced. As the supply of
empty monomeric receptors is depleted, dimerization and phosphorylation slow to a point
where phosphorylation and dephosphorylation occur at the same rate (d(pR)/dt = 0).
Beyond this point, receptor dephosphorylation becomes the faster overall process as
dimers break apart and ligand binds the free receptors produced by dimer uncoupling,
preventing dimers from reforming. This proposed mechanism requires a number of
things to be true about the relative time scales for ligand binding, receptor dimerization,
and receptor phosphorylation and dephosphorylation.

For example, receptors must

become maximally bound by ligand more slowly than dimerization can occur because
this difference in time scales enables receptor phosphorylation to temporarily achieve a
higher level of phosphorylation than is sustainable. Receptor dephosphorylation must
also occur more quickly than occupied and free receptors can dimerize once free
receptors become limiting.
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Figure 5-4: Transient peak formation in receptor phosphorylation with the ligandmediated dimerization (LMD) model.
(A) A schematic is shown to demonstrate the kinetic processes which lead to the nonmonotonic receptor phosphorylation dynamics predicted by the LMD model. Ligand
binding initially promotes receptor phosphorylation by promoting dimer formation and
receptor phosphorylation that is fast enough to overcome receptor dephosphorylation. As
empty receptor monomers become scarce, the rate of phosphorylation slows and is
balanced by the rate of dephosphorylation, forming a maximum in the percent of total
receptors that are phosphorylated (pR). At this point, ligand continues to bind receptors
that uncouple from receptor dimers, reducing the number of free receptor available to
participate in dimer formation and allowing dephosphorylation to reduce pR. (B-D) pR
was calculated with the LMD model as a function of time after introduction of 10-1 μM
ligand and for specific alterations to parameters relative to the base values (Table 1;
“base” curve). In panel (B), curves are shown for: a decrease in the rate constant for
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ligand-receptor association (kL,f) of 102-fold (blue); an increase of kL,f of 105-fold and
decrease of the rate constant for ligand-receptor dissociation (kL,r) of 105-fold (red);
increases of 105-fold for kL,f and kL,r (green). In panel (C), curves are shown for: an
increase in the rate constant for receptor dimerization (kd,f) of 105-fold and decrease of the
rate constant for dimer uncoupling (kd,r) of 105-fold (blue); and decreases in kd,f and kd,r of
102-fold (red). In panel (D), curves are shown for: a decrease in the rate constant for
receptor dephosphorylation (kdp) of 102-fold (blue); and decreases in kdp and the rate
constant for receptor phosphorylation (kcat) of 101-fold (red).

To test our proposed model, we explored a number of changes to model
parameters versus the values given in Table 1 for an L well in excess of the base value of
KD. As shown in Figure 5-4B, a number of different changes to the kinetics of ligand
binding can eliminate non-monotonic phosphorylation dynamics. A sufficient reduction
in the rate constant for ligand binding to receptor (kL,f) eliminates peak formation for the
simple reason that free receptors can no longer become limiting (i.e., KD is increased
above L). Increasing kL,f and decreasing the rate constant for ligand dissociation (kL,r)
results in receptors becoming virtually instantaneously and irreversibly bound by ligands,
which eliminates the ability for phosphorylation to occur at all. As a final example of
ligand-associated changes, we note that sufficient increases in both kL,f and kL,r without
changing KD can also eliminate peak formation because the time scale for receptor
equilibration with ligand becomes smaller than that for dimerization. Thus, even with L
in excess of KD, it is possible for peaks not to arise. As shown in Figure 5-4C, sufficient
and similar reductions of kd,f and kd,r (i.e., without changing the affinity of dimerization)
eliminate peak formation by slowing dimerization relative to ligand binding. Increasing
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kd,f and reducing kd,r also results in a high level of phosphorylation with monotonic
dynamics since this parametric change makes dimer formation less reversible. Finally, in
Figure 5-4D, we show that sufficient reduction of kdp, either with or without a similar
fold-change in kcat, results in monotonic phosphorylation dynamics as the time scale for
dephosphorylation becomes large compared to that for dimers to reform.
Sensitivity of steady-state phosphorylation to changes in receptor expression.
We next explored the sensitivity of steady receptor phosphorylation to changes in
receptor expression for the two dimerization topologies. For calculations at a particular
L, steady-state receptor phosphorylation was normalized to the maximum receptor
phosphorylation value, which occurs at the highest receptor expression level and changes
with L. For both models, increased receptor expression promotes phosphorylation due to
the second-order dependence of dimerization rate on receptor monomer concentration
(Figure 5-5A and 5-5B). For RMD (Figure 5-5A), increasing L sensitizes receptor
phosphorylation to increased receptor expression by increasing the fraction of receptors
bound by ligand. Sensitivity to changes in L vanishes roughly when L becomes > KD and
receptors are saturated with ligand.

For LMD (Figure 5-5B), steady receptor

phosphorylation is also sensitized to increased receptor expression for an increase from
low to medium L (for the same reason as the RMD model), but is desensitized to
increased receptor expression by further increases to high L as the limited availability of
empty receptors antagonizes phosphorylation rates.
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Figure 5-5: Effect of receptor expression on steady receptor phosphorylation.
(A and B) Using the (A) receptor-mediated dimerization (RMD) and (B) ligand-mediated
dimerization (LMD) models, the steady-state percentage of total receptor that is
phosphorylated (pR) was calculated as a function of receptor expression per cell for the
indicated ligand concentrations (L) and then normalized to the maximum pR value for a
particular L. (C) The number of receptors per cell required to achieve half-maximal
receptor phosphorylation (R50) was plotted as a function of ligand concentration. The
value of the dissociation constant for ligand binding to the receptor (KD) is shown by the
dashed vertical line.

To quantify the sensitivity of steady phosphorylation to changes in receptor
expression in a different way, we calculated the number of receptors required to reach
50% of the maximum receptor phosphorylation (R50) as a function of L (Figure 5-5C).
R50 is thus a reflection of the sensitivity of steady receptor phosphorylation to changes in
receptor expression. For RMD, increasing L decreases R50, but this effect vanishes as L
becomes larger than KD and receptors are saturated with ligand. For LMD, R50 decreases
with increasing L for L < KD and increases with increasing L for L > KD, reflecting a need
for increased receptor expression to counteract the antagonistic effects of higher L.
Comparing the models, R50 for RMD exceeds that for LMD at lower L, reflecting that
receptor phosphorylation is a more efficient process for LMD than RMD when free
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receptors are not limiting. We note as well that the magnitude of d(R50)/dL is larger for
RMD than LMD for lower L. This is observed because an incrementally larger L
increases the abundance of both species required for RMD, while the same increase in L
only increases the abundance of one of the species required for LMD.
Effects of preformed receptor dimers on dynamic and steady receptor
phosphorylation. Given experimental evidence for the existence of preformed dimers for
RTKs including EGFR and TrkA (174-177), we investigated how the presence of
preformed receptor dimers (PFDs) affects receptor phosphorylation for RMD and LMD.
Increasing the fraction of receptors present as PFDs leads to a negligible increase in
phosphorylation for RMD (Figure 5-6A) but has a striking effect for LMD (Figure 5-6B).
While PFDs promote receptor phosphorylation in both models by stabilizing dimers, they
also provide protection from the antagonistic effect of excess ligand in the LMD model,
leading to the substantially larger sensitivity to PFDs for LMD. Increasing PFDs also
reduces and eventually eliminates the extent of non-monotonic receptor phosphorylation
dynamics for LMD.
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Figure 5-6: Effect of preformed receptor dimers on receptor phosphorylation.
(A and B) Using the (A) receptor-mediated dimerization (RMD) and (B) ligand-mediated
dimerization (LMD) models, the percentage of total receptor that is phosphorylated (pR)
was calculated as a function of time for the indicated percentages of total receptors
present as preformed receptor dimers (PFDs) and a ligand concentration of 1 μM. (C and
D) Using the the (C) RMD and (D) LMD models, steady-state pR was calculated as a
function of ligand concentration (L) for the indicated percentages of total receptors
present as PFDs.

To further explore the effect of PFDs, we computed steady receptor
phosphorylation as a function of L and the fraction of receptors present as PFDs. As with
the dynamic simulations, the effect of PFDs on steady phosphorylation is smaller for
RMD than for LMD (Figs. 4-6C and 4-6D, respectively).
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This difference is most

pronounced at high L, where PFDs provide protection against ligand-mediated
antagonism of phosphorylation. Interestingly, increasing the abundance of PFDs slightly
impairs phosphorylation for lower L in the LMD model (Figure 5-6D) because an
inability of dimers to uncouple there antagonizes the amplification process, which is
maximized at lower L (Figure 5-3B).
Model

sensitivity

analysis.

Sensitivity

of

model-predicted

receptor

phosphorylation response to ligand (low or high L for 10 min) to perturbations of 10-fold
in the model parameters was assessed with both models (Figure 5-7). For low L, the
RMD model is more sensitive than the LMD model to perturbations in nearly all
parameters (Figure 5-7A). This is observed because receptor phosphorylation is so
severely impaired with RMD at low L that even small perturbations can significantly
affect phosphorylated receptor levels. The only parameter that was more sensitive in the
LMD compared to the RMD model was kdp, due to the role dephosphorylation plays in
the amplification process. Both RMD and LMD models are most sensitive to changes in
kL,f, because the availability of ligand-bound monomers limits phosphorylation for both
models. While a decrease in kL,r could also promote ligand binding to the receptor, the
models are less sensitive to this parameter because perturbations to this parameter do not
affect receptor phosphorylation within the 10 min timeframe of the simulation.
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Figure 5-7: Sensitivity analysis.
(A and B) Model-predicted sensitivity of phosphorylated receptor levels over a 10 min
ligand treatment to perturbations of 10-fold in the indicated model parameters (see Table
1 for definitions) and the receptor expression level (R0) was calculated for ligand
concentrations of (A) 10-5 μM or (B) 10-1 μM using the receptor-mediated dimerization
(RMD) and ligand-mediated dimerization (LMD) models.

At high L (Figure 5-7B), ligand saturation of receptors leads to reduced sensitivity
of the RMD model to changes in ligand binding and dimerization parameters relative to
what was observed at low L. For high L and RMD, receptor phosphorylation remains
fairly sensitive to perturbations in kcat and kdp since ligand saturation has no effect on
these processes, both of which directly influence receptor phosphorylation many times
within the 10 min time scale of our sensitivity calculations. For LMD, receptor
phosphorylation is relatively sensitive to perturbations in all parameters, consistent with
our previous observations that ligand binding, dimerization, phosphorylation and
dephosphorylation time scales influence peak formation in receptor phosphorylation in
response to high L in the LMD model.
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5-5 DISCUSSION
Receptor dimerization is an important step in the activation of downstream
signaling processes for RTKs such as EGFR, TrkA, and FGFR (3). While the structural
basis for dimerization has been well-studied for some receptors, the implications of
different topological dimerization schemes for receptor phosphorylation dynamics have
not been thoroughly explored. Here, we developed two mechanistic models to explore
the effects of an RMD versus LMD topology on receptor phosphorylation, motivated by
EGFR and TrkA as examples of these different mechanisms, respectively. We find that
RMD and LMD are generally characterized by very different steady and time-dependent
phosphorylation profiles in response to ligand, resulting mainly from an intrinsic
antagonistic effect of ligand at sufficiently high L that free receptors become limiting and
from altered competition between process time scales that arise for the different
dimerization topologies. Our models utilize a common set of parameters, based upon
studies of EGFR.

Our results thus delineate possibilities for how differences in

dimerization may enable important differential control over receptor-mediated signaling,
without any definitive comparative implications for specific RTKs versus EGFR.
Importantly, both models assume that receptors undergo dephosphorylation with a
time scale of less than one minute, based upon our previous experimental observations
and modeling work for EGFR in HeLa cells (89). While the smallness of this time scale
is not widely appreciated, it is important to comment on here because its size relative to
other process time scales is strongly determinative of receptor phosphorylation dynamics
predicted by our models. Indeed, both amplification (Figure 5-3) and non-monotonic
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receptor phosphorylation dynamics for LMD (Figure 5-4) exhibited significant sensitivity
to perturbations in kdp. Thus, our study also explores the differential role that relatively
rapid dephosphorylation might play in the context of ligand-initiated phosphorylation of
RTKs characterized by different dimerization schemes. Of course, it remains an open
question whether or not the kinetics we previously determined for EGFR
dephosphorylation apply to other RTKs, including those that utilize an LMD mechanism
such as TrkA. Answering this question for particular RTKs, with either dimerization
topology, will be an important component of utilizing these models in a predictive
capacity.
Our consideration of realistic rates of receptor dephosphorylation also enabled the
simulation of antagonism of receptor phosphorylation at saturating ligand concentrations
with the LMD model. Antagonistic effects of various kinds have been noted in previous
computational and experimental studies involving bivalent ligands. For example, the
binding of bivalent haptens to bivalent IgEs was computationally predicted to produce
non-monotonic oligomer formation as a function of ligand concentration through
competition between hapten-IgE binding and hapten-mediated IgE chain formation in a
process analogous to our predictions with the LMD model (180).

Another study

demonstrated experimentally that treatment of human basophils with bivalent hapten
resulted in non-monotonic histamine release consistent with their model, which
considered ligand-receptor binding and receptor complex formation (180, 181). These
findings may provide experimental support for the general notion that saturating
concentrations of a bivalent ligand could mediate a reduction in an output of receptor
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activation. However, it is important to recognize that such results could also be explained
by a number of other possibilities, including the increased expression or activity of
negative regulators of histamine release at high hapten concentrations.
In previous experimental studies, TrkA phosphorylation in PC12 cells was found
to increase monotonically with ligand concentration for 20 min treatments with 0.5, 5, or
50 ng/mL NGF (182), which corresponds to 0.02, 0.2, or 2 nM NGF, respectively
(assuming wild-type dimeric β-NGF with a molecular weight of 26 kDa (183)). Values
of KD,NGF from multiple studies range from 10-10 - 10-11 M (0.1 - 0.01 nM) (183-186). To
compare our model to these experimental results, we set kL,f = 5×101 μM-1min-1,
consistent with measurements of NGF-TrkA binding (187), and kL,r such that KD,NGF =
10-10 M and used the LMD model to calculate receptor phosphorylation as a function of
time for L = 0.02, 0.2, or 2 nM. Interestingly, the LMD model predicts that, for these
parameters, receptor phosphorylation increases monotonically with L for t = 20 min
(Figure S5-9). Non-monotonic variation in receptor phosphorylation with L was only
observed for t > 50 min, which is outside the times for which TrkA phosphorylation was
reported in the study by Chang et al. (182) Thus, these published experimental results are
qualitatively consistent with our model predictions. However, even with the relatively
simple accounting of receptor processes in our models, our calculations suggest the
possibility that this monotonic response to increasing L may not have been observed for
longer times after ligand addition.
In another study, ligand-mediated EGFR and TrkA phosphorylation in PC12 cells
were compared as a function of time for EGF and NGF concentrations ranging from 0.5 162

50 ng/mL, which correspond to 0.08 - 8 nM for EGF or 0.02 - 2 nM for NGF (178). Both
ligand concentration ranges spanned the KD values for the respective receptors, but peaks
were formed in both EGFR and TrkA phosphorylation after less than 10 min of treatment
with L ≥ KD. Our relatively simple models would predict peak formation for TrkA
(LMD) with sufficiently high L only, but not for EGFR (RMD). A potential explanation
for this inconsistency is that processes not included in our models, but that reduce EGFR
phosphorylation (and possibly that of TrkA as well), such as ligand-mediated receptor
internalization (3, 188), receptor degradation (39, 189), or induction of receptor
phosphatase activity, might significantly influence receptor phosphorylation dynamics.
Receptor internalization might contribute to peaks in phosphorylation response due to
translocation of receptors to the endosome, where ligand binding is generally less favored
due to a more acidic environment (44, 45). Peaks in EGFR and TrkA phosphorylation
could also potentially result from ligand-mediated receptor degradation, but the time
scale for that process for both receptors is probably too large for this effect to account for
peaks observed less than 10 min after the addition of ligand (39, 189). Finally, ligandmediated induction of phosphatase activity downstream of each receptor would result, in
the context of our models, in an increased kdp as a function of time, which could also
clearly contribute to peaks in receptor phosphorylation. Interestingly, ligand-mediated
activation of EGFR and TrkA has been shown to induce activity of the phosphatases
SHP2 and PTP1B, respectively (115, 190). However, relatively little is known about
these processes and how they might affect receptor phosphorylation.

163

Overall, our results suggest that differences in dimerization mechanisms among
RTKs could account for significant diversity in receptor phosphorylation response to
ligand. In living cells, the ligand concentration regimes over which the phenomena
discussed here (e.g., amplification, formation of peaks in receptor phosphorylation as a
function of time) would be observed would be a function of multiple variables, including
the rate constants in Table 1.

These are likely to be quite different for different

receptor/ligand pairs and across different cell types. These issues notwithstanding, the
results of our relatively simple models point to the general conclusion that, compared to
RMD, the LMD topology enables a greater degree of complexity in the regulation of
receptor phosphorylation in response to ligand binding and a greater degree of sensitivity
to changes in kinetic parameters.
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5-7 SUPPLEMENTAL MATERIAL

Figure S5-8: Amplification and dimer uncoupling.
(A and B) The steady-state ratio of the number of phosphorylated receptors to the number
of bound ligands (pR/Lb) was calculated as a function of ligand concentration (L) for the
indicated values of the dephosphorylation rate constant (kdp) with the (A) ligand-mediated
dimerization (LMD) and (B) receptor-mediated dimerization (RMD) models. These
calculations were made with a receptor dimer uncoupling rate constant 105-fold lower
than the base value.
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Figure S5-9: Qualitative comparison of model to published data.
The percent of total receptor that is phosphorylated (pR) was calculated as a function of
time for the indicated ligand concentrations (L) with the ligand-mediated dimerization
(LMD) model. To match the experimental conditions described in the Discussion section,
we set kL,f = 5×101 μM-1min-1, an experimentally measured value, and kL,r such that
KD,NGF was equal to the experimentally measured value of 10-10 M. The 20 min time point
from the experiment is indicated by the dashed vertical line.
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Chapter 6 : Implications and Conclusions

6-1 INTRODUCTION
One of the most important findings of this thesis is that, at least in some cells,
EGFR dephosphorylation can occur with a timescale of ~10 s regardless of EGFR
cellular localization (Chapters 2 and 3). This dephosphorylation process represents one
step of a relatively rapid cycling process of regulatory receptor tyrosines between
phosphorylated and unphosphorylated states (“phosphate cycling”; see Chapter 2). The
computational and experimental approaches used to measure EGFR phosphate cycling
also constitute a general framework with which phosphate cycling of other proteins can
be quantified. Our quantification of dephosphorylation kinetics has significant
consequences even for processes that were thought to be relatively well understood. For
example, for protein tyrosine phosphatases (PTPs) to access phosphotyrosines on the
relatively small time scales we identify, adapter proteins that bind EGFR
phosphotyrosines, and consequently protect them from dephosphorylation (191), must
also cycle relatively rapidly between bound and unbound states (“association cycling”;
see Chapter 3). Importantly, association cycling with a relatively small timescale was
recently demonstrated for the adapter protein GRB2 binding to phosphorylated EGFR
(123). The notion of association cycling directly contradicts the common view that
EGFR-adapter protein complexes formed by interactions between adapter SH2/PTB
domains and EGFR phosphotyrosines persist for relatively long time scales. Instead, our
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data are consistent with the hypothesis that protein complexes involving EGFR
phosphotyrosines are cycling between different conformations with relatively small
timescales (< 1 s for GRB2; Chapter 3). This update to the textbook understanding of a
“signaling complex” is supported by another recent study (192), and has significant
implications (193). Here, we discuss implications of some of our findings and suggest
directions for future studies.

6-2 POST TRANSLATIONAL MODIFICATION CYCLING
While our data clearly support the notion of cycling of EGFR phosphotyrosines
multiple times each minute after the addition of exogenous ligand, the rate to which
phosphoresidues on other proteins cycle between phosphorylated and unphosphorylated
states is unknown. Interestingly, a study by Pan and coworkers (194) used a mass
spectrometry-based phosphoproteomic approach to quantify phosphorylation of proteins
in mouse hepatoma cells after a 10 min treatment with pervanadate (to reduce PTP
activity) and calyculin A and deltamethrin (to reduce serine/threonine phosphatase
activity). The study found that phosphorylation of 70% of tyrosines predicted to be
phosphorylation sites were increased at least two-fold by treatment with these inhibitors,
compared to only 41% and 26% of predicted threonine and serine phosphorylation sites,
respectively. The study by Pan and coworkers supports the hypothesis that
phosphorylation of most tyrosines is basally suppressed by the action of PTPs. However,
a phosphorylation site is identified by this analysis only if processes that mediate this
sites phosphorylation in the presence of the phosphatase inhibitor cocktail are fast enough
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to promote phosphorylation within the 10 min timeframe of the experiment. Thus,
phosphorylation sites might only be revealed by this type of analysis in the presence of a
specific stimulus. Based on this observation, a similar approach involving treatment of
cells with stimulatory ligand either with or without the phosphatase inhibitor cocktail for
a relatively short (e.g., 1 min) period of time would be more appropriate for identification
of proteins that are characterized by relatively rapid ligand-mediated tyrosine phosphate
cycling. Even for this redesigned approach, careful follow-up experiments should be
performed to rule out false positives, which would most likely be due to proteins whose
increased phosphorylation compared to control was due to increased activation of
upstream kinases by the phosphatase inhibitor treatment.
The finding by Pan and coworkers that serine and threonine residues become
phosphorylated in the presence of serine/threonine phosphatase inhibitors may also
support the hypothesis that a smaller fraction of serine/threonine residues compared to
tyrosine residues may also undergo relatively rapid phosphate cycling (194). In addition
to performing a nearly identical study to that described above for tyrosine phosphate
cycling, we also propose a study very similar to our work in Chapters 2 and 3 to quantify
serine/threonine phosphate cycling of a candidate protein. For this study, we suggest the
transforming growth factor beta (TGFβ) receptor as a model system due to its similarities
to EGFR. For example, TGFβ receptor undergoes ligand-mediated oligomerization that
results in phosphorylation of intracellular serine residues, linking the receptor to
downstream signaling (195) and internalization (196). Also, TGFβ receptor-mediated
signaling plays an important role in multiple areas of human health through its mediation
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of the epithelial to mesenchymal transition, which is a differentiation program that plays
a key role in cancer metastasis (197) and cellular sensitivity to EGFR-targeted therapy
(198). As with EGFR, pharmacological inhibitors of the TGFβ receptor kinase have been
developed and characterized (e.g., SB-431542 (199)), which are useful tools for the study
of receptor phosphate cycling (Chapter 2). Finally, significant study has led to multiple
estimates of the kinetics for processes involved in TGFβ-mediated signaling (200),
enabling mechanistic modeling of this system. The study should follow the approaches
outlined in Chapters 2 and 3 to first quantify the rate of TGFβ receptor dephosphorylation
in different cellular compartments and then explore how this dephosphorylation affects
downstream receptor phosphorylation-dependent processes.
Our findings in Chapters 2 and 3 support a critical role for PTPs in regulating
some EGFR-mediated processes via dephosphorylation of the receptor. However,
determining the identities of the PTPs responsible for this regulation remains an
important area of investigation. Specifically, it is important to identify the PTPs that
regulate EGFR in the context of EGFR mutations that promote ligand-independent EGFR
phosphorylation (e.g., EGFRL858R). It is unknown if the same subset of PTPs regulate the
wild-type and mutant receptor. While aberrant EGFR phosphorylation is commonly
attributed to increased kinase activity in the context of EGFR mutants (201), the
possibility that disregulated PTP activity contributes in this context has not been directly
addressed. One possible though technically challenging way to identify the subset of
PTPs that regulates a given tyrosine substrate would involve first generating a library of
substrate trapping PTP mutants, which lack intrinsic catalytic activity but retain an ability
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to bind their substrates (202, 203). Instead of highly transient, PTP-substrate interactions,
substrate-trapping PTPs form stable association with their substrates. Using a display
technique, such as ribosome display (204), to link the DNA to the protein it encodes,
libraries of substrate-trapping PTPs could be screened for interaction with an
immobilized substrate of interest, such as a peptide corresponding to an EGFR
phosphorylation site. A screen performed in this way would suggest candidates for the
subset of PTPs that dephosphorylate a given substrate. Follow up experiments would then
determine if the set of candidate PTPs corresponded to the PTPs responsible for
regulating that substrate in cells. Unfortunately, a library of substrate-trapping PTPs has
not yet been created, to our knowledge, and generation of such a library would be
technically intensive.
While experimental evidence supports the notion of that phosphorylated residues
cycle between phosphorylated and unphosphorylated states, the rate of cycling of other
post-translational modifications (PTMs) has not be measured. In the context of EGFR, we
would argue that the highest priority for a quantitative study of the cycling of a PTM
other than phosphorylation is ubiquitination due to its importance in regulating EGFR
internalization (33, 132, 205), which influences receptor-mediated signaling (34, 46, 47)
and the cellular response to EGFR inhibitors (48-50, 145). If receptor deubiquitination
were found to occur at the cell surface with a time scale that is small relative to the time
scale for EGFR internalization, this would suggest that deubiquitinases might exert
control over receptor internalization. A similar regulatory relationship between a
modification required for internalization and a negative regulator of that modification
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was argued for phosphorylation and PTPs (51). However, our study described in Chapter
3 clearly argues against this finding. Thus, a study that examines ubiquitin cycling and
control of internalization by deubiquitination should consider the possibility that
deubiquitinases may not act rapidly enough to slow EGFR internalization, as we found
for PTPs (Chapter 3). However, some of the protein-protein associations between
activated EGFR and coated pit proteins are mediated by ubiquitination (e.g., Epsin1 (33))
suggesting that ubiquitination, unlike phosphorylation, may remain important for EGFR
internalization after EGFR becomes recruited to a clathrin-coated pit. This suggests that
the time scale over which deubiquitination is able to slow EGFR internalization may be
significantly larger than our estimate of the time scale over which PTPs are able to slow
EGFR internalization. In general, these observations support a study focused on
quantifying the rate at which deubiquitinases deubiquitinate a particular substrate, which
could be determined using a quantitative framework similar to that present in Chapter 3.
However, it is important to note that assessing the importance of ubiquitination in
processes such as EGFR internalization has been particularly difficult due to technical
limitations in detecting ubiquitination (34, 36).

6-3 DYNAMICS OF PROTEIN-PROTEIN ASSOCIATION
One implication of relatively rapid EGFR phosphate cycling is that association
between EGFR and proteins that bind EGFR phosphotyrosines (referred to here as
binding partners) must also cycle between associated and unassociated states relatively
rapidly for PTPs to access EGFR phosphotyrosines with the necessary time scales. This
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implication is supported by measurements of the kinetics of EGFR-GRB2 binding (123),
which suggest that, for a specified GRB2 cellular concentration (85), EGFR cycles
between GRB2-bound and -unbound states in less than 1 s (Chapter 3). A recent study
demonstrated that, as a consequence, the time scale with which GRB2 diffuses away
from membranes containing phosphorylated EGFR is significantly larger than the time
scale for GRB2-EGFR dissociation (192). This is explained by the finding that once
GRB2 dissociates from a particular phosphorylated EGFR it then preferentially rebinds to
an adjacent phosphorylated EGFR ~20 times before diffusing away into the cytosol.
Thus, phosphorylated receptors may be able to maintain an increased concentration of
SH2- or PTB-domain containing proteins in a boundary layer near the plasma membrane.
This hypothesis is generally supported by a study from our lab by Furcht and coworkers
(49) which demonstrated that impaired internalization of phosphorylated EGFR can
sequester activated SHP2 at the plasma membrane (49).
Together, these findings suggest that the relationship between protein diffusion
and protein rebinding might have important consequences for cellular processes.
Quantitatively, this relationship can be assessed by evaluating a ratio of the time scales
for binding partner diffusion and receptor-binding partner association. Considering the
similarity of this ratio to the well-known dimensionless Damköhler number (a ratio of
reaction and diffusion rates) we refer to this ratio as Da. For Da << 1, where diffusion
over a particular length scale is much more rapid than receptor-binding partner
association, binding partner diffusion is not perturbed by association with a
phosphorylated receptor. For Da >> 1, where diffusion is slow compared to receptor174

binding partner association, the binding partner will preferentially associate with a
receptor instead of diffusing away. Based on this and in cells, Da should increase with
increasing exogenous ligand concentration or with activating receptor mutations since
these changes promote receptor phosphorylation which would decrease the receptorbinding partner time scale. Conversely, increased PTP activity, which would reduce
phosphorylated receptor and increase the time scale for binding partner-receptor
association, should decrease Da.
The findings by Furcht and coworkers (49) raise an interesting question: When a
receptor translocates, such as during EGFR internalization, do receptor-bound proteins
also translocate? The answer to this question is related to the relative rates of the involved
processes. Consider a single phosphorylated receptor and a single protein binding partner
that interacts with the receptor via a phosphorylated receptor residue. At t = 0, the
receptor and the binding partner are placed next to one another and the receptor begins
translocating with constant velocity (vtrans). For this discussion, the relevant time scale
(ttrans) is the time it takes the translocating receptor to move a distance equal to the
interaction radius between the receptor and the binding partner (s), such that ttrans =
s/vtrans. If the receptor is able to move s before the receptor and binding partner associate,
then the receptor will leave the binding partner behind during translocation. However, if
the binding partner is able to rebind before the receptor moves s the binding partner
would be carried, at least briefly, by the translocating receptor.
Some experimental studies suggest that receptors are indeed able to mediate
translocation of binding partners. For example, the E3 ubiquitin ligase CBL, which
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associates with EGFR directly via a PTB domain and indirectly via the adapter protein
GRB2, was suggested to remain associated with EGFR during the internalization process
(32). However, these data do not rule out the possibility that instead of remaining
associated to the same CBL molecule, EGFR may unbind and bind many different CBL
molecules throughout the trafficking process. Also, the hypothesis presented by Furcht
and coworkers suggests that EGFR internalization is able to mediate the redistribution of
activated SHP2 to the cell interior during receptor internalization (49). Lastly, EGFR
internalization was shown to be required for STAT3 translocation to the nucleus and
STAT3-mediated gene regulation (206). Assuming that binding partner association with
the receptor is rapid such that a receptor can indeed mediate phosphorylation-dependent
translocation of a binding partner, PTPs could potentially regulate this processes. For
example, sufficiently rapid receptor dephosphorylation kinetics could result in receptor
dephosphorylation before the binding partner was able to bind, allowing the receptor to
move s without any association taking place. Thus, increased PTP activity would
decrease the effective s or decrease the association time scale required for receptormediated binding partner translocation.
Based on this discussion we suggest two hypotheses: 1. PTPs control the ability of
phosphorylated receptors to sequester adapter proteins near the plasma membrane, and 2.
PTPs control the ability of receptor internalization to mediate binding partner
relocalization. Testing the first hypothesis could utilize techniques such as those used to
explore the kinetics of GRB2-EGFR association, specifically total internal reﬂection
(TIR) microscopy (192). We would recommend beginning with experiments in which
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the time a protein spends near the plasma membrane (dwell time (192)) is measured with
EGF alone, with inhibition of PTPs, or with overexpression of a cytoplasmic EGFR PTP.
If PTPs control EGFR-mediated binding partner sequestration, we would hypothesize
that PTP inhibition would increase binding partner dwell time, while PTP overexpression
would reduce binding partner dwell time. To test the second hypothesis, we would build
on the study by Bild and coworkers, which demonstrated that EGFR internalization was
required for appearance of STAT3 in a nuclear fraction prepared from cell lysates (206).
Repeating this measurement in the presence of PTP inhibitors or overexpression of an
EGFR PTP would determine if PTPs are capable of regulating receptor-mediated
translocation of STAT3 to the nucleus. If PTPs control this process, PTP inhibition would
increase the amount of STAT3 appearing in a nuclear fraction, while inhibition of
internalization should reduce nuclear STAT3 levels to baseline.

6-4 RECEPTOR-MEDIATED REGULATION OF PTP ACTIVITY
While our simulations assume that EGFR is regulated by PTP activity that does
not vary with time, multiple previous studies support the possibility that treatment of cells
with growth factors may increase the activity of cellular PTPs. For example, total PTP
activity was found to increase in cells treated with insulin, EGF, or PDGF compared to
BSA control (207). EGF treatment also resulted in an increase in serine/threonine
phosphatase activity in cytosolic fractions from A431 cells (208). More recent studies
have revealed that the activity of the PTPs SHP2 and PTP1B are increased by stimulation
of cells with EGF and nerve growth factor, respectively (115, 190). Considering the
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importance of PTP activity in regulating EGFR phosphorylation and therapeutic efficacy
(Chapters 2-5), it is critical that receptor-mediated regulation of PTP activity be
quantitatively addressed. A study of this nature could begin by measuring the activity of
specific PTPs known to interact with EGFR (e.g., DEP1 (51), PTP1B (57) etc.) as a
function of time after addition of different EGFR ligands. This study could also quantify
general PTP activity of whole cell lysates, which has been done previously (207, 208).
Use of multiple EGFR ligands would address the intriguing hypothesis that different
EGFR ligands might mediate upregulation of PTP activity with different efficiencies.
Pharmacological inhibitors or knockdown of proteins downstream of EGFR should then
be used to explore the mechanistic details of the connectivity between EGFR
phosphorylation and altered PTP activity. Finally, a mechanistic model should be used to
determine if the growth factor-mediated increase in PTP activity is consistent with EGFR
phosphorylation dynamics.
Assuming that PTPs are found to increase in activity downstream of
phosphorylated EGFR, it would be particularly important to determine if this regulatory
relationship is intact in the context of EGFR mutants, such as EGFR L858R, which are
characterized by increased receptor phosphorylation in the absence of ligand. Aberrant
EGFR phosphorylation should lead to increased cellular PTP activity, which should at
least partially negatively feedback and antagonize EGFR phosphorylation. The fact that
EGFRL858R is characterized by increased receptor phosphorylation suggests that negative
feedback involving a receptor-mediated increase in PTP activity is not able to completely
reduce aberrant EGFR phosphorylation. This might be because: 1. induced PTP activity
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is not strong enough to oppose aberrant phosphorylation of the EGFR L858R mutant, 2. the
negative feedback mechanism is disrupted in this context, or 3. ligand binding is
somehow required for this negative feedback. A relatively simple exploratory study
would involve measuring PTP activity in whole cell lysates from cells expressing similar
levels of exogenous WT EGFR or EGFRL858R both in the presence and absence of EGFR
ligands. The measurement of PTP activity could be done using
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P-based (207, 208) or

absorbance-based (49) assays. An identical cellular background for expression of wildtype EGFR and EGFRL858R is necessary to control for possible baseline differences in
PTP expression. If cellular PTP activity is shown to increase with ligand but not with
expression of EGFRL858R compared to wild-type without ligand, this would suggest that
this negative feedback mechanism is disrupted in the context of EGFRL858R which may
contribute to its oncogenic potential. Though purely speculative, one interesting
hypothesis is that internalization of EGFR, which is impaired in the context of
EGFRL858R, is required for this negative feedback.

6-5 IMMUNODETECTION OF EGFR
One of the technical issues that hampered the completion of our experimental
work was the reduced ability of some EGFR antibodies to bind in vitro to EGFR from
HeLa cells treated with at least 1.6 nM (10 ng/mL) EGF for as little as 4 min (Chapters 2
and 3). This disruption resulted in a reduced total EGFR signal by western blot for EGFtreated conditions compared to control. Degradation of EGFR within 4 min of EGF
treatment is inconsistent with
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S-based measurements, which do not rely on EGFR179

antibody binding, of EGFR degradation in SUM102 cells (209). Thus, a more likely
explanation is that EGFR is altered by EGF treatment in a manner that impairs EGFRantibody binding. Consistent with this, treatment of cells with 4 μM of the EGFR tyrosine
kinase inhibitor gefitinib for 45 min after a short EGF stimulation restored EGFR levels
by western blot (89).
We used several approaches to explore how exogenous EGF could impair EGFR
detection by western blotting, leading to multiple findings. First, multiple EGFR
antibodies, including some directed against extracellular EGFR epitopes, were
characterized by this issue. Second, treatment of cells with matrix metalloprotease
inhibitors had no effect on EGF-mediated reductions in EGFR levels, suggesting that
protease-mediated cleavage of EGFR, which has been described previously (210), was
not responsible for loss of EGFR signal from western blots. Third, treatment of cells with
ubiquitin ligase inhibitors (to determine if EGFR ubiquitination disrupted EGFR antibody
binding) did not reverse this effect. Fourth, treatment of cell lysates with deubiquitinases
reduced the ubiquitin signal at high molecular weights by western blot but did not restore
EGFR antibody binding. Thus, the data from our efforts to elucidate the mechanism for
EGFR non-detection did not suggest a clear hypothesis for its occurrence.
Despite our lack of success testing this hypothesis, previous work suggests that
EGFR ubiquitination results in EGFR antibody binding disruption (37). This is consistent
with our finding that treatment with gefitinib, which promotes EGFR deubiquitination
(112), reversed this effect. Understanding and correcting this technical issue should be a
priority due to the false conclusions that could result. For example, one paper
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demonstrated that the ubiquitin ligase inhibitor PYR-41 affected EGFR levels as
measured by western blotting after only 5 min of 100 ng/mL EGF treatment (211). They
concluded that PYR-41 inhibited EGFR degradation. However, this treatment condition
is inconsistent with the EGFR degradation time scale, as described above. Interestingly,
these data are consistent with the notion that EGFR ubiquitination disrupts EGFRantibody binding. Given the importance of accurate quantitative data in studies such as
those presented in Chapters 2 and 3, this technical issue should be addressed or at least
considered when interpreting data.

6-6 EGFR INTERNALIZATION AND EGFR-TARGETED THERAPEUTICS
In addition to the contribution of this thesis to our understanding of the EGFR
internalization mechanism and its regulation by PTPs in the studies in Chapters 2 and 3,
we also participated in a collaboration that elucidated a novel therapeutic resistance
mechanism involving disregulated EGFR internalization (145). Previously, PC9 cells,
which express the activated EGFR mutant EGFRDelE746A750 and are sensitive to treatment
with gefitinib, were made gefinitib-resistant through long-term culture in the presence of
gefitinib (212). The resulting cell line (referred to as PC9 GR) was shown to be sensitive
to the novel, irreversible EGFR tyrosine kinase inhibitor WZ4002 (212). Our
collaborative effort involved rendering PC9 GR cells resistant to WZ4002 through the
same long-term culturing approach and analyzing the mechanism through which
resistance to WZ4002 was conferred (145). The study found that PC9 GR cells rendered
resistant to WZ4002 (PC9 WZR) were characterized by amplification of ERK2, a protein
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involved in pro-survival cellular signaling. Consistent with this, inhibiting MEK, a kinase
upstream of ERK, restored sensitivity of the PC9 WZR cells to WZ4002. Additionally,
introduction of an activated MEK1 allele into the WZ4002-sensitivite PC9 GR cells
conferred WZ4002 resistance. In addition to other functions, ERK can phosphorylate
EGFR at T669 in a process that may affect EGFR turnover (213-215). Consistent with
this, PC9 WZR cells, which are characterized by amplification of ERK2, were
characterized by hyperphosphorylation of EGFR T669. Interestingly, we showed that the
EGF-mediated EGFR internalization rate constant (ke) was elevated in the PC9 WZR
cells compared to control (PC9 GR) cells. This increase in ke was partially rescued by
inhibiting MEK, suggesting that feedback through the ERK pathway is able to increase
EGF-mediated EGFR internalization rates. Previous studies have identified EGFR
internalization as an important controller of EGF-mediated activation of the ERK
signaling pathway (46). Thus, our study identified a novel EGFR kinase inhibitor
resistance mechanism and strengthens the hypothesis that EGFR internalization is an
important controller of the cellular response to EGFR inhibitor treatment.

6-7 EGFR-TARGETED THERAPEUTICS
Therapeutic-mediated reduction of phosphorylated EGFR is a treatment strategy
for some cancers characterized by upregulation of EGFR-mediated signaling (e.g., some
lung cancers (13, 216)). Our findings in Chapter 4 identify EGFR dephosphorylation as a
key process in some contexts for therapeutic-mediated reduction in phosphorylated
EGFR. Furthermore, a previous study by Sharma and coworkers (154) suggests that in
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some cellular contexts, therapeutics trigger cell death by mediating a more rapid
reduction in pro-survival signaling compared to pro-apoptotic signaling, triggering
apoptosis (154, 155). Thus, the time scale with which therapeutics mediate a reduction in
phosphorylated EGFR, which is controlled by PTPs (Chapter 4), may also be an
important determinant of the ability of therapeutics to induce cell death. Sharma and
coworkers partially explore this possibility by treating cells with the general phosphatase
inhibitor okadaic acid (OA), which led to EGFR ligand independent phosphorylation of
AKT, ERK and p38, which are each proteins involved in EGFR-mediated signaling. Cotreatment of cells with gefitinib and OA eliminated phosphorylation of these proteins,
suggesting that EGFR kinase activity is required for OA-mediated AKT, ERK, and p38
phosphorylation. These data support an important role for phosphatases in regulating
proteins that are downstream of EGFR.
Consistent with this, a study by Morris and coworkers (82) involving the PTP
PTPRS observed that PTPRS was deleted in 26% of patient tumor samples from a cohort
of HNSCC patients. Compared to normal tissue, tumors with PTPRS deletion were
characterized by elevated EGFR and AKT phosphorylation. In the same study, siRNAmediated knockdown of PTPRS promoted ligand-independent EGFR phosphorylation in
MDA-584 and FaDu cells (HNSCC cell lines). PTPRS knockdown also increased cellular
resistance to erlotinib (EGFR TKI) in HCC827 and H3255 cells (HNSCC and NSCLC
cell lines, respectively). Lastly, cellular resistance of HNSCC cell lines to treatment with
the EGFR antibody cetuximab and poor prognosis in lung adenocarcinoma patients with
TKI-sensitizing EGFR mutations was predicted by low PTPRS expression. The findings
183

by Morris and coworkers are consistent with our findings in Chapter 2 and 4 for an
important role of receptor dephosphorylation in EGFR-targeted therapeutic efficacy.
Importantly, at least one previous study supports regulation of EGFR phosphorylation by
PTPRS by demonstrating that overexpression of PTPRS in A431 cells reduced EGFR
phosphorylation (62).
Together the studies by Sharma and coworkers and Morris and coworkers support
our prediction of an important role for PTPs in therapeutic efficacy. However, further
work is required to determine if the effect of PTPs in these contexts occurs via
dephosphorylation of EGFR or through direct dephosphorylation of proteins downstream
of EGFR. We propose a study that directly addresses this question by focusing on
PTPRS. Firstly, the proposed study should show that overexpression or knockdown of
PTPRS shifts EGFR-targeted therapeutic dose-response curves for therapeutic-mediated
reduction in EGFR phosphorylation and therapeutic-mediated cell death. If PTPRSmediated dephosphorylation of EGFR affects cellular sensitivity to EGFR-targeted
therapeutics by reducing EGFR-mediated signaling through the AKT pathway, as the
previous studies implies (82), expression of constitutively active PI3K, which is upstream
of AKT, should rescue an increase in sensitivity of cells to therapeutic with PTPRS
overexpression. The study by Morris and coworkers suggests that the EGFR-targeted
therapeutics gefitinib, erlotinib and cetuximab could all be used to test these hypotheses
(82). It would also be interesting to determine if expression of another receptor-like PTP
that has been shown to regulate EGFR phosphorylation (e.g., DEP1 (51, 71)) has the
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same qualitative effect on therapeutic-mediated cell death and reduction in
phosphorylated EGFR.

185

BIBLIOGRAPHY

1.

Y. Yarden, M. X. Sliwkowski, Untangling the ErbB signalling network. Nature
reviews. Molecular cell biology 2, 127 (Feb, 2001).

2.

G. S. Martin, Cell signaling and cancer. Cancer cell 4, 167 (Sep, 2003).

3.

M. A. Lemmon, J. Schlessinger, Cell signaling by receptor tyrosine kinases. Cell
141, 1117 (Jun 25, 2010).

4.

G. Manning, D. B. Whyte, R. Martinez, T. Hunter, S. Sudarsanam, The protein
kinase complement of the human genome. Science 298, 1912 (Dec 6, 2002).

5.

J. Schlessinger, M. A. Lemmon, SH2 and PTB domains in tyrosine kinase
signaling. Science's STKE : signal transduction knowledge environment 2003,
RE12 (Jul 15, 2003).

6.

R. Roskoski, Jr., Src kinase regulation by phosphorylation and dephosphorylation.
Biochemical and biophysical research communications 331, 1 (May 27, 2005).

7.

S. V. Sharma, D. W. Bell, J. Settleman, D. A. Haber, Epidermal growth factor
receptor mutations in lung cancer. Nat Rev Cancer 7, 169 (Mar, 2007).

8.

V. P. Eswarakumar, I. Lax, J. Schlessinger, Cellular signaling by fibroblast
growth factor receptors. Cytokine & growth factor reviews 16, 139 (Apr, 2005).

9.

C. L. Corless, M. C. Heinrich, Molecular pathobiology of gastrointestinal stromal
sarcomas. Annual review of pathology 3, 557 (2008).

10.

P. Wulfing et al., HER2-positive circulating tumor cells indicate poor clinical
outcome in stage I to III breast cancer patients. Clinical cancer research : an
186

official journal of the American Association for Cancer Research 12, 1715 (Mar
15, 2006).
11.

T. Kobayashi et al., A phase II trial of erlotinib in patients with EGFR wild-type
advanced non-small-cell lung cancer. Cancer chemotherapy and pharmacology
69, 1241 (May, 2012).

12.

A. E. Wakeling et al., ZD1839 (Iressa): an orally active inhibitor of epidermal
growth factor signaling with potential for cancer therapy. Cancer Res 62, 5749
(Oct 15, 2002).

13.

T. J. Lynch et al., Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to gefitinib. The New
England journal of medicine 350, 2129 (May 20, 2004).

14.

N. K. Tonks, Protein tyrosine phosphatases: from genes, to function, to disease.
Nature reviews. Molecular cell biology 7, 833 (Nov, 2006).

15.

S. G. Julien, N. Dube, S. Hardy, M. L. Tremblay, Inside the human cancer
tyrosine phosphatome. Nat Rev Cancer 11, 35 (Jan, 2011).

16.

A. Ullrich, J. Schlessinger, Signal transduction by receptors with tyrosine kinase
activity. Cell 61, 203 (Apr 20, 1990).

17.

W. X. Schulze, L. Deng, M. Mann, Phosphotyrosine interactome of the ErbBreceptor kinase family. Molecular systems biology 1, 2005 0008 (2005).

18.

A. Sorkin, L. K. Goh, Endocytosis and intracellular trafficking of ErbBs. Exp Cell
Res 315, 683 (Feb 15, 2009).

187

19.

B. Linggi, G. Carpenter, ErbB receptors: new insights on mechanisms and
biology. Trends in cell biology 16, 649 (Dec, 2006).

20.

N. E. Hynes, H. A. Lane, ERBB receptors and cancer: the complexity of targeted
inhibitors. Nat Rev Cancer 5, 341 (May, 2005).

21.

R. Iwamoto, E. Mekada, ErbB and HB-EGF signaling in heart development and
function. Cell structure and function 31, 1 (2006).

22.

A. M. Honegger et al., A mutant epidermal growth factor receptor with defective
protein tyrosine kinase is unable to stimulate proto-oncogene expression and
DNA synthesis. Molecular and cellular biology 7, 4568 (Dec, 1987).

23.

A.

Sorkin,

C.

Waters,

K.

A.

Overholser,

G.

Carpenter,

Multiple

autophosphorylation site mutations of the epidermal growth factor receptor.
Analysis of kinase activity and endocytosis. J Biol Chem 266, 8355 (May 5,
1991).
24.

D. Alvarado, D. E. Klein, M. A. Lemmon, Structural basis for negative
cooperativity in growth factor binding to an EGF receptor. Cell 142, 568 (Aug 20,
2010).

25.

H. Ogiso et al., Crystal structure of the complex of human epidermal growth
factor and receptor extracellular domains. Cell 110, 775 (Sep 20, 2002).

26.

A. W. Burgess et al., An open-and-shut case? Recent insights into the activation
of EGF/ErbB receptors. Mol Cell 12, 541 (Sep, 2003).

27.

T. Tiganis, Protein tyrosine phosphatases: dephosphorylating the epidermal
growth factor receptor. IUBMB life 53, 3 (Jan, 2002).
188

28.

X. Jiang, F. Huang, A. Marusyk, A. Sorkin, Grb2 regulates internalization of EGF
receptors through clathrin-coated pits. Mol Biol Cell 14, 858 (Mar, 2003).

29.

H. Meisner, B. R. Conway, D. Hartley, M. P. Czech, Interactions of Cbl with
Grb2 and phosphatidylinositol 3'-kinase in activated Jurkat cells. Molecular and
cellular biology 15, 3571 (Jul, 1995).

30.

A. B. Sparks et al., Distinct ligand preferences of Src homology 3 domains from
Src, Yes, Abl, Cortactin, p53bp2, PLCgamma, Crk, and Grb2. Proc Natl Acad Sci
U S A 93, 1540 (Feb 20, 1996).

31.

F. Huang, D. Kirkpatrick, X. Jiang, S. Gygi, A. Sorkin, Differential regulation of
EGF receptor internalization and degradation by multiubiquitination within the
kinase domain. Mol Cell 21, 737 (Mar 17, 2006).

32.

A. A. de Melker, G. van der Horst, J. Calafat, H. Jansen, J. Borst, c-Cbl
ubiquitinates the EGF receptor at the plasma membrane and remains receptor
associated throughout the endocytic route. J Cell Sci 114, 2167 (Jun, 2001).

33.

M. Kazazic et al., Epsin 1 is involved in recruitment of ubiquitinated EGF
receptors into clathrin-coated pits. Traffic 10, 235 (Feb, 2009).

34.

L. K. Goh, F. Huang, W. Kim, S. Gygi, A. Sorkin, Multiple mechanisms
collectively regulate clathrin-mediated endocytosis of the epidermal growth factor
receptor. J Cell Biol 189, 871 (May 31, 2010).

35.

V. Bertelsen et al., A chimeric pre-ubiquitinated EGF receptor is constitutively
endocytosed in a clathrin-dependent, but kinase-independent manner. Traffic 12,
507 (Apr).
189

36.

I. H. Madshus, E. Stang, Internalization and intracellular sorting of the EGF
receptor: a model for understanding the mechanisms of receptor trafficking. J Cell
Sci 122, 3433 (Oct 1, 2009).

37.

F. Huang, L. K. Goh, A. Sorkin, EGF receptor ubiquitination is not necessary for
its internalization. Proc Natl Acad Sci U S A 104, 16904 (Oct 23, 2007).

38.

D. Loerke et al., Cargo and dynamin regulate clathrin-coated pit maturation. PLoS
Biol 7, e57 (Mar 17, 2009).

39.

S. Sigismund et al., Clathrin-mediated internalization is essential for sustained
EGFR signaling but dispensable for degradation. Developmental cell 15, 209
(Aug, 2008).

40.

Y. Frosi et al., A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via
kinase suppression and receptor degradation. J Cell Biol 189, 557 (May 3, 2010).

41.

H. Ying et al., Mig-6 controls EGFR trafficking and suppresses gliomagenesis.
Proceedings of the National Academy of Sciences of the United States of America
107, 6912 (Apr 13, 2010).

42.

S. Sigismund et al., Clathrin-independent endocytosis of ubiquitinated cargos.
Proc Natl Acad Sci U S A 102, 2760 (Feb 22, 2005).

43.

H. S. Wiley et al., The role of tyrosine kinase activity in endocytosis,
compartmentation, and down-regulation of the epidermal growth factor receptor.
J Biol Chem 266, 11083 (Jun 15, 1991).

44.

M. J. Geisow, W. H. Evans, pH in the endosome. Measurements during
pinocytosis and receptor-mediated endocytosis. Exp Cell Res 150, 36 (Jan, 1984).
190

45.

M. Nunez, K. H. Mayo, C. Starbuck, D. Lauffenburger, pH sensitivity of
epidermal growth factor receptor complexes. Journal of cellular biochemistry 51,
312 (Mar, 1993).

46.

A. V. Vieira, C. Lamaze, S. L. Schmid, Control of EGF receptor signaling by
clathrin-mediated endocytosis. Science 274, 2086 (Dec 20, 1996).

47.

L. P. Sousa et al., Suppression of EGFR endocytosis by dynamin depletion
reveals that EGFR signaling occurs primarily at the plasma membrane. Proc Natl
Acad Sci U S A 109, 4419 (Mar 20, 2012).

48.

M. J. Lazzara et al., Impaired SHP2-mediated extracellular signal-regulated
kinase activation contributes to gefitinib sensitivity of lung cancer cells with
epidermal growth factor receptor-activating mutations. Cancer Res 70, 3843 (May
1, 2010).

49.

C. M. Furcht, A. R. Munoz Rojas, D. Nihalani, M. J. Lazzara, Diminished
functional role and altered localization of SHP2 in non-small cell lung cancer
cells with EGFR-activating mutations. Oncogene, (Jul 9, 2012).

50.

B. S. Hendriks et al., Decreased internalisation of erbB1 mutants in lung cancer is
linked with a mechanism conferring sensitivity to gefitinib. Systems biology 153,
457 (Nov, 2006).

51.

G. Tarcic et al., An unbiased screen identifies DEP-1 tumor suppressor as a
phosphatase controlling EGFR endocytosis. Curr Biol 19, 1788 (Nov 17, 2009).

191

52.

T. Sorkina, F. Huang, L. Beguinot, A. Sorkin, Effect of tyrosine kinase inhibitors
on clathrin-coated pit recruitment and internalization of epidermal growth factor
receptor. J Biol Chem 277, 27433 (Jul 26, 2002).

53.

A. Alonso et al., Protein tyrosine phosphatases in the human genome. Cell 117,
699 (Jun 11, 2004).

54.

N. K. Tonks, C. D. Diltz, E. H. Fischer, Purification of the major protein-tyrosinephosphatases of human placenta. J Biol Chem 263, 6722 (May 15, 1988).

55.

N. K. Tonks, C. D. Diltz, E. H. Fischer, Characterization of the major proteintyrosine-phosphatases of human placenta. J Biol Chem 263, 6731 (May 15, 1988).

56.

J. V. Frangioni, P. H. Beahm, V. Shifrin, C. A. Jost, B. G. Neel, The
nontransmembrane tyrosine phosphatase PTP-1B localizes to the endoplasmic
reticulum via its 35 amino acid C-terminal sequence. Cell 68, 545 (Feb 7, 1992).

57.

R. Lammers et al., Differential activities of protein tyrosine phosphatases in intact
cells. J Biol Chem 268, 22456 (Oct 25, 1993).

58.

Y. Zhang et al., Time-resolved mass spectrometry of tyrosine phosphorylation
sites in the epidermal growth factor receptor signaling network reveals dynamic
modules. Molecular & cellular proteomics : MCP 4, 1240 (Sep, 2005).

59.

K. A. Lund, L. K. Opresko, C. Starbuck, B. J. Walsh, H. S. Wiley, Quantitative
analysis of the endocytic system involved in hormone-induced receptor
internalization. J Biol Chem 265, 15713 (Sep 15, 1990).

60.

I. A. Yudushkin et al., Live-cell imaging of enzyme-substrate interaction reveals
spatial regulation of PTP1B. Science 315, 115 (Jan 5, 2007).
192

61.

S. Sebastian et al., The complexity of targeting EGFR signalling in cancer: from
expression to turnover. Biochimica et biophysica acta 1766, 120 (Aug, 2006).

62.

E. Suarez Pestana et al., The transmembrane protein tyrosine phosphatase
RPTPsigma modulates signaling of the epidermal growth factor receptor in A431
cells. Oncogene 18, 4069 (Jul 15, 1999).

63.

Y. Xu, L. J. Tan, V. Grachtchouk, J. J. Voorhees, G. J. Fisher, Receptor-type
protein-tyrosine phosphatase-kappa regulates epidermal growth factor receptor
function. J Biol Chem 280, 42694 (Dec 30, 2005).

64.

N. Hashimoto, W. R. Zhang, B. J. Goldstein, Insulin receptor and epidermal
growth factor receptor dephosphorylation by three major rat liver protein-tyrosine
phosphatases expressed in a recombinant bacterial system. Biochem J 284 ( Pt 2),
569 (Jun 1, 1992).

65.

D. T. Kulas, B. J. Goldstein, R. A. Mooney, The transmembrane protein-tyrosine
phosphatase LAR modulates signaling by multiple receptor tyrosine kinases. J
Biol Chem 271, 748 (Jan 12, 1996).

66.

T. Tenev et al., Both SH2 domains are involved in interaction of SHP-1 with the
epidermal growth factor receptor but cannot confer receptor-directed activity to
SHP-1/SHP-2 chimera. J Biol Chem 272, 5966 (Feb 28, 1997).

67.

H. Keilhack et al., Phosphotyrosine 1173 mediates binding of the protein-tyrosine
phosphatase SHP-1 to the epidermal growth factor receptor and attenuation of
receptor signaling. J Biol Chem 273, 24839 (Sep 18, 1998).

193

68.

T. Tiganis, A. M. Bennett, K. S. Ravichandran, N. K. Tonks, Epidermal growth
factor receptor and the adaptor protein p52Shc are specific substrates of T-cell
protein tyrosine phosphatase. Molecular and cellular biology 18, 1622 (Mar,
1998).

69.

M. Klingler-Hoffmann et al., The protein tyrosine phosphatase TCPTP suppresses
the tumorigenicity of glioblastoma cells expressing a mutant epidermal growth
factor receptor. J Biol Chem 276, 46313 (Dec 7, 2001).

70.

Z. Wang, M. Wang, J. S. Lazo, B. I. Carr, Identification of epidermal growth
factor receptor as a target of Cdc25A protein phosphatase. J Biol Chem 277,
19470 (May 31, 2002).

71.

T. A. Berset, E. F. Hoier, A. Hajnal, The C. elegans homolog of the mammalian
tumor suppressor Dep-1/Scc1 inhibits EGFR signaling to regulate binary cell fate
decisions. Genes Dev 19, 1328 (Jun 1, 2005).

72.

K. Horsch, M. D. Schaller, N. E. Hynes, The protein tyrosine phosphatase-PEST
is implicated in the negative regulation of epidermal growth factor on PRL
signaling in mammary epithelial cells. Mol Endocrinol 15, 2182 (Dec, 2001).

73.

R. Schaapveld, B. Wieringa, W. Hendriks, Receptor-like protein tyrosine
phosphatases: alike and yet so different. Mol Biol Rep 24, 247 (Nov, 1997).

74.

T. Tenev et al., Perinuclear localization of the protein-tyrosine phosphatase SHP1 and inhibition of epidermal growth factor-stimulated STAT1/3 activation in
A431 cells. Eur J Cell Biol 79, 261 (Apr, 2000).

194

75.

A. Charest, J. Wagner, S. H. Shen, M. L. Tremblay, Murine protein tyrosine
phosphatase-PEST, a stable cytosolic protein tyrosine phosphatase. Biochem J
308 ( Pt 2), 425 (Jun 1, 1995).

76.

M. C. Monteleone et al., ER-bound protein tyrosine phosphatase PTP1B interacts
with Src at the plasma membrane/substrate interface. PloS one 7, e38948 (2012).

77.

A. Bourdeau, N. Dube, M. L. Tremblay, Cytoplasmic protein tyrosine
phosphatases, regulation and function: the roles of PTP1B and TC-PTP. Curr
Opin Cell Biol 17, 203 (Apr, 2005).

78.

T. Tiganis, B. E. Kemp, N. K. Tonks, The protein-tyrosine phosphatase TCPTP
regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3kinase-dependent signaling. J Biol Chem 274, 27768 (Sep 24, 1999).

79.

H. Kallstrom, A. Lindqvist, V. Pospisil, A. Lundgren, C. K. Rosenthal, Cdc25A
localisation and shuttling: characterisation of sequences mediating nuclear export
and import. Exp Cell Res 303, 89 (Feb 1, 2005).

80.

M. Offterdinger, V. Georget, A. Girod, P. I. Bastiaens, Imaging phosphorylation
dynamics of the epidermal growth factor receptor. J Biol Chem 279, 36972 (Aug
27, 2004).

81.

G. Huyer et al., Mechanism of inhibition of protein-tyrosine phosphatases by
vanadate and pervanadate. J Biol Chem 272, 843 (Jan 10, 1997).

82.

L. G. Morris et al., Genomic dissection of the epidermal growth factor receptor
(EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase

195

PTPRS in head and neck cancers. Proc Natl Acad Sci U S A 108, 19024 (Nov 22,
2011).
83.

M. J. Lazzara, D. A. Lauffenburger, Quantitative modeling perspectives on the
ErbB system of cell regulatory processes. Exp Cell Res 315, 717 (Feb 15, 2009).

84.

C. Starbuck, D. A. Lauffenburger, Mathematical model for the effects of
epidermal growth factor receptor trafficking dynamics on fibroblast proliferation
responses. Biotechnology progress 8, 132 (Mar-Apr, 1992).

85.

B. N. Kholodenko, O. V. Demin, G. Moehren, J. B. Hoek, Quantification of short
term signaling by the epidermal growth factor receptor. J Biol Chem 274, 30169
(Oct 15, 1999).

86.

B. Schoeberl et al., Therapeutically targeting ErbB3: a key node in ligand-induced
activation of the ErbB receptor-PI3K axis. Science signaling 2, ra31 (2009).

87.

B. S. Hendriks, L. K. Opresko, H. S. Wiley, D. Lauffenburger, Quantitative
analysis of HER2-mediated effects on HER2 and epidermal growth factor
receptor endocytosis: distribution of homo- and heterodimers depends on relative
HER2 levels. J Biol Chem 278, 23343 (Jun 27, 2003).

88.

B. S. Hendriks et al., Computational modelling of ErbB family phosphorylation
dynamics in response to transforming growth factor alpha and heregulin indicates
spatial compartmentation of phosphatase activity. Systems biology 153, 22 (Jan,
2006).

196

89.

C. S. Monast, C. M. Furcht, M. J. Lazzara, Computational analysis of the
regulation of EGFR by protein tyrosine phosphatases. Biophysical journal 102,
2012 (May 2, 2012).

90.

Z. A. Knight, K. M. Shokat, Features of selective kinase inhibitors. Chemistry &
biology 12, 621 (Jun, 2005).

91.

F. G. Haj, B. Markova, L. D. Klaman, F. D. Bohmer, B. G. Neel, Regulation of
receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B. J Biol
Chem 278, 739 (Jan 10, 2003).

92.

C. Gomez-Uribe, G. C. Verghese, L. A. Mirny, Operating regimes of signaling
cycles: statics, dynamics, and noise filtering. PLoS Comput Biol 3, e246 (Dec,
2007).

93.

H. Qian, D. A. Beard, Metabolic futile cycles and their functions: a systems
analysis of energy and control. Syst Biol (Stevenage) 153, 192 (Jul, 2006).

94.

A. Goldbeter, D. E. Koshland, Jr., An amplified sensitivity arising from covalent
modification in biological systems. Proc Natl Acad Sci U S A 78, 6840 (Nov,
1981).

95.

R. Heinrich, B. G. Neel, T. A. Rapoport, Mathematical models of protein kinase
signal transduction. Mol Cell 9, 957 (May, 2002).

96.

F. G. Haj, P. J. Verveer, A. Squire, B. G. Neel, P. I. Bastiaens, Imaging sites of
receptor dephosphorylation by PTP1B on the surface of the endoplasmic
reticulum. Science 295, 1708 (Mar 1, 2002).

197

97.

B. S. Hendriks, L. K. Opresko, H. S. Wiley, D. Lauffenburger, Coregulation of
epidermal growth factor receptor/human epidermal growth factor receptor 2
(HER2) levels and locations: quantitative analysis of HER2 overexpression
effects. Cancer Res 63, 1130 (Mar 1, 2003).

98.

B. Schoeberl, C. Eichler-Jonsson, E. D. Gilles, G. Muller, Computational
modeling of the dynamics of the MAP kinase cascade activated by surface and
internalized EGF receptors. Nature biotechnology 20, 370 (Apr, 2002).

99.

J. Purvis, V. Ilango, R. Radhakrishnan, Role of network branching in eliciting
differential short-term signaling responses in the hypersensitive epidermal growth
factor receptor mutants implicated in lung cancer. Biotechnology progress 24, 540
(May-Jun, 2008).

100.

A. R. French, D. K. Tadaki, S. K. Niyogi, D. A. Lauffenburger, Intracellular
trafficking of epidermal growth factor family ligands is directly influenced by the
pH sensitivity of the receptor/ligand interaction. J Biol Chem 270, 4334 (Mar 3,
1995).

101.

Y. X. Fan, L. Wong, T. B. Deb, G. R. Johnson, Ligand regulates epidermal
growth factor receptor kinase specificity: activation increases preference for
GAB1 and SHC versus autophosphorylation sites. J Biol Chem 279, 38143 (Sep
10, 2004).

102.

M. V. Zamaraeva et al., Cells die with increased cytosolic ATP during apoptosis:
a bioluminescence study with intracellular luciferase. Cell Death Differ 12, 1390
(Nov, 2005).
198

103.

M. J. Hubley, R. C. Rosanske, T. S. Moerland, Diffusion coefficients of ATP and
creatine phosphate in isolated muscle: pulsed gradient 31P NMR of small
biological samples. NMR Biomed 8, 72 (Apr, 1995).

104.

D. Lauffenburger, J. Linderman, Receptors: Models for Binding, Trafficking, and
Signaling. (Oxford University Press, USA, 1996).

105.

M. W. Pedersen, N. Pedersen, L. H. Ottesen, H. S. Poulsen, Differential response
to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J
Cancer 93, 915 (Oct 17, 2005).

106.

I. G. Ganley, K. Carroll, L. Bittova, S. Pfeffer, Rab9 GTPase regulates late
endosome size and requires effector interaction for its stability. Mol Biol Cell 15,
5420 (Dec, 2004).

107.

M. Zhou et al., Real-time measurements of kinetics of EGF binding to soluble
EGF receptor monomers and dimers support the dimerization model for receptor
activation. Biochemistry 32, 8193 (Aug 17, 1993).

108.

J. F. Doody et al., Inhibitory activity of cetuximab on epidermal growth factor
receptor mutations in non small cell lung cancers. Molecular cancer therapeutics
6, 2642 (Oct, 2007).

109.

M. F. Ciaccio, J. P. Wagner, C. P. Chuu, D. A. Lauffenburger, R. B. Jones,
Systems analysis of EGF receptor signaling dynamics with microwestern arrays.
Nature methods 7, 148 (Feb, 2010).

199

110.

J. A. Berkers, P. M. van Bergen en Henegouwen, J. Boonstra, Three classes of
epidermal growth factor receptors on HeLa cells. J Biol Chem 266, 922 (Jan 15,
1991).

111.

H. Schmidt, M. Jirstrand, Systems Biology Toolbox for MATLAB: a
computational platform for research in systems biology. Bioinformatics 22, 514
(Feb 15, 2006).

112.

K. Umebayashi, H. Stenmark, T. Yoshimori, Ubc4/5 and c-Cbl continue to
ubiquitinate EGF receptor after internalization to facilitate polyubiquitination and
degradation. Mol Biol Cell 19, 3454 (Aug, 2008).

113.

E. E. Sel'kov, N. V. Avseenko, B. Kirsta Iu, [Allosteric regulation in the open
futile cycle fructose-6-P--fructose-1,6-P2]. Biofizika 24, 829 (Sep-Oct, 1979).

114.

F. Buttgereit, M. D. Brand, A hierarchy of ATP-consuming processes in
mammalian cells. Biochem J 312 ( Pt 1), 163 (Nov 15, 1995).

115.

T. Araki, H. Nawa, B. G. Neel, Tyrosyl phosphorylation of Shp2 is required for
normal ERK activation in response to some, but not all, growth factors. J Biol
Chem 278, 41677 (Oct 24, 2003).

116.

M. G. Lampugnani, F. Orsenigo, M. C. Gagliani, C. Tacchetti, E. Dejana,
Vascular endothelial cadherin controls VEGFR-2 internalization and signaling
from intracellular compartments. J Cell Biol 174, 593 (Aug 14, 2006).

117.

S. Kermorgant, P. J. Parker, Receptor trafficking controls weak signal delivery: a
strategy used by c-Met for STAT3 nuclear accumulation. J Cell Biol 182, 855
(Sep 8, 2008).
200

118.

N. Li, M. Lorinczi, K. Ireton, L. A. Elferink, Specific Grb2-mediated interactions
regulate clathrin-dependent endocytosis of the cMet-tyrosine kinase. J Biol Chem
282, 16764 (Jun 8, 2007).

119.

N. W. Gale, S. Kaplan, E. J. Lowenstein, J. Schlessinger, D. Bar-Sagi, Grb2
mediates the EGF-dependent activation of guanine nucleotide exchange on Ras.
Nature 363, 88 (May 6, 1993).

120.

C. Ponzetto et al., A novel recognition motif for phosphatidylinositol 3-kinase
binding mediates its association with the hepatocyte growth factor/scatter factor
receptor. Molecular and cellular biology 13, 4600 (Aug, 1993).

121.

Y. Xu et al., Receptor-type protein tyrosine phosphatase beta (RPTP-beta)
directly dephosphorylates and regulates hepatocyte growth factor receptor
(HGFR/Met) function. J Biol Chem 286, 15980 (May 6, 2011).

122.

M. Y. Hsieh, S. Yang, M. A. Raymond-Stinz, J. S. Edwards, B. S. Wilson, Spatiotemporal modeling of signaling protein recruitment to EGFR. BMC systems
biology 4, 57 (2010).

123.

M. Morimatsu et al., Multiple-state reactions between the epidermal growth factor
receptor and Grb2 as observed by using single-molecule analysis. Proc Natl Acad
Sci U S A 104, 18013 (Nov 13, 2007).

124.

S. Felder et al., SH2 domains exhibit high-affinity binding to tyrosinephosphorylated peptides yet also exhibit rapid dissociation and exchange.
Molecular and cellular biology 13, 1449 (Mar, 1993).

201

125.

A. C. Myers, J. S. Kovach, S. Vuk-Pavlovic, Binding, internalization, and
intracellular processing of protein ligands. Derivation of rate constants by
computer modeling. J Biol Chem 262, 6494 (May 15, 1987).

126.

Y. Shan et al., Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR
Kinase and Promote Receptor Dimerization. Cell 149, 860 (May 11).

127.

R. De Wit, M. Makkinje, J. Boonstra, A. J. Verkleij, J. A. Post, Hydrogen
peroxide

reversibly

inhibits

epidermal

growth

factor

(EGF)

receptor

internalization and coincident ubiquitination of the EGF receptor and Eps15.
FASEB journal : official publication of the Federation of American Societies for
Experimental Biology 15, 306 (Feb, 2001).
128.

A. Sorkin, J. E. Duex, Quantitative analysis of endocytosis and turnover of
epidermal growth factor (EGF) and EGF receptor. Current protocols in cell
biology / editorial board, Juan S. Bonifacino ... [et al.] Chapter 15, Unit 15 14
(Mar, 2010).

129.

T. Sorkina, A. Bild, F. Tebar, A. Sorkin, Clathrin, adaptors and eps15 in
endosomes containing activated epidermal growth factor receptors. J Cell Sci 112
( Pt 3), 317 (Feb, 1999).

130.

J. Raguz, S. Wagner, I. Dikic, D. Hoeller, Suppressor of T-cell receptor signalling
1 and 2 differentially regulate endocytosis and signalling of receptor tyrosine
kinases. FEBS Lett 581, 4767 (Oct 2, 2007).

131.

T. Zhang, J. Ma, X. Cao, Grb2 regulates Stat3 activation negatively in epidermal
growth factor signalling. The Biochemical journal 376, 457 (Dec 1, 2003).
202

132.

E. Stang et al., Cbl-dependent ubiquitination is required for progression of EGF
receptors into clathrin-coated pits. Mol Biol Cell 15, 3591 (Aug, 2004).

133.

P. Burke, K. Schooler, H. S. Wiley, Regulation of epidermal growth factor
receptor signaling by endocytosis and intracellular trafficking. Mol Biol Cell 12,
1897 (Jun, 2001).

134.

P. Liu et al., A single ligand is sufficient to activate EGFR dimers. Proc Natl
Acad Sci U S A 109, 10861 (Jul 3, 2012).

135.

V. A. Pollack et al., Inhibition of epidermal growth factor receptor-associated
tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of
receptor inhibition in situ and antitumor effects in athymic mice. The Journal of
pharmacology and experimental therapeutics 291, 739 (Nov, 1999).

136.

S. Li et al., Structural basis for inhibition of the epidermal growth factor receptor
by cetuximab. Cancer cell 7, 301 (Apr, 2005).

137.

J. Amann et al., Aberrant epidermal growth factor receptor signaling and
enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65, 226 (Jan
1, 2005).

138.

Y. Lu, K. Liang, X. Li, Z. Fan, Responses of cancer cells with wild-type or
tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to
EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor1alpha. Molecular cancer 6, 63 (2007).

203

139.

S. Yoshikawa et al., Structural basis for the altered drug sensitivities of non-small
cell lung cancer-associated mutants of human epidermal growth factor receptor.
Oncogene 32, 27 (Jan 3, 2013).

140.

K. Yonesaka et al., Autocrine production of amphiregulin predicts sensitivity to
both gefitinib and cetuximab in EGFR wild-type cancers. Clinical cancer
research : an official journal of the American Association for Cancer Research
14, 6963 (Nov 1, 2008).

141.

R. P. Araujo, E. F. Petricoin, L. A. Liotta, A mathematical model of combination
therapy using the EGFR signaling network. Bio Systems 80, 57 (Apr, 2005).

142.

F. Lange, K. Rateitschak, C. Kossow, O. Wolkenhauer, R. Jaster, Insights into
erlotinib action in pancreatic cancer cells using a combined experimental and
mathematical approach. World journal of gastroenterology : WJG 18, 6226 (Nov
21, 2012).

143.

Y. Cheng, W. H. Prusoff, Relationship between the inhibition constant (K1) and
the concentration of inhibitor which causes 50 per cent inhibition (I50) of an
enzymatic reaction. Biochemical pharmacology 22, 3099 (Dec 1, 1973).

144.

Y. Naruo et al., Epidermal growth factor receptor mutation in combination with
expression of MIG6 alters gefitinib sensitivity. BMC systems biology 5, 29
(2011).

145.

D. Ercan et al., Reactivation of ERK Signaling Causes Resistance to EGFR
Kinase Inhibitors. Cancer discovery 2, 934 (Oct, 2012).

204

146.

D. Patel et al., Monoclonal antibody cetuximab binds to and down-regulates
constitutively activated epidermal growth factor receptor vIII on the cell surface.
Anticancer research 27, 3355 (Sep-Oct, 2007).

147.

C. M. Waters, K. A. Overholser, A. Sorkin, G. Carpenter, Analysis of the
influences of the E5 transforming protein on kinetic parameters of epidermal
growth factor binding and metabolism. Journal of cellular physiology 152, 253
(Aug, 1992).

148.

M. Shoyab, G. D. Plowman, V. L. McDonald, J. G. Bradley, G. J. Todaro,
Structure and function of human amphiregulin: a member of the epidermal growth
factor family. Science 243, 1074 (Feb 24, 1989).

149.

R. Adam et al., Modulation of the receptor binding affinity of amphiregulin by
modification of its carboxyl terminal tail. Biochimica et biophysica acta 1266, 83
(Apr 6, 1995).

150.

K. A. Stern, T. L. Place, N. L. Lill, EGF and amphiregulin differentially regulate
Cbl recruitment to endosomes and EGF receptor fate. The Biochemical journal
410, 585 (Mar 15, 2008).

151.

J. Albanell et al., Pharmacodynamic studies of the epidermal growth factor
receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and
molecular consequences of receptor inhibition. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 20, 110 (Jan 1,
2002).

205

152.

T. Mukohara et al., Differential effects of gefitinib and cetuximab on non-smallcell lung cancers bearing epidermal growth factor receptor mutations. Journal of
the National Cancer Institute 97, 1185 (Aug 17, 2005).

153.

D. Ercan et al., Amplification of EGFR T790M causes resistance to an
irreversible EGFR inhibitor. Oncogene 29, 2346 (Apr 22, 2010).

154.

S. V. Sharma et al., A common signaling cascade may underlie "addiction" to the
Src, BCR-ABL, and EGF receptor oncogenes. Cancer cell 10, 425 (Nov, 2006).

155.

S. V. Sharma, M. A. Fischbach, D. A. Haber, J. Settleman, "Oncogenic shock":
explaining oncogene addiction through differential signal attenuation. Clinical
cancer research : an official journal of the American Association for Cancer
Research 12, 4392s (Jul 15, 2006).

156.

S. Sebastian et al., Validation of gefitinib effectiveness in a broad panel of head
and neck squamous carcinoma cells. International journal of molecular medicine
21, 809 (Jun, 2008).

157.

C. D. Coldren et al., Baseline gene expression predicts sensitivity to gefitinib in
non-small cell lung cancer cell lines. Molecular cancer research : MCR 4, 521
(Aug, 2006).

158.

C. H. Yun et al., The T790M mutation in EGFR kinase causes drug resistance by
increasing the affinity for ATP. Proc Natl Acad Sci U S A 105, 2070 (Feb 12,
2008).

159.

C. Hegedus et al., Interaction of the EGFR inhibitors gefitinib, vandetanib,
pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the
206

emergence and reversal of cancer drug resistance. Biochemical pharmacology 84,
260 (Aug 1, 2012).
160.

C. Montagut et al., Identification of a mutation in the extracellular domain of the
Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal
cancer. Nature medicine 18, 221 (Feb, 2012).

161.

Y. Lu et al., Epidermal growth factor receptor (EGFR) ubiquitination as a
mechanism of acquired resistance escaping treatment by the anti-EGFR
monoclonal antibody cetuximab. Cancer Res 67, 8240 (Sep 1, 2007).

162.

D. L. Wheeler et al., Mechanisms of acquired resistance to cetuximab: role of
HER (ErbB) family members. Oncogene 27, 3944 (Jun 26, 2008).

163.

W. K. Wu et al., Expression of ErbB receptors and their cognate ligands in gastric
and colon cancer cell lines. Anticancer research 29, 229 (Jan, 2009).

164.

C. Li, M. Iida, E. F. Dunn, A. J. Ghia, D. L. Wheeler, Nuclear EGFR contributes
to acquired resistance to cetuximab. Oncogene 28, 3801 (Oct 29, 2009).

165.

P. Matar et al., Combined epidermal growth factor receptor targeting with the
tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody
cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clinical
cancer research : an official journal of the American Association for Cancer
Research 10, 6487 (Oct 1, 2004).

166.

J. Y. Wu et al., Use of cetuximab after failure of gefitinib in patients with
advanced non-small-cell lung cancer. Clinical lung cancer 11, 257 (Jul 1, 2010).

207

167.

A. N. Plotnikov, J. Schlessinger, S. R. Hubbard, M. Mohammadi, Structural basis
for FGF receptor dimerization and activation. Cell 98, 641 (Sep 3, 1999).

168.

T. P. Garrett et al., Crystal structure of a truncated epidermal growth factor
receptor extracellular domain bound to transforming growth factor alpha. Cell
110, 763 (Sep 20, 2002).

169.

W. A. Barton et al., Crystal structures of the Tie2 receptor ectodomain and the
angiopoietin-2-Tie2 complex. Nature structural & molecular biology 13, 524
(Jun, 2006).

170.

K. T. Kim et al., Oligomerization and multimerization are critical for
angiopoietin-1 to bind and phosphorylate Tie2. J Biol Chem 280, 20126 (May 20,
2005).

171.

J. P. Himanen, D. B. Nikolov, Eph signaling: a structural view. Trends in
neurosciences 26, 46 (Jan, 2003).

172.

T. Wehrman et al., Structural and mechanistic insights into nerve growth factor
interactions with the TrkA and p75 receptors. Neuron 53, 25 (Jan 4, 2007).

173.

R. A. Bradshaw et al., Nerve growth factor: structure/function relationships.
Protein Sci 3, 1901 (Nov, 1994).

174.

X. Yu, K. D. Sharma, T. Takahashi, R. Iwamoto, E. Mekada, Ligand-independent
dimer formation of epidermal growth factor receptor (EGFR) is a step separable
from ligand-induced EGFR signaling. Mol Biol Cell 13, 2547 (Jul, 2002).

208

175.

T. Moriki, H. Maruyama, I. N. Maruyama, Activation of preformed EGF receptor
dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 311,
1011 (Aug 31, 2001).

176.

J. Shen, I. N. Maruyama, Nerve growth factor receptor TrkA exists as a
preformed, yet inactive, dimer in living cells. FEBS Lett 585, 295 (Jan 21, 2011).

177.

P. S. Mischel et al., Nerve growth factor signals via preexisting TrkA receptor
oligomers. Biophys J 83, 968 (Aug, 2002).

178.

S. Sasagawa, Y. Ozaki, K. Fujita, S. Kuroda, Prediction and validation of the
distinct dynamics of transient and sustained ERK activation. Nat Cell Biol 7, 365
(Apr, 2005).

179.

A. S. Perelson, C. DeLisi, F. W. Wiegel, Eds., Cell Surface Dynamics: Concepts
and Models, (Marcel Dekker, Inc., New York, 1984), pp. 223-276.

180.

M. Dembo, B. Goldstein, Theory of equilibrium binding of symmetric bivalent
haptens to cell surface antibody: application to histamine release from basophils. J
Immunol 121, 345 (Jul, 1978).

181.

D. W. MacGlashan, Jr., M. Dembo, B. Goldstein, Test of a theory relating to the
cross-linking of IgE antibody on the surface of human basophils. J Immunol 135,
4129 (Dec, 1985).

182.

J. H. Chang, E. Mellon, N. C. Schanen, J. L. Twiss, Persistent TrkA activity is
necessary to maintain transcription in neuronally differentiated PC12 cells. J Biol
Chem 278, 42877 (Oct 31, 2003).

209

183.

S. Maliartchouk, H. U. Saragovi, Optimal nerve growth factor trophic signals
mediated by synergy of TrkA and p75 receptor-specific ligands. J Neurosci 17,
6031 (Aug 15, 1997).

184.

B. R. Pflug, C. Dionne, D. R. Kaplan, J. Lynch, D. Djakiew, Expression of a Trk
high affinity nerve growth factor receptor in the human prostate. Endocrinology
136, 262 (Jan, 1995).

185.

S. Chevalier et al., Expression and functionality of the trkA proto-oncogene
product/NGF receptor in undifferentiated hematopoietic cells. Blood 83, 1479
(Mar 15, 1994).

186.

A. Sutter, R. J. Riopelle, R. M. Harris-Warrick, E. M. Shooter, Nerve growth
factor receptors. Characterization of two distinct classes of binding sites on chick
embryo sensory ganglia cells. J Biol Chem 254, 5972 (Jul 10, 1979).

187.

D. Mahadeo, L. Kaplan, M. V. Chao, B. L. Hempstead, High affinity nerve
growth factor binding displays a faster rate of association than p140trk binding.
Implications for multi-subunit polypeptide receptors. J Biol Chem 269, 6884 (Mar
4, 1994).

188.

A. Zapf-Colby, J. M. Olefsky, Nerve growth factor processing and trafficking
events following TrkA-mediated endocytosis. Endocrinology 139, 3232 (Jul,
1998).

189.

Y. Takahashi et al., Ligand-induced downregulation of TrkA is partly regulated
through ubiquitination by Cbl. FEBS Lett 585, 1741 (Jun 23, 2011).

210

190.

P. J. Chacon, M. A. Arevalo, A. R. Tebar, NGF-activated protein tyrosine
phosphatase 1B mediates the phosphorylation and degradation of I-kappa-Balpha
coupled to NF-kappa-B activation, thereby controlling dendrite morphology.
Molecular and cellular neurosciences 43, 384 (Apr, 2010).

191.

D. Rotin et al., SH2 domains prevent tyrosine dephosphorylation of the EGF
receptor: identification of Tyr992 as the high-affinity binding site for SH2
domains of phospholipase C gamma. EMBO J 11, 559 (Feb, 1992).

192.

D. Oh et al., Fast rebinding increases dwell time of Src homology 2 (SH2)containing proteins near the plasma membrane. Proc Natl Acad Sci U S A 109,
14024 (Aug 28, 2012).

193.

B. J. Mayer, Perspective: Dynamics of receptor tyrosine kinase signaling
complexes. FEBS Lett 586, 2575 (Aug 14, 2012).

194.

C. Pan, F. Gnad, J. V. Olsen, M. Mann, Quantitative phosphoproteome analysis of
a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8,
4534 (Nov, 2008).

195.

J. Massague, TGFbeta signalling in context. Nature reviews. Molecular cell
biology 13, 616 (Oct, 2012).

196.

G. M. Di Guglielmo, C. Le Roy, A. F. Goodfellow, J. L. Wrana, Distinct
endocytic pathways regulate TGF-beta receptor signalling and turnover. Nature
cell biology 5, 410 (May, 2003).

197.

C. L. Chaffer, R. A. Weinberg, A perspective on cancer cell metastasis. Science
331, 1559 (Mar 25, 2011).
211

198.

L. A. Byers et al., An epithelial-mesenchymal transition gene signature predicts
resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target
for overcoming EGFR inhibitor resistance. Clinical cancer research : an official
journal of the American Association for Cancer Research 19, 279 (Jan 1, 2013).

199.

G. J. Inman et al., SB-431542 is a potent and specific inhibitor of transforming
growth factor-beta superfamily type I activin receptor-like kinase (ALK)
receptors ALK4, ALK5, and ALK7. Molecular pharmacology 62, 65 (Jul, 2002).

200.

D. C. Clarke, X. Liu, Decoding the quantitative nature of TGF-beta/Smad
signaling. Trends in cell biology 18, 430 (Sep, 2008).

201.

C. H. Yun et al., Structures of lung cancer-derived EGFR mutants and inhibitor
complexes: mechanism of activation and insights into differential inhibitor
sensitivity. Cancer cell 11, 217 (Mar, 2007).

202.

A. J. Flint, T. Tiganis, D. Barford, N. K. Tonks, Development of "substratetrapping" mutants to identify physiological substrates of protein tyrosine
phosphatases. Proc Natl Acad Sci U S A 94, 1680 (Mar 4, 1997).

203.

C. Blanchetot, M. Chagnon, N. Dube, M. Halle, M. L. Tremblay, Substratetrapping techniques in the identification of cellular PTP targets. Methods 35, 44
(Jan, 2005).

204.

J. Hanes, A. Pluckthun, In vitro selection and evolution of functional proteins by
using ribosome display. Proc Natl Acad Sci U S A 94, 4937 (May 13, 1997).

212

205.

V. Bertelsen et al., A chimeric pre-ubiquitinated EGF receptor is constitutively
endocytosed in a clathrin-dependent, but kinase-independent manner. Traffic 12,
507 (Apr, 2011).

206.

A. H. Bild, J. Turkson, R. Jove, Cytoplasmic transport of Stat3 by receptormediated endocytosis. EMBO J 21, 3255 (Jul 1, 2002).

207.

C. P. Chan, S. J. McNall, E. G. Krebs, E. H. Fischer, Stimulation of protein
phosphatase activity by insulin and growth factors in 3T3 cells. Proc Natl Acad
Sci U S A 85, 6257 (Sep, 1988).

208.

S. D. Yang, C. K. Chou, M. Huang, J. S. Song, H. C. Chen, Epidermal growth
factor induces activation of protein kinase FA and ATP.Mg-dependent protein
phosphatase in A431 cells. J Biol Chem 264, 5407 (Apr 5, 1989).

209.

X. Li et al., Brk/PTK6 sustains activated EGFR signaling through inhibiting
EGFR degradation and transactivating EGFR. Oncogene 31, 4372 (Oct 4, 2012).

210.

S. S. Bae et al., Proteolytic cleavage of epidermal growth factor receptor by
caspases. FEBS Lett 491, 16 (Feb 23, 2001).

211.

Y. Yang et al., Inhibitors of ubiquitin-activating enzyme (E1), a new class of
potential cancer therapeutics. Cancer Res 67, 9472 (Oct 1, 2007).

212.

W. Zhou et al., Novel mutant-selective EGFR kinase inhibitors against EGFR
T790M. Nature 462, 1070 (Dec 24, 2009).

213.

X. Li, Y. Huang, J. Jiang, S. J. Frank, ERK-dependent threonine phosphorylation
of EGF receptor modulates receptor downregulation and signaling. Cellular
signalling 20, 2145 (Nov, 2008).
213

214.

K. Takishima, I. Griswold-Prenner, T. Ingebritsen, M. R. Rosner, Epidermal
growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGFstimulated "MAP" kinase. Proc Natl Acad Sci U S A 88, 2520 (Mar 15, 1991).

215.

I. C. Northwood, F. A. Gonzalez, M. Wartmann, D. L. Raden, R. J. Davis,
Isolation and characterization of two growth factor-stimulated protein kinases that
phosphorylate the epidermal growth factor receptor at threonine 669. J Biol Chem
266, 15266 (Aug 15, 1991).

216.

R. Sordella, D. W. Bell, D. A. Haber, J. Settleman, Gefitinib-sensitizing EGFR
mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163
(Aug 20, 2004).

214

